ID ACACB_HUMAN Reviewed; 2458 AA. AC O00763; A6NK36; Q16852; Q1HEC1; Q6KE87; Q6KE89; Q6TY48; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 3. DT 28-JAN-2026, entry version 224. DE RecName: Full=Acetyl-CoA carboxylase 2 {ECO:0000305}; DE EC=6.4.1.2 {ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:19236960, ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656, ECO:0000269|PubMed:26976583}; DE AltName: Full=ACC-beta; DE Flags: Precursor; GN Name=ACACB {ECO:0000312|HGNC:HGNC:85}; Synonyms=ACC2, ACCB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Liver; RX PubMed=9099716; DOI=10.1074/jbc.272.16.10669; RA Abu-Elheiga L., Almarza-Ortega D.B., Baldini A., Wakil S.J.; RT "Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, RT chromosomal mapping, and evidence for two isoforms."; RL J. Biol. Chem. 272:10669-10677(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, RP BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND RP VARIANT ILE-2141. RX PubMed=16854592; DOI=10.1016/j.pep.2006.06.005; RA Cheng D., Chu C.-H., Chen L., Feder J.N., Mintier G.A., Wu Y., Cook J.W., RA Harpel M.R., Locke G.A., An Y., Tamura J.K.; RT "Expression, purification, and characterization of human and rat acetyl RT coenzyme A carboxylase (ACC) isozymes."; RL Protein Expr. Purif. 51:11-21(2007). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-2141. RC TISSUE=Heart; RA Peng X.R., Lindgren K., Corneliussen B.; RT "Corrected sequence for human acetyl-CoA carboxylase 2 obtained by RT alignment to human genomic DNA and PCR cloning from human skeletal muscle RT and heart cDNA."; RL Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Heart; RA Mao J., Wakil S.J.; RT "Alternative splicing in the human acetyl-CoA carboxylase 2 (ACC2) gene."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1324-2109. RC TISSUE=Adipose tissue; RX PubMed=8670171; DOI=10.1042/bj3160915; RA Widmer J., Fassihi K.S., Schlichter S.C., Wheeler K.S., Crute B.E., RA King N., Nutile-Mcmenemy N., Noll W.W., Daniel S., Ha J., Kim K.-H., RA Witters L.A.; RT "Identification of a second human acetyl-CoA carboxylase gene."; RL Biochem. J. 316:915-922(1996). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=10677481; DOI=10.1073/pnas.97.4.1444; RA Abu-Elheiga L., Brinkley W.R., Zhong L., Chirala S.S., Woldegiorgis G., RA Wakil S.J.; RT "The subcellular localization of acetyl-CoA carboxylase 2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:1444-1449(2000). RN [8] RP PHOSPHORYLATION AT SER-222 BY AMPK, AND ACTIVITY REGULATION. RX PubMed=12488245; DOI=10.1152/ajpendo.00436.2002; RA Wojtaszewski J.F., MacDonald C., Nielsen J.N., Hellsten Y., Hardie D.G., RA Kemp B.E., Kiens B., Richter E.A.; RT "Regulation of 5'AMP-activated protein kinase activity and substrate RT utilization in exercising human skeletal muscle."; RL Am. J. Physiol. 284:E813-E822(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=19236960; DOI=10.1016/j.bbapap.2009.02.004; RA Kaushik V.K., Kavana M., Volz J.M., Weldon S.C., Hanrahan S., Xu J., RA Caplan S.L., Hubbard B.K.; RT "Characterization of recombinant human acetyl-CoA carboxylase-2 steady- RT state kinetics."; RL Biochim. Biophys. Acta 1794:961-967(2009). RN [11] RP BIOPHYSICOCHEMICAL PROPERTIES, ALTERNATIVE SPLICING (ISOFORM 3), AND TISSUE RP SPECIFICITY. RX PubMed=19190759; DOI=10.1371/journal.pone.0004369; RA Castle J.C., Hara Y., Raymond C.K., Garrett-Engele P., Ohwaki K., Kan Z., RA Kusunoki J., Johnson J.M.; RT "ACC2 is expressed at high levels in human white adipose and has an isoform RT with a novel N-terminus."; RL PLoS ONE 4:E4369-E4369(2009). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND INTERACTION RP WITH MID1IP1. RX PubMed=20457939; DOI=10.1073/pnas.1001292107; RA Kim C.W., Moon Y.A., Park S.W., Cheng D., Kwon H.J., Horton J.D.; RT "Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 RT provides a tertiary level of regulation of fatty acid synthesis."; RL Proc. Natl. Acad. Sci. U.S.A. 107:9626-9631(2010). RN [13] RP CATALYTIC ACTIVITY, SUBUNIT, ACTIVITY REGULATION, AND INTERACTION WITH RP MID1IP1. RX PubMed=20952656; DOI=10.1073/pnas.1012736107; RA Colbert C.L., Kim C.W., Moon Y.A., Henry L., Palnitkar M., McKean W.B., RA Fitzgerald K., Deisenhofer J., Horton J.D., Kwon H.J.; RT "Crystal structure of Spot 14, a modulator of fatty acid synthesis."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18820-18825(2010). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35; THR-70; SER-91; SER-95; RP SER-200; SER-469 AND THR-1342, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 217-775. RX PubMed=17876819; DOI=10.1002/prot.21611; RA Cho Y.S., Lee J.I., Shin D., Kim H.T., Cheon Y.H., Seo C.I., Kim Y.E., RA Hyun Y.L., Lee Y.S., Sugiyama K., Park S.Y., Ro S., Cho J.M., Lee T.G., RA Heo Y.S.; RT "Crystal structure of the biotin carboxylase domain of human acetyl-CoA RT carboxylase 2."; RL Proteins 70:268-272(2008). RN [16] RP STRUCTURE BY NMR OF 885-971. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of RSGI RUH-053, an apo-biotin carboxy carrier protein RT from human transcarboxylase."; RL Submitted (OCT-2006) to the PDB data bank. RN [17] RP STRUCTURE BY NMR OF 891-965, BIOTINYLATION AT LYS-929, COFACTOR, AND RP DOMAIN. RX PubMed=18247344; DOI=10.1002/prot.21952; RA Lee C.K., Cheong H.K., Ryu K.S., Lee J.I., Lee W., Jeon Y.H., Cheong C.; RT "Biotinoyl domain of human acetyl-CoA carboxylase: Structural insights into RT the carboxyl transfer mechanism."; RL Proteins 72:613-624(2008). RN [18] RP X-RAY CRYSTALLOGRAPHY (3.19 ANGSTROMS) OF 1693-2450 IN COMPLEX WITH RP INHIBITOR, AND DOMAIN. RX PubMed=19390150; DOI=10.1107/s0907444909008014; RA Madauss K.P., Burkhart W.A., Consler T.G., Cowan D.J., Gottschalk W.K., RA Miller A.B., Short S.A., Tran T.B., Williams S.P.; RT "The human ACC2 CT-domain C-terminus is required for full functionality and RT has a novel twist."; RL Acta Crystallogr. D 65:449-461(2009). RN [19] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 217-775 IN COMPLEX WITH SORAPHEN RP A, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PATHWAY, SUBUNIT, RP PHOSPHORYLATION AT SER-222, AND MUTAGENESIS OF ARG-277 AND GLU-671. RX PubMed=19900410; DOI=10.1016/j.bbrc.2009.11.029; RA Cho Y.S., Lee J.I., Shin D., Kim H.T., Jung H.Y., Lee T.G., Kang L.W., RA Ahn Y.J., Cho H.S., Heo Y.S.; RT "Molecular mechanism for the regulation of human ACC2 through RT phosphorylation by AMPK."; RL Biochem. Biophys. Res. Commun. 391:187-192(2010). RN [20] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 238-760 IN COMPLEX WITH RP INHIBITOR, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=26976583; DOI=10.1073/pnas.1520686113; RA Harriman G., Greenwood J., Bhat S., Huang X., Wang R., Paul D., Tong L., RA Saha A.K., Westlin W.F., Kapeller R., Harwood H.J. Jr.; RT "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, RT improves insulin sensitivity, and modulates dyslipidemia in rats."; RL Proc. Natl. Acad. Sci. U.S.A. 113:E1796-E1805(2016). RN [21] RP VARIANT [LARGE SCALE ANALYSIS] LEU-193. RX PubMed=18772397; DOI=10.1126/science.1164368; RA Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., RA Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., RA Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., RA Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., RA Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., RA Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., RA Velculescu V.E., Kinzler K.W.; RT "Core signaling pathways in human pancreatic cancers revealed by global RT genomic analyses."; RL Science 321:1801-1806(2008). CC -!- FUNCTION: Mitochondrial enzyme that catalyzes the carboxylation of CC acetyl-CoA to malonyl-CoA and plays a central role in fatty acid CC metabolism (PubMed:16854592, PubMed:19236960, PubMed:19900410, CC PubMed:20457939, PubMed:20952656, PubMed:26976583). Catalyzes a 2 steps CC reaction starting with the ATP-dependent carboxylation of the biotin CC carried by the biotin carboxyl carrier (BCC) domain followed by the CC transfer of the carboxyl group from carboxylated biotin to acetyl-CoA CC (PubMed:19236960, PubMed:20457939, PubMed:20952656, PubMed:26976583). CC Through the production of malonyl-CoA that allosterically inhibits CC carnitine palmitoyltransferase 1 at the mitochondria, negatively CC regulates fatty acid oxidation (By similarity). Together with its CC cytosolic isozyme ACACA, which is involved in de novo fatty acid CC biosynthesis, promotes lipid storage (By similarity). CC {ECO:0000250|UniProtKB:E9Q4Z2, ECO:0000269|PubMed:16854592, CC ECO:0000269|PubMed:19236960, ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656, CC ECO:0000269|PubMed:26976583}. CC -!- CATALYTIC ACTIVITY: CC Reaction=hydrogencarbonate + acetyl-CoA + ATP = malonyl-CoA + ADP + CC phosphate + H(+); Xref=Rhea:RHEA:11308, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:17544, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:57288, ChEBI:CHEBI:57384, ChEBI:CHEBI:456216; EC=6.4.1.2; CC Evidence={ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:19236960, CC ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, CC ECO:0000269|PubMed:20952656, ECO:0000269|PubMed:26976583}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:11309; CC Evidence={ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:26976583}; CC -!- COFACTOR: CC Name=biotin; Xref=ChEBI:CHEBI:57586; CC Evidence={ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:18247344}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00409, CC ECO:0000255|PROSITE-ProRule:PRU00969}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00409, CC ECO:0000255|PROSITE-ProRule:PRU00969}; CC Note=Binds 2 magnesium or manganese ions per subunit. CC {ECO:0000255|PROSITE-ProRule:PRU00409, ECO:0000255|PROSITE- CC ProRule:PRU00969}; CC -!- ACTIVITY REGULATION: Activity is increased by oligomerization of the CC protein into filaments (PubMed:19900410). The oligomerization and the CC activity of the enzyme are inhibited by phosphorylation at Ser-222 CC (PubMed:12488245). Inhibited by its product, malonyl-CoA CC (PubMed:16854592). Activated by citrate (PubMed:16854592). Activation CC by MID1IP1 is citrate-dependent (PubMed:20457939). Soraphen A, inhibits CC the enzyme by preventing the formation of active filamentous oligomers CC (Probable). {ECO:0000269|PubMed:12488245, ECO:0000269|PubMed:16854592, CC ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, CC ECO:0000305|PubMed:19236960}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=120 uM for ATP {ECO:0000269|PubMed:16854592}; CC KM=110 uM for ATP (isoform 2) {ECO:0000269|PubMed:19190759}; CC KM=58 uM for acetyl-CoA {ECO:0000269|PubMed:16854592}; CC KM=94 uM for acetyl-CoA (isoform 3) {ECO:0000269|PubMed:19190759}; CC KM=6.5 mM for NaHCO3 (isoform 3) {ECO:0000269|PubMed:19190759}; CC KM=3.0 mM for NaHCO(3) {ECO:0000269|PubMed:16854592}; CC pH dependence: CC Optimum pH is 7.5. {ECO:0000305|PubMed:19236960}; CC -!- PATHWAY: Lipid metabolism; malonyl-CoA biosynthesis; malonyl-CoA from CC acetyl-CoA: step 1/1. {ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:26976583}. CC -!- SUBUNIT: Monomer, homodimer, and homotetramer (PubMed:18772397, CC PubMed:20952656). Forms filamentous polymers (PubMed:19900410, CC PubMed:20457939, PubMed:20952656). Interacts with MID1IP1; interaction CC with MID1IP1 promotes oligomerization and increases its activity in a CC citrate-dependent manner (PubMed:20457939, PubMed:20952656). CC {ECO:0000269|PubMed:18772397, ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656}. CC -!- INTERACTION: CC O00763; O00763: ACACB; NbExp=2; IntAct=EBI-2211739, EBI-2211739; CC O00763; P50747: HLCS; NbExp=4; IntAct=EBI-2211739, EBI-3915568; CC O00763; Q9CQ20: Mid1ip1; Xeno; NbExp=4; IntAct=EBI-2211739, EBI-473024; CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:10677481}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Long; CC IsoId=O00763-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=O00763-2; Sequence=VSP_000547; CC Name=3 {ECO:0000305}; Synonyms=ACC2.v2 {ECO:0000303|PubMed:19190759}; CC IsoId=O00763-3; Sequence=VSP_057081, VSP_057082; CC -!- TISSUE SPECIFICITY: Widely expressed with highest levels in heart, CC skeletal muscle, liver, adipose tissue, mammary gland, adrenal gland CC and colon (PubMed:9099716). Isoform 3 is expressed in skeletal muscle, CC adipose tissue and liver (at protein level) (PubMed:19190759). Isoform CC 3 is detected at high levels in adipose tissue with lower levels in CC heart, liver, skeletal muscle and testis (PubMed:19190759). CC {ECO:0000269|PubMed:19190759, ECO:0000269|PubMed:9099716}. CC -!- DOMAIN: Consists of an N-terminal biotin carboxylation/carboxylase (BC) CC domain that catalyzes the ATP-dependent transient carboxylation of the CC biotin covalently attached to the central biotinyl-binding/biotin CC carboxyl carrier (BCC) domain (Probable). The C-terminal carboxyl CC transferase (CT) domain catalyzes the transfer of the carboxyl group CC from carboxylated biotin to acetyl-CoA to produce malonyl-CoA CC (Probable). {ECO:0000305|PubMed:18247344, ECO:0000305|PubMed:19390150}. CC -!- PTM: The biotin cofactor is covalently attached to the central CC biotinyl-binding domain and is required for the catalytic activity. CC {ECO:0000305|PubMed:18247344}. CC -!- PTM: Phosphorylation at Ser-222 by AMPK inactivates the enzyme CC (PubMed:12488245). Required for the maintenance of skeletal muscle CC lipid and glucose homeostasis (By similarity). CC {ECO:0000250|UniProtKB:E9Q4Z2, ECO:0000269|PubMed:12488245}. CC -!- BIOTECHNOLOGY: Inhibition of ACACB may prevent lipid-induced insulin CC resistance and type 2 diabetes, making the enzyme a potential CC pharmaceutical target for treatment of obesity and type 2 diabetes. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB58382.1; Type=Miscellaneous discrepancy; Note=Many Frameshifts and conflicts.; Evidence={ECO:0000305}; CC Sequence=CAE01470.2; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U89344; AAB58382.1; ALT_SEQ; mRNA. DR EMBL; DQ493870; ABF48723.1; -; mRNA. DR EMBL; AJ575431; CAE01470.2; ALT_SEQ; mRNA. DR EMBL; AJ575592; CAE01471.3; -; mRNA. DR EMBL; AY382667; AAR37018.1; -; mRNA. DR EMBL; AC007637; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; U34591; AAC50571.1; -; mRNA. DR CCDS; CCDS31898.1; -. [O00763-1] DR PIR; S71091; S71091. DR RefSeq; NP_001084.3; NM_001093.4. [O00763-1] DR RefSeq; NP_001399663.1; NM_001412734.1. [O00763-1] DR RefSeq; NP_001399664.1; NM_001412735.1. [O00763-1] DR RefSeq; NP_001399665.1; NM_001412736.1. [O00763-3] DR PDB; 2DN8; NMR; -; A=885-971. DR PDB; 2HJW; X-ray; 2.50 A; A=217-775. DR PDB; 2KCC; NMR; -; A=891-965. DR PDB; 3FF6; X-ray; 3.19 A; A/B/C/D=1693-2450. DR PDB; 3GID; X-ray; 2.30 A; A/B=238-760. DR PDB; 3GLK; X-ray; 2.10 A; A=238-760. DR PDB; 3JRW; X-ray; 2.60 A; A=217-775. DR PDB; 3JRX; X-ray; 2.50 A; A=217-775. DR PDB; 3TDC; X-ray; 2.41 A; A=1690-2445. DR PDB; 4HQ6; X-ray; 2.70 A; A=217-776. DR PDB; 5KKN; X-ray; 2.60 A; B/C=238-760. DR PDBsum; 2DN8; -. DR PDBsum; 2HJW; -. DR PDBsum; 2KCC; -. DR PDBsum; 3FF6; -. DR PDBsum; 3GID; -. DR PDBsum; 3GLK; -. DR PDBsum; 3JRW; -. DR PDBsum; 3JRX; -. DR PDBsum; 3TDC; -. DR PDBsum; 4HQ6; -. DR PDBsum; 5KKN; -. DR AlphaFoldDB; O00763; -. DR SMR; O00763; -. DR BioGRID; 106550; 180. DR DIP; DIP-51617N; -. DR FunCoup; O00763; 2599. DR IntAct; O00763; 69. DR MINT; O00763; -. DR STRING; 9606.ENSP00000341044; -. DR BindingDB; O00763; -. DR ChEMBL; CHEMBL4829; -. DR DrugBank; DB03781; 2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid. DR DrugBank; DB00173; Adenine. DR DrugBank; DB00121; Biotin. DR DrugBank; DB07870; Haloxyfop-P. DR DrugBank; DB00331; Metformin. DR DrugBank; DB12096; PF-05175157. DR DrugBank; DB02859; Soraphen A. DR GuidetoPHARMACOLOGY; 1264; -. DR SwissLipids; SLP:000000730; -. DR GlyGen; O00763; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O00763; -. DR PhosphoSitePlus; O00763; -. DR BioMuta; ACACB; -. DR jPOST; O00763; -. DR MassIVE; O00763; -. DR PaxDb; 9606-ENSP00000341044; -. DR PeptideAtlas; O00763; -. DR ProteomicsDB; 48022; -. [O00763-1] DR ProteomicsDB; 48023; -. [O00763-2] DR Antibodypedia; 1321; 163 antibodies from 30 providers. DR DNASU; 32; -. DR Ensembl; ENST00000338432.12; ENSP00000341044.7; ENSG00000076555.16. [O00763-1] DR Ensembl; ENST00000377848.7; ENSP00000367079.3; ENSG00000076555.16. [O00763-1] DR GeneID; 32; -. DR KEGG; hsa:32; -. DR MANE-Select; ENST00000338432.12; ENSP00000341044.7; NM_001093.4; NP_001084.3. DR UCSC; uc001tob.4; human. [O00763-1] DR AGR; HGNC:85; -. DR ClinPGx; PA24422; -. DR CTD; 32; -. DR DisGeNET; 32; -. DR GeneCards; ACACB; -. DR HGNC; HGNC:85; ACACB. DR HPA; ENSG00000076555; Tissue enhanced (adipose tissue, skeletal muscle). DR MalaCards; ACACB; -. DR MIM; 601557; gene. DR OpenTargets; ENSG00000076555; -. DR VEuPathDB; HostDB:ENSG00000076555; -. DR eggNOG; KOG0368; Eukaryota. DR GeneTree; ENSGT00940000155049; -. DR HOGENOM; CLU_000395_5_0_1; -. DR InParanoid; O00763; -. DR OMA; TEHCKVA; -. DR OrthoDB; 14612at2759; -. DR PAN-GO; O00763; 3 GO annotations based on evolutionary models. DR PhylomeDB; O00763; -. DR BioCyc; MetaCyc:HS01211-MONOMER; -. DR BRENDA; 6.3.4.14; 2681. DR BRENDA; 6.4.1.2; 2681. DR PathwayCommons; O00763; -. DR Reactome; R-HSA-163765; ChREBP activates metabolic gene expression. DR Reactome; R-HSA-196780; Biotin transport and metabolism. DR Reactome; R-HSA-200425; Carnitine shuttle. DR Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP). DR SABIO-RK; O00763; -. DR SignaLink; O00763; -. DR SIGNOR; O00763; -. DR UniPathway; UPA00655; UER00711. DR Agora; ENSG00000076555; -. DR BioGRID-ORCS; 32; 8 hits in 1154 CRISPR screens. DR ChiTaRS; ACACB; human. DR EvolutionaryTrace; O00763; -. DR GeneWiki; ACACB; -. DR GenomeRNAi; 32; -. DR Pharos; O00763; Tchem. DR PRO; PR:O00763; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; O00763; protein. DR Bgee; ENSG00000076555; Expressed in tendon of biceps brachii and 208 other cell types or tissues. DR ExpressionAtlas; O00763; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0016507; C:mitochondrial fatty acid beta-oxidation multienzyme complex; IEA:Ensembl. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003989; F:acetyl-CoA carboxylase activity; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0009374; F:biotin binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0006084; P:acetyl-CoA metabolic process; IDA:UniProtKB. DR GO; GO:0046323; P:D-glucose import; IEA:Ensembl. DR GO; GO:0097009; P:energy homeostasis; IEA:Ensembl. DR GO; GO:0006633; P:fatty acid biosynthetic process; IBA:GO_Central. DR GO; GO:0055089; P:fatty acid homeostasis; TAS:Reactome. DR GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl. DR GO; GO:0090459; P:intracellular aspartate homeostasis; IEA:Ensembl. DR GO; GO:0090461; P:intracellular glutamate homeostasis; IEA:Ensembl. DR GO; GO:0046722; P:lactic acid secretion; IEA:Ensembl. DR GO; GO:2001295; P:malonyl-CoA biosynthetic process; IEA:UniProtKB-UniPathway. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IEA:Ensembl. DR GO; GO:0006098; P:pentose-phosphate shunt; IEA:Ensembl. DR GO; GO:0060421; P:positive regulation of heart growth; IEA:Ensembl. DR GO; GO:0010884; P:positive regulation of lipid storage; IEA:Ensembl. DR GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB. DR GO; GO:1903242; P:regulation of cardiac muscle hypertrophy in response to stress; IEA:Ensembl. DR GO; GO:0010906; P:regulation of glucose metabolic process; IEA:Ensembl. DR GO; GO:0061771; P:response to caloric restriction; IEA:Ensembl. DR GO; GO:0007584; P:response to nutrient; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072350; P:tricarboxylic acid metabolic process; IEA:Ensembl. DR CDD; cd06850; biotinyl_domain; 1. DR FunFam; 2.40.460.10:FF:000001; Acetyl-CoA carboxylase 1; 1. DR FunFam; 2.40.50.100:FF:000005; Acetyl-CoA carboxylase 1; 1. DR FunFam; 3.30.470.20:FF:000005; Acetyl-CoA carboxylase 1; 1. DR FunFam; 3.90.1770.10:FF:000001; acetyl-CoA carboxylase 1; 1. DR FunFam; 3.30.1490.20:FF:000003; acetyl-CoA carboxylase isoform X1; 1. DR FunFam; 3.40.50.20:FF:000005; acetyl-CoA carboxylase isoform X2; 1. DR FunFam; 3.90.226.10:FF:000010; acetyl-CoA carboxylase isoform X2; 1. DR Gene3D; 2.40.50.100; -; 1. DR Gene3D; 3.40.50.20; -; 1. DR Gene3D; 3.90.226.10; 2-enoyl-CoA Hydratase, Chain A, domain 1; 2. DR Gene3D; 3.30.1490.20; ATP-grasp fold, A domain; 1. DR Gene3D; 3.30.470.20; ATP-grasp fold, B domain; 1. DR Gene3D; 2.40.460.10; Biotin dependent carboxylase carboxyltransferase; 1. DR Gene3D; 3.90.1770.10; PreATP-grasp domain; 1. DR InterPro; IPR049076; ACCA. DR InterPro; IPR049074; ACCA_BT. DR InterPro; IPR034733; AcCoA_carboxyl_beta. DR InterPro; IPR013537; AcCoA_COase_cen. DR InterPro; IPR011761; ATP-grasp. DR InterPro; IPR013815; ATP_grasp_subdomain_1. DR InterPro; IPR005481; BC-like_N. DR InterPro; IPR011764; Biotin_carboxylation_dom. DR InterPro; IPR005482; Biotin_COase_C. DR InterPro; IPR000089; Biotin_lipoyl. DR InterPro; IPR029045; ClpP/crotonase-like_dom_sf. DR InterPro; IPR011763; COA_CT_C. DR InterPro; IPR011762; COA_CT_N. DR InterPro; IPR005479; CPAse_ATP-bd. DR InterPro; IPR016185; PreATP-grasp_dom_sf. DR InterPro; IPR011054; Rudment_hybrid_motif. DR InterPro; IPR011053; Single_hybrid_motif. DR PANTHER; PTHR45728:SF1; ACETYL-COA CARBOXYLASE 2; 1. DR PANTHER; PTHR45728; ACETYL-COA CARBOXYLASE, ISOFORM A; 1. DR Pfam; PF08326; ACC_central; 1. DR Pfam; PF21385; ACCA_BT; 1. DR Pfam; PF02785; Biotin_carb_C; 1. DR Pfam; PF00289; Biotin_carb_N; 1. DR Pfam; PF00364; Biotin_lipoyl; 1. DR Pfam; PF01039; Carboxyl_trans; 1. DR Pfam; PF02786; CPSase_L_D2; 1. DR SMART; SM00878; Biotin_carb_C; 1. DR SUPFAM; SSF52096; ClpP/crotonase; 2. DR SUPFAM; SSF56059; Glutathione synthetase ATP-binding domain-like; 1. DR SUPFAM; SSF52440; PreATP-grasp domain; 1. DR SUPFAM; SSF51246; Rudiment single hybrid motif; 1. DR SUPFAM; SSF51230; Single hybrid motif; 1. DR PROSITE; PS50975; ATP_GRASP; 1. DR PROSITE; PS50979; BC; 1. DR PROSITE; PS50968; BIOTINYL_LIPOYL; 1. DR PROSITE; PS50989; COA_CT_CTER; 1. DR PROSITE; PS50980; COA_CT_NTER; 1. DR PROSITE; PS00866; CPSASE_1; 1. DR PROSITE; PS00867; CPSASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Allosteric enzyme; Alternative splicing; ATP-binding; Biotin; KW Fatty acid biosynthesis; Fatty acid metabolism; Ligase; Lipid biosynthesis; KW Lipid metabolism; Magnesium; Manganese; Metal-binding; Mitochondrion; KW Multifunctional enzyme; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Transit peptide. FT TRANSIT 1..? FT /note="Mitochondrion" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT CHAIN ?..2458 FT /note="Acetyl-CoA carboxylase 2" FT /evidence="ECO:0000305" FT /id="PRO_0000146767" FT DOMAIN 259..761 FT /note="Biotin carboxylation" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00969" FT DOMAIN 414..609 FT /note="ATP-grasp" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409" FT DOMAIN 888..962 FT /note="Biotinyl-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01066" FT DOMAIN 1695..2025 FT /note="CoA carboxyltransferase N-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01136" FT DOMAIN 2029..2345 FT /note="CoA carboxyltransferase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01137" FT REGION 35..155 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 174..193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1695..2345 FT /note="Carboxyltransferase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01138" FT COMPBIAS 51..60 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 77..87 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 103..146 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 584 FT /evidence="ECO:0000250" FT BINDING 458..463 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409" FT BINDING 567 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 567 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 582 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 582 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 1934 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT BINDING 2238 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT BINDING 2240 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT MOD_RES 35 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 70 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 95 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 169 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 175 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 192 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 195 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 200 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 207 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 220 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P11497" FT MOD_RES 222 FT /note="Phosphoserine; by AMPK" FT /evidence="ECO:0000269|PubMed:12488245, FT ECO:0000269|PubMed:19900410" FT MOD_RES 469 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 753 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 929 FT /note="N6-biotinyllysine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01066, FT ECO:0000269|PubMed:18247344" FT MOD_RES 1340 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 1342 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1360 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 1405 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT VAR_SEQ 1..202 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000269|PubMed:19190759" FT /id="VSP_057081" FT VAR_SEQ 203..218 FT /note="AYLTTGEAETRVPTMR -> MSPAKCKICFPDREVK (in isoform 3)" FT /evidence="ECO:0000269|PubMed:19190759" FT /id="VSP_057082" FT VAR_SEQ 1118..1187 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9099716" FT /id="VSP_000547" FT VARIANT 193 FT /note="R -> L (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:18772397" FT /id="VAR_062667" FT VARIANT 552 FT /note="I -> V (in dbSNP:rs16940029)" FT /id="VAR_031255" FT VARIANT 651 FT /note="A -> T (in dbSNP:rs2300455)" FT /id="VAR_031256" FT VARIANT 2141 FT /note="V -> I (in dbSNP:rs2075260)" FT /evidence="ECO:0000269|PubMed:16854592, ECO:0000269|Ref.3" FT /id="VAR_031257" FT MUTAGEN 277 FT /note="R->A: Loss of regulation of oligomerization by FT phosphorylation at S-222." FT /evidence="ECO:0000269|PubMed:19900410" FT MUTAGEN 671 FT /note="E->A: Altered regulation of oligomerization by FT phosphorylation at S-222." FT /evidence="ECO:0000269|PubMed:19900410" FT CONFLICT 9 FT /note="C -> R (in Ref. 2; ABF48723)" FT /evidence="ECO:0000305" FT CONFLICT 120 FT /note="T -> I (in Ref. 4; AAR37018)" FT /evidence="ECO:0000305" FT CONFLICT 422 FT /note="I -> T (in Ref. 4; AAR37018)" FT /evidence="ECO:0000305" FT CONFLICT 1340 FT /note="S -> N (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1383 FT /note="D -> G (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1425 FT /note="V -> M (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1819..1821 FT /note="AEG -> PEA (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1892..1893 FT /note="MI -> IM (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT HELIX 247..253 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 262..265 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 269..287 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 292..299 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 301..305 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 309..313 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 314..319 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 328..330 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 332..341 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 359..366 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 370..373 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 376..379 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 385..394 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 403..406 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 426..431 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 437..447 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 449..455 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 464..467 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 470..472 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 473..483 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 489..493 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 496..507 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 509..511 FT /evidence="ECO:0007829|PDB:3JRX" FT STRAND 513..523 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 524..527 FT /evidence="ECO:0007829|PDB:4HQ6" FT STRAND 530..535 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 541..558 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 562..571 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 572..574 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 576..582 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 589..596 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 600..608 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 613..615 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 617..622 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 635..637 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 646..653 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 669..671 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 679..685 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 700..709 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 710..724 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 728..730 FT /evidence="ECO:0007829|PDB:2HJW" FT HELIX 732..742 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 744..748 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 754..756 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 896..898 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 900..902 FT /evidence="ECO:0007829|PDB:2KCC" FT STRAND 903..910 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 914..916 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 921..927 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 930..935 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 937..944 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 957..961 FT /evidence="ECO:0007829|PDB:2DN8" FT TURN 1698..1700 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 1703..1711 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1717..1719 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1720..1732 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1742..1750 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1756..1759 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1767..1777 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1786..1793 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1798..1800 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1804..1820 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1824..1828 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1839..1842 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1846..1850 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1855..1857 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1859..1864 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1866..1872 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 1873..1876 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1878..1885 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1888..1896 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1899..1901 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1905..1924 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1927..1931 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1933..1936 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1938..1946 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1948..1952 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1956..1960 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1962..1969 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1977..1981 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1983..1986 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 1987..1990 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1993..1998 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1999..2010 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2045..2050 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2055..2057 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2072..2075 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2082..2089 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2092..2099 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2104..2108 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2120..2124 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2131..2147 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2151..2154 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2164..2168 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2171..2183 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2189..2193 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2198..2200 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2201..2205 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2209..2211 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 2213..2215 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2216..2221 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2225..2229 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2231..2238 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2241..2251 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2253..2261 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2269..2299 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2300..2302 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2304..2309 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2312..2317 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2319..2321 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2322..2344 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2345..2348 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2352..2365 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2369..2376 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2378..2388 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2404..2420 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 2423..2425 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2426..2435 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2439..2448 FT /evidence="ECO:0007829|PDB:3FF6" SQ SEQUENCE 2458 AA; 276541 MW; ED12674A1A8A0706 CRC64; MVLLLCLSCL IFSCLTFSWL KIWGKMTDSK PITKSKSEAN LIPSQEPFPA SDNSGETPQR NGEGHTLPKT PSQAEPASHK GPKDAGRRRN SLPPSHQKPP RNPLSSSDAA PSPELQANGT GTQGLEATDT NGLSSSARPQ GQQAGSPSKE DKKQANIKRQ LMTNFILGSF DDYSSDEDSV AGSSRESTRK GSRASLGALS LEAYLTTGEA ETRVPTMRPS MSGLHLVKRG REHKKLDLHR DFTVASPAEF VTRFGGDRVI EKVLIANNGI AAVKCMRSIR RWAYEMFRNE RAIRFVVMVT PEDLKANAEY IKMADHYVPV PGGPNNNNYA NVELIVDIAK RIPVQAVWAG WGHASENPKL PELLCKNGVA FLGPPSEAMW ALGDKIASTV VAQTLQVPTL PWSGSGLTVE WTEDDLQQGK RISVPEDVYD KGCVKDVDEG LEAAERIGFP LMIKASEGGG GKGIRKAESA EDFPILFRQV QSEIPGSPIF LMKLAQHARH LEVQILADQY GNAVSLFGRD CSIQRRHQKI VEEAPATIAP LAIFEFMEQC AIRLAKTVGY VSAGTVEYLY SQDGSFHFLE LNPRLQVEHP CTEMIADVNL PAAQLQIAMG VPLHRLKDIR LLYGESPWGV TPISFETPSN PPLARGHVIA ARITSENPDE GFKPSSGTVQ ELNFRSSKNV WGYFSVAATG GLHEFADSQF GHCFSWGENR EEAISNMVVA LKELSIRGDF RTTVEYLINL LETESFQNND IDTGWLDYLI AEKVQAEKPD IMLGVVCGAL NVADAMFRTC MTDFLHSLER GQVLPADSLL NLVDVELIYG GVKYILKVAR QSLTMFVLIM NGCHIEIDAH RLNDGGLLLS YNGNSYTTYM KEEVDSYRIT IGNKTCVFEK ENDPTVLRSP SAGKLTQYTV EDGGHVEAGS SYAEMEVMKM IMTLNVQERG RVKYIKRPGA VLEAGCVVAR LELDDPSKVH PAEPFTGELP AQQTLPILGE KLHQVFHSVL ENLTNVMSGF CLPEPVFSIK LKEWVQKLMM TLRHPSLPLL ELQEIMTSVA GRIPAPVEKS VRRVMAQYAS NITSVLCQFP SQQIATILDC HAATLQRKAD REVFFINTQS IVQLVQRYRS GIRGYMKTVV LDLLRRYLRV EHHFQQAHYD KCVINLREQF KPDMSQVLDC IFSHAQVAKK NQLVIMLIDE LCGPDPSLSD ELISILNELT QLSKSEHCKV ALRARQILIA SHLPSYELRH NQVESIFLSA IDMYGHQFCP ENLKKLILSE TTIFDVLPTF FYHANKVVCM ASLEVYVRRG YIAYELNSLQ HRQLPDGTCV VEFQFMLPSS HPNRMTVPIS ITNPDLLRHS TELFMDSGFS PLCQRMGAMV AFRRFEDFTR NFDEVISCFA NVPKDTPLFS EARTSLYSED DCKSLREEPI HILNVSIQCA DHLEDEALVP ILRTFVQSKK NILVDYGLRR ITFLIAQEKE FPKFFTFRAR DEFAEDRIYR HLEPALAFQL ELNRMRNFDL TAVPCANHKM HLYLGAAKVK EGVEVTDHRF FIRAIIRHSD LITKEASFEY LQNEGERLLL EAMDELEVAF NNTSVRTDCN HIFLNFVPTV IMDPFKIEES VRYMVMRYGS RLWKLRVLQA EVKINIRQTT TGSAVPIRLF ITNESGYYLD ISLYKEVTDS RSGNIMFHSF GNKQGPQHGM LINTPYVTKD LLQAKRFQAQ TLGTTYIYDF PEMFRQALFK LWGSPDKYPK DILTYTELVL DSQGQLVEMN RLPGGNEVGM VAFKMRFKTQ EYPEGRDVIV IGNDITFRIG SFGPGEDLLY LRASEMARAE GIPKIYVAAN SGARIGMAEE IKHMFHVAWV DPEDPHKGFK YLYLTPQDYT RISSLNSVHC KHIEEGGESR YMITDIIGKD DGLGVENLRG SGMIAGESSL AYEEIVTISL VTCRAIGIGA YLVRLGQRVI QVENSHIILT GASALNKVLG REVYTSNNQL GGVQIMHYNG VSHITVPDDF EGVYTILEWL SYMPKDNHSP VPIITPTDPI DREIEFLPSR APYDPRWMLA GRPHPTLKGT WQSGFFDHGS FKEIMAPWAQ TVVTGRARLG GIPVGVIAVE TRTVEVAVPA DPANLDSEAK IIQQAGQVWF PDSAYKTAQA VKDFNREKLP LMIFANWRGF SGGMKDMYDQ VLKFGAYIVD GLRQYKQPIL IYIPPYAELR GGSWVVIDAT INPLCIEMYA DKESRGGVLE PEGTVEIKFR KKDLIKSMRR IDPAYKKLME QLGEPDLSDK DRKDLEGRLK AREDLLLPIY HQVAVQFADF HDTPGRMLEK GVISDILEWK TARTFLYWRL RRLLLEDQVK QEILQASGEL SHVHIQSMLR RWFVETEGAV KAYLWDNNQV VVQWLEQHWQ AGDGPRSTIR ENITYLKHDS VLKTIRGLVE ENPEVAVDCV IYLSQHISPA ERAQVVHLLS TMDSPAST // ID ITA2B_HUMAN Reviewed; 1039 AA. AC P08514; B2RCY8; O95366; Q14443; Q17R67; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 14-APR-2009, sequence version 3. DT 28-JAN-2026, entry version 272. DE RecName: Full=Integrin alpha-IIb {ECO:0000305}; DE AltName: Full=GPalpha IIb; DE Short=GPIIb {ECO:0000303|PubMed:2345548}; DE AltName: Full=Platelet membrane glycoprotein IIb; DE AltName: CD_antigen=CD41; DE Contains: DE RecName: Full=Integrin alpha-IIb heavy chain; DE Contains: DE RecName: Full=Integrin alpha-IIb light chain, form 1; DE Contains: DE RecName: Full=Integrin alpha-IIb light chain, form 2; DE Flags: Precursor; GN Name=ITGA2B {ECO:0000312|HGNC:HGNC:6138}; Synonyms=GP2B, ITGAB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-313. RX PubMed=2439501; DOI=10.1016/s0021-9258(18)47438-8; RA Poncz M., Eisman R., Heidenreich R., Silver S.M., Vilaire G., Surrey S., RA Schwartz E., Bennett J.S.; RT "Structure of the platelet membrane glycoprotein IIb. Homology to the alpha RT subunits of the vitronectin and fibronectin membrane receptors."; RL J. Biol. Chem. 262:8476-8482(1987). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-313. RX PubMed=2345548; DOI=10.1007/bf00422712; RA Frachet P., Uzan G., Thevenon D., Denarier E., Prandini M.H., Marguerie G.; RT "GPIIb and GPIIIa amino acid sequences deduced from human megakaryocyte RT cDNAs."; RL Mol. Biol. Rep. 14:27-33(1990). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=2322558; DOI=10.1021/bi00457a020; RA Heidenreich R., Eisman R., Surrey S., Delgrosso K., Bennett J.S., RA Schwartz E., Poncz M.; RT "Organization of the gene for platelet glycoprotein IIb."; RL Biochemistry 29:1232-1244(1990). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Spleen; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-62 AND 1021-1039. RX PubMed=2845986; DOI=10.1016/s0006-291x(88)80884-2; RA Prandini M.H., Denarier E., Frachet P., Uzan G., Marguerie G.; RT "Isolation of the human platelet glycoprotein IIb gene and characterization RT of the 5' flanking region."; RL Biochem. Biophys. Res. Commun. 156:595-601(1988). RN [8] RP PROTEIN SEQUENCE OF 32-56 AND 903-917. RX PubMed=3534886; DOI=10.1073/pnas.83.21.8351; RA Charo I.F., Fitzgerald L.A., Steiner B., Rall S.C., Bekeart L.S., RA Phillips D.R.; RT "Platelet glycoproteins IIb and IIIa: evidence for a family of RT immunologically and structurally related glycoproteins in mammalian RT cells."; RL Proc. Natl. Acad. Sci. U.S.A. 83:8351-8355(1986). RN [9] RP PROTEIN SEQUENCE OF 32-42. RX PubMed=1953640; DOI=10.1042/bj2790419; RA Catimel B., Parmentier S., Leung L.L., McGregor J.L.; RT "Separation of important new platelet glycoproteins (GPIa, GPIc, GPIc*, RT GPIIa and GMP-140) by F.P.L.C. Characterization by monoclonal antibodies RT and gas-phase sequencing."; RL Biochem. J. 279:419-425(1991). RN [10] RP PROTEIN SEQUENCE OF 32 AND 872. RX PubMed=8620874; DOI=10.1111/j.1432-1033.1996.0205n.x; RA Makogonenko E.M., Yakubenko V.P., Ingham K.C., Medved L.V.; RT "Thermal stability of individual domains in platelet glycoprotein RT IIbIIIa."; RL Eur. J. Biochem. 237:205-211(1996). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 392-1039 (ISOFORM 1). RX PubMed=3422188; DOI=10.1111/j.1432-1033.1988.tb13762.x; RA Uzan G., Frachet P., Lajmanovich A., Prandini M.-H., Denarier E., RA Duperray A., Loftus J., Ginsberg M., Plow E., Marguerie G.; RT "cDNA clones for human platelet GPIIb corresponding to mRNA from RT megakaryocytes and HEL cells. Evidence for an extensive homology to other RT Arg-Gly-Asp adhesion receptors."; RL Eur. J. Biochem. 171:87-93(1988). RN [12] RP PROTEIN SEQUENCE OF 487-501 AND 1026-1038. RX PubMed=3801670; RA Hiraiwa A., Matsukage A., Shiku H., Takahashi T., Naito K., Yamada K.; RT "Purification and partial amino acid sequence of human platelet membrane RT glycoproteins IIb and IIIa."; RL Blood 69:560-564(1987). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 753-1039 (ISOFORM 3), AND TISSUE SPECIFICITY. RX PubMed=9809974; RA Trikha M., Cai Y., Grignon D., Honn K.V.; RT "Identification of a novel truncated alphaIIb integrin."; RL Cancer Res. 58:4771-4775(1998). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 868-1039 (ISOFORM 1). RX PubMed=3479442; DOI=10.1172/jci113277; RA Bray P.F., Rosa J.P., Johnston G.I., Shiu D.T., Cook R.G., Lau C., RA Kan Y.W., McEver R.P., Shuman M.A.; RT "Platelet glycoprotein IIb. Chromosomal localization and tissue RT expression."; RL J. Clin. Invest. 80:1812-1817(1987). RN [15] RP PROTEIN SEQUENCE OF 903-922 AND 934-939. RX PubMed=2476117; DOI=10.1042/bj2610551; RA Calvete J.J., Alvarez M.V., Rivas G., Hew C.L., Henschen A., RA Gonzalez-Rodriguez J.; RT "Interchain and intrachain disulphide bonds in human platelet glycoprotein RT IIb. Localization of the epitopes for several monoclonal antibodies."; RL Biochem. J. 261:551-560(1989). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 938-997 (ISOFORMS 1 AND 2), AND TISSUE RP SPECIFICITY. RC TISSUE=Erythroleukemia; RX PubMed=2351656; DOI=10.1016/s0021-9258(19)38705-8; RA Bray P.F., Leung C.S.-I., Shuman M.A.; RT "Human platelets and megakaryocytes contain alternately spliced RT glycoprotein IIb mRNAs."; RL J. Biol. Chem. 265:9587-9590(1990). RN [17] RP PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-46; RP ASN-280; ASN-601 AND ASN-711. RX PubMed=2775232; DOI=10.1042/bj2610561; RA Calvete J.J., Henschen A., Gonzalez-Rodriguez J.; RT "Complete localization of the intrachain disulphide bonds and the N- RT glycosylation points in the alpha-subunit of human platelet glycoprotein RT IIb."; RL Biochem. J. 261:561-568(1989). RN [18] RP PARTIAL PROTEIN SEQUENCE, AND GLYCOSYLATION AT SER-878. RX PubMed=7688323; DOI=10.1016/0014-5793(93)80959-x; RA Calvete J.J., Muniz-Diaz E.; RT "Localization of an O-glycosylation site in the alpha-subunit of the human RT platelet integrin GPIIb/IIIa involved in Baka (HPA-3a) alloantigen RT expression."; RL FEBS Lett. 328:30-34(1993). RN [19] RP PROTEOLYTIC CLEAVAGE, AND PYROGLUTAMATE FORMATION AT GLN-891. RX PubMed=2226834; DOI=10.1016/0014-5793(90)80443-m; RA Calvete J.J., Schafer W., Henschen A., Gonzalez-Rodriguez J.; RT "Characterization of the beta-chain N-terminus heterogeneity and the alpha- RT chain C-terminus of human platelet GPIIb. Posttranslational cleavage RT sites."; RL FEBS Lett. 272:37-40(1990). RN [20] RP INTERACTION WITH CIB1. RC TISSUE=Fetal liver; RX PubMed=9030514; DOI=10.1074/jbc.272.8.4651; RA Naik U.P., Patel P.M., Parise L.V.; RT "Identification of a novel calcium-binding protein that interacts with the RT integrin alphaIIb cytoplasmic domain."; RL J. Biol. Chem. 272:4651-4654(1997). RN [21] RP FUNCTION, AND PROTEOLYTIC CLEAVAGE BY ELANE. RX PubMed=9111081; DOI=10.1074/jbc.272.17.11636; RA Si-Tahar M., Pidard D., Balloy V., Moniatte M., Kieffer N., RA Van Dorsselaer A., Chignard M.; RT "Human neutrophil elastase proteolytically activates the platelet integrin RT alphaIIbbeta3 through cleavage of the carboxyl terminus of the alphaIIb RT subunit heavy chain. Involvement in the potentiation of platelet RT aggregation."; RL J. Biol. Chem. 272:11636-11647(1997). RN [22] RP INTERACTION WITH CIB1. RX PubMed=10477286; DOI=10.1042/bj3420729; RA Shock D.D., Naik U.P., Brittain J.E., Alahari S.K., Sondek J., Parise L.V.; RT "Calcium-dependent properties of CIB binding to the integrin alphaIIb RT cytoplasmic domain and translocation to the platelet cytoskeleton."; RL Biochem. J. 342:729-735(1999). RN [23] RP MUTAGENESIS OF 1029-PRO-PRO-1030. RX PubMed=10212286; DOI=10.1074/jbc.274.18.12945; RA Leisner T.M., Wencel-Drake J.D., Wang W., Lam S.C.; RT "Bidirectional transmembrane modulation of integrin alphaIIbbeta3 RT conformations."; RL J. Biol. Chem. 274:12945-12949(1999). RN [24] RP FUNCTION. RX PubMed=12477717; DOI=10.1074/jbc.m211282200; RA Hermand P., Gane P., Huet M., Jallu V., Kaplan C., Sonneborn H.H., RA Cartron J.P., Bailly P.; RT "Red cell ICAM-4 is a novel ligand for platelet-activated alpha IIbbeta 3 RT integrin."; RL J. Biol. Chem. 278:4892-4898(2003). RN [25] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-601. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [26] RP INTERACTION WITH RNF181. RX PubMed=18331836; DOI=10.1016/j.bbrc.2008.02.142; RA Brophy T.M., Raab M., Daxecker H., Culligan K.G., Lehmann I., Chubb A.J., RA Treumann A., Moran N.; RT "RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif RT of platelet integrin alpha(IIb)beta3."; RL Biochem. Biophys. Res. Commun. 369:1088-1093(2008). RN [27] RP INTERACTION WITH CIB1. RX PubMed=21388953; DOI=10.1074/jbc.m110.179028; RA Huang H., Ishida H., Yamniuk A.P., Vogel H.J.; RT "Solution structures of Ca2+-CIB1 and Mg2+-CIB1 and their interactions with RT the platelet integrin alphaIIb cytoplasmic domain."; RL J. Biol. Chem. 286:17181-17192(2011). RN [28] RP INTERACTION WITH CIB1; CIB2; CIB3 AND CIB4. RX PubMed=22779914; DOI=10.1139/o2012-021; RA Huang H., Bogstie J.N., Vogel H.J.; RT "Biophysical and structural studies of the human calcium- and integrin- RT binding protein family: understanding their functional similarities and RT differences."; RL Biochem. Cell Biol. 90:646-656(2012). RN [29] RP INTERACTION WITH CIB1. RX PubMed=22283712; DOI=10.1021/ja2111306; RA Huang H., Vogel H.J.; RT "Structural basis for the activation of platelet integrin alphaIIbbeta3 by RT calcium- and integrin-binding protein 1."; RL J. Am. Chem. Soc. 134:3864-3872(2012). RN [30] RP INTERACTION WITH SELP. RX PubMed=37184585; DOI=10.26508/lsa.202201747; RA Takada Y.K., Simon S.I., Takada Y.; RT "The C-type lectin domain of CD62P (P-selectin) functions as an integrin RT ligand."; RL Life. Sci Alliance 6:0-0(2023). RN [31] {ECO:0007744|PDB:1TYE} RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 32-483 IN COMPLEX WITH ITGB3 AND RP CALCIUM, GLYCOSYLATION AT ASN-46, AND DISULFIDE BONDS. RX PubMed=15378069; DOI=10.1038/nature02976; RA Xiao T., Takagi J., Coller B.S., Wang J.H., Springer T.A.; RT "Structural basis for allostery in integrins and binding to fibrinogen- RT mimetic therapeutics."; RL Nature 432:59-67(2004). RN [32] {ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU} RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 32-989 IN COMPLEX WITH ITGB3 AND RP CALCIUM, GLYCOSYLATION AT ASN-46; ASN-280 AND ASN-601, AND DISULFIDE BONDS. RX PubMed=19111664; DOI=10.1016/j.molcel.2008.11.018; RA Zhu J., Luo B.H., Xiao T., Zhang C., Nishida N., Springer T.A.; RT "Structure of a complete integrin ectodomain in a physiologic resting state RT and activation and deactivation by applied forces."; RL Mol. Cell 32:849-861(2008). RN [33] RP REVIEW ON GT1 VARIANTS. RX PubMed=7878622; RA Bray P.F.; RT "Inherited diseases of platelet glycoproteins: considerations for rapid RT molecular characterization."; RL Thromb. Haemost. 72:492-502(1994). RN [34] RP VARIANT SER-874, POLYMORPHISM, AND DESCRIPTION OF ALLOANTIGEN SYSTEM BAK. RX PubMed=2350579; RA Lyman S., Aster R.H., Visentin G.P., Newman P.J.; RT "Polymorphism of human platelet membrane glycoprotein IIb associated with RT the Baka/Bakb alloantigen system."; RL Blood 75:2343-2348(1990). RN [35] RP POLYMORPHISM, DESCRIPTION OF ALLOANTIGEN SYSTEM BAK, AND INVOLVEMENT IN RP FMAIT2. RX PubMed=7197082; DOI=10.1111/j.1423-0410.1980.tb01845.x; RA von dem Borne A.E., von Riesz E., Verheugt F.W., ten Cate J.W., Koppe J.G., RA Engelfriet C.P., Nijenhuis L.E.; RT "Baka, a new platelet-specific antigen involved in neonatal allo-immune RT thrombocytopenia."; RL Vox Sang. 39:113-120(1980). RN [36] RP VARIANT GT1 ASP-273. RX PubMed=8282784; DOI=10.1172/jci116942; RA Poncz M., Rifat S., Coller B.S., Newman P.J., Shattil S.J., Parrella T., RA Fortina P., Bennett J.S.; RT "Glanzmann thrombasthenia secondary to a Gly273-->Asp mutation adjacent to RT the first calcium-binding domain of platelet glycoprotein IIb."; RL J. Clin. Invest. 93:172-179(1994). RN [37] RP VARIANT GT1 ASP-449. RX PubMed=7508443; DOI=10.1016/s0021-9258(17)41800-x; RA Wilcox D.A., Wautier J.-L., Pidard D., Newman P.J.; RT "A single amino acid substitution flanking the fourth calcium binding RT domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin RT complex."; RL J. Biol. Chem. 269:4450-4457(1994). RN [38] RP VARIANT MET-868, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=7620155; RA Noris P., Simsek S., de Bruijne-Admiraal L.G., Porcelijn L., Huiskes E., RA van der Vlist G.J., van Leeuwen E.F., van der Schoot C.E., RA von dem Borne A.E.; RT "Max(a), a new low-frequency platelet-specific antigen localized on RT glycoprotein IIb, is associated with neonatal alloimmune RT thrombocytopenia."; RL Blood 86:1019-1026(1995). RN [39] RP VARIANT GT1 HIS-358. RX PubMed=7706461; DOI=10.1172/jci117828; RA Wilcox D.A., Paddock C.M., Lyman S., Gill J.C., Newman P.J.; RT "Glanzmann thrombasthenia resulting from a single amino acid substitution RT between the second and third calcium-binding domains of GPIIb. Role of the RT GPIIb amino terminus in integrin subunit association."; RL J. Clin. Invest. 95:1553-1560(1995). RN [40] RP VARIANT GT1 456-VAL-ASP-457 DEL, AND CHARACTERIZATION OF VARIANT GT1 RP 456-VAL-ASP-457 DEL. RX PubMed=8704171; RA Basani R.B., Vilaire G., Shattil S.J., Kolodziej M.A., Bennett J.S., RA Poncz M.; RT "Glanzmann thrombasthenia due to a two amino acid deletion in the fourth RT calcium-binding domain of alpha IIb: demonstration of the importance of RT calcium-binding domains in the conformation of alpha IIb beta 3."; RL Blood 88:167-173(1996). RN [41] RP VARIANTS GT1 ILE-207; THR-596 AND GLN-1026. RX PubMed=9215749; DOI=10.1006/bcmd.1997.0117; RA French D.L., Coller B.S.; RT "Hematologically important mutations: Glanzmann thrombasthenia."; RL Blood Cells Mol. Dis. 23:39-51(1997). RN [42] RP VARIANT GT1 PRO-214, AND CHARACTERIZATION OF VARIANT GT1 PRO-214. RX PubMed=9473221; RA Grimaldi C.M., Chen F., Wu C., Weiss H.J., Coller B.S., French D.L.; RT "Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with RT both quantitative and qualitative abnormalities in GPIIb/IIIa."; RL Blood 91:1562-1571(1998). RN [43] RP VARIANT GT1 PRO-778. RX PubMed=9763559; RA Tadokoro S., Tomiyama Y., Honda S., Arai M., Yamamoto N., Shiraga M., RA Kosugi S., Kanakura Y., Kurata Y., Matsuzawa Y.; RT "A Gln747-->Pro substitution in the IIb subunit is responsible for a RT moderate IIbbeta3 deficiency in Glanzmann thrombasthenia."; RL Blood 92:2750-2758(1998). RN [44] RP VARIANT BDPLT16 GLN-1026, AND CHARACTERIZATION OF VARIANT BDPLT16 GLN-1026. RX PubMed=9834222; RA Peyruchaud O., Nurden A.T., Milet S., Macchi L., Pannochia A., Bray P.F., RA Kieffer N., Bourre F.; RT "R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic RT domain of the integrin IIb subunit in a patient with a Glanzmann's RT thrombasthenia-like syndrome."; RL Blood 92:4178-4187(1998). RN [45] RP VARIANTS GT1 SER-320; LYS-355 AND PRO-778. RX PubMed=9722314; DOI=10.1046/j.1365-2141.1998.00824.x; RA Ambo H., Kamata T., Handa M., Kawai Y., Oda A., Murata M., Takada Y., RA Ikeda Y.; RT "Novel point mutations in the alphaIIb subunit (Phe289-->Ser, Glu324-->Lys RT and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese RT patients."; RL Br. J. Haematol. 102:829-840(1998). RN [46] RP VARIANTS GT1 LYS-355 AND THR-596. RX PubMed=9734640; DOI=10.1046/j.1365-2141.1998.00852.x; RA Ruan J., Peyruchaud O., Alberio L., Valles G., Clemetson K., Bourre F., RA Nurden A.T.; RT "Double heterozygosity of the GPIIb gene in a Swiss patient with RT Glanzmann's thrombasthenia."; RL Br. J. Haematol. 102:918-925(1998). RN [47] RP VARIANTS ILE-40; SER-874 AND ASN-968. RX PubMed=10391209; DOI=10.1038/10290; RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., RA Lander E.S.; RT "Characterization of single-nucleotide polymorphisms in coding regions of RT human genes."; RL Nat. Genet. 22:231-238(1999). RN [48] RP VARIANT GT1 ARG-705, AND CHARACTERIZATION OF VARIANT GT1 ARG-705. RX PubMed=9920835; RA Gonzalez-Manchon C., Fernandez-Pinel M., Arias-Salgado E.G., Ferrer M., RA Alvarez M.-V., Garcia-Munoz S., Ayuso M.S., Parrilla R.; RT "Molecular genetic analysis of a compound heterozygote for the glycoprotein RT (GP) IIb gene associated with Glanzmann's thrombasthenia: disruption of the RT 674-687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa RT complexes."; RL Blood 93:866-875(1999). RN [49] RP ERRATUM OF PUBMED:9920835. RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., RA Lander E.S.; RL Nat. Genet. 23:373-373(1999). RN [50] RP VARIANTS GT1 ALA-176 AND LEU-176. RX PubMed=10607701; RA Basani R.B., French D.L., Vilaire G., Brown D.L., Chen F., Coller B.S., RA Derrick J.M., Gartner T.K., Bennett J.S., Poncz M.; RT "A naturally occurring mutation near the amino terminus of alphaIIb defines RT a new region involved in ligand binding to alphaIIbbeta3."; RL Blood 95:180-188(2000). RN [51] RP VARIANTS GT1 TRP-161; LEU-222; ARG-412 AND PRO-847. RX PubMed=11798398; DOI=10.1080/095371001317126383; RA Vinciguerra C., Bordet J.C., Beaune G., Grenier C., Dechavanne M., RA Negrier C.; RT "Description of 10 new mutations in platelet glycoprotein IIb (alphaIIb) RT and glycoprotein IIIa (beta3) genes."; RL Platelets 12:486-495(2001). RN [52] RP VARIANT GT1 PRO-86, AND CHARACTERIZATION OF VARIANT GT1 PRO-86. RX PubMed=12181054; DOI=10.1046/j.1365-2141.2002.03678.x; RA Tanaka S., Hayashi T., Hori Y., Terada C., Han K.S., Ahn H.S., Bourre F., RA Tani Y.; RT "A Leu55 to Pro substitution in the integrin alphaIIb is responsible for a RT case of Glanzmann's thrombasthenia."; RL Br. J. Haematol. 118:833-835(2002). RN [53] RP VARIANTS GT1 VAL-139; ALA-176; GLU-267; ASP-380; THR-405; ASP-581; ARG-705; RP VAL-752 AND PRO-755. RX PubMed=12083483; RA D'Andrea G., Colaizzo D., Vecchione G., Grandone E., Di Minno G., RA Margaglione M.; RT "Glanzmann's thrombasthenia: identification of 19 new mutations in 30 RT patients."; RL Thromb. Haemost. 87:1034-1042(2002). RN [54] RP VARIANTS GT1 PHE-329 AND THR-405, AND CHARACTERIZATION OF VARIANTS GT1 RP PHE-329 AND THR-405. RX PubMed=12424194; DOI=10.1182/blood-2002-07-2266; RA Mitchell W.B., Li J.H., Singh F., Michelson A.D., Bussel J., Coller B.S., RA French D.L.; RT "Two novel mutations in the alpha IIb calcium-binding domains identify RT hydrophobic regions essential for alpha IIbbeta 3 biogenesis."; RL Blood 101:2268-2276(2003). RN [55] RP VARIANT GT1 HIS-174, AND CHARACTERIZATION OF VARIANT GT1 HIS-174. RX PubMed=12506038; DOI=10.1182/blood-2002-07-2144; RA Kiyoi T., Tomiyama Y., Honda S., Tadokoro S., Arai M., Kashiwagi H., RA Kosugi S., Kato H., Kurata Y., Matsuzawa Y.; RT "A naturally occurring Tyr143His alpha IIb mutation abolishes alpha IIb RT beta 3 function for soluble ligands but retains its ability for mediating RT cell adhesion and clot retraction: comparison with other mutations causing RT ligand-binding defects."; RL Blood 101:3485-3491(2003). RN [56] RP POLYMORPHISM. RX PubMed=14516468; DOI=10.1046/j.1423-0410.2003.00331.x; RA Metcalfe P., Watkins N.A., Ouwehand W.H., Kaplan C., Newman P., RA Kekomaki R., De Haas M., Aster R., Shibata Y., Smith J., Kiefel V., RA Santoso S.; RT "Nomenclature of human platelet antigens."; RL Vox Sang. 85:240-245(2003). RN [57] RP VARIANT GT1 MET-982, CHARACTERIZATION OF VARIANT GT1 MET-982, AND VARIANT RP THR-989. RX PubMed=15099289; DOI=10.1046/j.1538-7836.2004.00711.x; RA Nurden A.T., Breillat C., Jacquelin B., Combrie R., Freedman J., RA Blanchette V.S., Schmugge M., Rand M.L.; RT "Triple heterozygosity in the integrin alphaIIb subunit in a patient with RT Glanzmann's thrombasthenia."; RL J. Thromb. Haemost. 2:813-819(2004). RN [58] RP VARIANT GT1 CYS-202, AND CHARACTERIZATION OF VARIANT GT1 CYS-202. RX PubMed=15219201; DOI=10.1111/j.1538-7836.2004.00758.x; RA Rosenberg N., Landau M., Luboshitz J., Rechavi G., Seligsohn U.; RT "A novel Phe171Cys mutation in integrin alpha causes Glanzmann RT thrombasthenia by abrogating alphaIIbbeta3 complex formation."; RL J. Thromb. Haemost. 2:1167-1175(2004). RN [59] RP POLYMORPHISM, DESCRIPTION OF ALLOANTIGEN SYSTEM BAK, AND INVOLVEMENT IN RP FMAIT2. RX PubMed=15569236; DOI=10.1111/j.1365-3148.2004.00537.x; RA Kataoka S., Kobayashi H., Chiba K., Nakamura M., Shinada S., Morita S., RA Lin M., Shibata Y.; RT "Neonatal alloimmune thrombocytopenia due to an antibody against a labile RT component of human platelet antigen-3b (Bak b)."; RL Transfus. Med. 14:419-423(2004). RN [60] RP VARIANT GT1 LEU-943, AND CHARACTERIZATION OF VARIANT GT1 LEU-943. RX PubMed=17018384; RA Jayo A., Pabon D., Lastres P., Jimenez-Yuste V., Gonzalez-Manchon C.; RT "Type II Glanzmann thrombasthenia in a compound heterozygote for the alpha RT IIb gene. A novel missense mutation in exon 27."; RL Haematologica 91:1352-1359(2006). RN [61] RP VARIANTS GT1 THR-405; THR-596; ARG-705; PRO-778; PHE-934; LEU-957; MET-982 RP AND THR-989, CHARACTERIZATION OF VARIANTS GT1 PHE-934 AND LEU-957, AND RP SUBCELLULAR LOCATION. RX PubMed=20020534; DOI=10.1002/humu.21179; RA Jallu V., Dusseaux M., Panzer S., Torchet M.F., Hezard N., Goudemand J., RA de Brevern A.G., Kaplan C.; RT "AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, RT effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure- RT function."; RL Hum. Mutat. 31:237-246(2010). RN [62] RP VARIANT MET-650, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=19821948; DOI=10.1111/j.1537-2995.2009.02438.x; RA Peterson J.A., Gitter M.L., Kanack A., Curtis B., McFarland J., Bougie D., RA Aster R.; RT "New low-frequency platelet glycoprotein polymorphisms associated with RT neonatal alloimmune thrombocytopenia."; RL Transfusion 50:324-333(2010). RN [63] RP VARIANT LEU-771, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=23305224; DOI=10.1111/trf.12067; RA Poles A., Wozniak M.J., Walser P., Ridgwell K., Fitzgerald J., Green A., RA Gilmore R., Lucas G.; RT "A V740L mutation in glycoprotein IIb defines a novel epitope (War) RT associated with fetomaternal alloimmune thrombocytopenia."; RL Transfusion 53:1965-1973(2013). RN [64] RP VARIANT BDPLT16 TRP-1026, AND CHARACTERIZATION OF VARIANT BDPLT16 TRP-1026. RX PubMed=21454453; DOI=10.1182/blood-2010-12-323691; RA Kunishima S., Kashiwagi H., Otsu M., Takayama N., Eto K., Onodera M., RA Miyajima Y., Takamatsu Y., Suzumiya J., Matsubara K., Tomiyama Y., RA Saito H.; RT "Heterozygous ITGA2B R995W mutation inducing constitutive activation of the RT alphaIIbbeta3 receptor affects proplatelet formation and causes congenital RT macrothrombocytopenia."; RL Blood 117:5479-5484(2011). CC -!- FUNCTION: Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for CC fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and CC vitronectin. It recognizes the sequence R-G-D in a wide array of CC ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in CC fibrinogen gamma chain (By similarity). Following activation integrin CC alpha-IIb/beta-3 brings about platelet/platelet interaction through CC binding of soluble fibrinogen (PubMed:9111081). This step leads to CC rapid platelet aggregation which physically plugs ruptured endothelial CC cell surface (By similarity). Integrin ITGA2B:ITGB3 is also the CC receptor of erythrocyte-specific ICAM4 ligand involved in heterotypic CC cell-cell adhesion between erythrocytes and activated platelets CC (PubMed:12477717). {ECO:0000250|UniProtKB:O54890, CC ECO:0000269|PubMed:12477717, ECO:0000269|PubMed:9111081}. CC -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. The alpha subunit CC is composed of a heavy and a light chain linked by a disulfide bond. CC Alpha-IIb associates with beta-3. Directly interacts with RNF181. CC Interacts (via C-terminus cytoplasmic tail region) with CIB1; the CC interaction is direct and calcium-dependent. Interacts (via C-terminus CC cytoplasmic tail region) with CIB2, CIB3 and CIB4; the interactions are CC stabilized/increased in a calcium and magnesium-dependent manner. CC ITGA2B:ITGB3 interacts with PPIA/CYPA; the interaction is ROS and CC PPIase activity-dependent and is increased in the presence of thrombin CC (By similarity). ITGA2B:ITGB3 interacts with SELP (via C-type lectin CC domain); the interaction mediates cell-cell interaction and adhesion CC (PubMed:37184585). {ECO:0000250|UniProtKB:Q9QUM0, CC ECO:0000269|PubMed:10477286, ECO:0000269|PubMed:18331836, CC ECO:0000269|PubMed:21388953, ECO:0000269|PubMed:22283712, CC ECO:0000269|PubMed:22779914, ECO:0000269|PubMed:37184585, CC ECO:0000269|PubMed:9030514}. CC -!- INTERACTION: CC P08514; P08514: ITGA2B; NbExp=7; IntAct=EBI-702693, EBI-702693; CC P08514; P05106: ITGB3; NbExp=12; IntAct=EBI-702693, EBI-702847; CC P08514-1; P21333: FLNA; NbExp=3; IntAct=EBI-15805658, EBI-350432; CC P08514-1; P05106: ITGB3; NbExp=4; IntAct=EBI-15805658, EBI-702847; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20020534}; CC Single-pass type I membrane protein {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P08514-1; Sequence=Displayed; CC Name=2; CC IsoId=P08514-2; Sequence=VSP_002737; CC Name=3; Synonyms=tr-alpha-IIb {ECO:0000303|PubMed:9809974}; CC IsoId=P08514-3; Sequence=VSP_002736; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in platelets CC and megakaryocytes, but not in reticulocytes. Not detected in Jurkat, CC nor in U937 cell lines (PubMed:2351656). Isoform 3 is expressed in CC prostate adenocarcinoma, as well as in several erythroleukemia, CC prostate adenocarcinoma and melanoma cell lines, including PC-3, DU- CC 145, HEL, WM983A, WM983B and WM35. Not detected in platelets, nor in CC normal prostate (at protein level) (PubMed:9809974). CC {ECO:0000269|PubMed:2351656, ECO:0000269|PubMed:9809974}. CC -!- PTM: [Integrin alpha-IIb heavy chain]: Cleaved by ELANE; the cleavage CC promotes activation of platelet fibrinogen receptor integrin alpha- CC IIb/beta-3. {ECO:0000269|PubMed:9111081}. CC -!- POLYMORPHISM: Genetic variants in ITGA2B define different platelet- CC specific alloantigen systems that are involved in fetomaternal CC alloimmune thromobocytopenia. Alloantigen system Bak, also known as CC HPA-3 or Lek, is characterized by variant p.Ser874Ile (alloantigen CC Bak(a) or Lek(a) or HPA-3a) and variant p.Ile874Ser (alloantigen Bak(b) CC or Lek(b) or HPA-3b) (PubMed:2350579, PubMed:7197082, PubMed:14516468, CC PubMed:15569236). Additional platelet-specific alloantigens involved in CC fetomaternal alloimmune thromobocytopenia are known (PubMed:7620155, CC PubMed:19821948, PubMed:23305224). {ECO:0000269|PubMed:14516468, CC ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:19821948, CC ECO:0000269|PubMed:23305224, ECO:0000269|PubMed:2350579, CC ECO:0000269|PubMed:7197082, ECO:0000269|PubMed:7620155}. CC -!- DISEASE: Fetomaternal alloimmune thrombocytopenia 2 (FMAIT2) CC [MIM:621266]: A form of fetomaternal alloimmune thrombocytopenia, a CC bleeding disorder caused by maternal/fetal incompatibility for platelet CC alloantigens and arising when a fetus inherits a paternal platelet CC alloantigen that the mother does not possess. During pregnancy, as well CC as parturition, maternal alloantibodies against paternally-inherited CC platelet antigens cause destruction of fetal platelets and CC fetal/neonatal thrombocytopenia. Disease severity and clinical features CC in the fetus or neonate are heterogeneous. While most fetuses remain CC asymptomatic, others develop skin bleedings (petechiae) or internal CC organ bleedings. The most severe symptom is intracranial hemorrhage CC that is mostly discovered postnatally and can result in neurological CC complications or even death. Mothers with circulating platelet CC alloantibodies may experience miscarriage. FMAIT2 transmission pattern CC is consistent with autosomal dominant paternal inheritance. CC {ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:19821948, CC ECO:0000269|PubMed:23305224, ECO:0000269|PubMed:7197082, CC ECO:0000269|PubMed:7620155}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Glanzmann thrombasthenia 1 (GT1) [MIM:273800]: A form of CC Glanzmann thrombasthenia, a disorder characterized by failure of CC platelet aggregation, absent or diminished clot retraction, and CC mucocutaneous bleeding of mild-to-moderate severity. Glanzmann CC thrombasthenia has been classified into clinical types I and II. In CC type I, platelets show absence of glycoprotein IIb-IIIa complexes at CC their surface and lack fibrinogen and clot retraction capability. In CC type II, the platelets express glycoprotein IIb-IIIa complexes at CC reduced levels, have detectable amounts of fibrinogen, and have low or CC moderate clot retraction capability. GT1 inheritance is autosomal CC recessive. {ECO:0000269|PubMed:10607701, ECO:0000269|PubMed:11798398, CC ECO:0000269|PubMed:12083483, ECO:0000269|PubMed:12181054, CC ECO:0000269|PubMed:12424194, ECO:0000269|PubMed:12506038, CC ECO:0000269|PubMed:15099289, ECO:0000269|PubMed:15219201, CC ECO:0000269|PubMed:17018384, ECO:0000269|PubMed:20020534, CC ECO:0000269|PubMed:7508443, ECO:0000269|PubMed:7706461, CC ECO:0000269|PubMed:8282784, ECO:0000269|PubMed:8704171, CC ECO:0000269|PubMed:9215749, ECO:0000269|PubMed:9473221, CC ECO:0000269|PubMed:9722314, ECO:0000269|PubMed:9734640, CC ECO:0000269|PubMed:9763559, ECO:0000269|PubMed:9920835}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Bleeding disorder, platelet-type, 16 (BDPLT16) [MIM:187800]: CC An autosomal dominant form of congenital macrothrombocytopenia CC associated with platelet anisocytosis. It is a disorder of platelet CC production. Affected individuals may have no or only mildly increased CC bleeding tendency. In vitro studies show mild platelet functional CC abnormalities. {ECO:0000269|PubMed:21454453, CC ECO:0000269|PubMed:9834222}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the integrin alpha chain family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J02764; AAA60114.1; -; mRNA. DR EMBL; M34480; AAA35926.1; -; mRNA. DR EMBL; M34344; AAA53150.1; -; Genomic_DNA. DR EMBL; M33319; AAA53150.1; JOINED; Genomic_DNA. DR EMBL; M33320; AAA53150.1; JOINED; Genomic_DNA. DR EMBL; AK315335; BAG37735.1; -; mRNA. DR EMBL; AC003043; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117443; AAI17444.1; -; mRNA. DR EMBL; BC126442; AAI26443.1; -; mRNA. DR EMBL; M22568; AAA52587.1; -; Genomic_DNA. DR EMBL; M22569; AAA52588.1; -; Genomic_DNA. DR EMBL; X06831; CAA29987.1; -; mRNA. DR EMBL; AF098114; AAC98507.1; -; mRNA. DR EMBL; M18085; AAA52597.1; -; mRNA. DR EMBL; M54799; AAA52599.1; -; Genomic_DNA. DR CCDS; CCDS32665.1; -. [P08514-1] DR PIR; A34269; A34269. DR RefSeq; NP_000410.2; NM_000419.5. [P08514-1] DR PDB; 1DPK; NMR; -; A=1020-1039. DR PDB; 1DPQ; NMR; -; A=1020-1039. DR PDB; 1KUP; NMR; -; A=1018-1028. DR PDB; 1KUZ; NMR; -; A=1018-1028. DR PDB; 1M8O; NMR; -; A=1020-1039. DR PDB; 1S4W; NMR; -; A=1020-1039. DR PDB; 1TYE; X-ray; 2.90 A; A/C/E=32-483. DR PDB; 2K1A; NMR; -; A=989-1029. DR PDB; 2K9J; NMR; -; A=989-1029. DR PDB; 2KNC; NMR; -; A=991-1039. DR PDB; 2MTP; NMR; -; B=1019-1039. DR PDB; 2N9Y; NMR; -; A=989-1029. DR PDB; 2VC2; X-ray; 3.10 A; A=32-483. DR PDB; 2VDK; X-ray; 2.80 A; A=32-483. DR PDB; 2VDL; X-ray; 2.75 A; A=32-483. DR PDB; 2VDM; X-ray; 2.90 A; A=32-483. DR PDB; 2VDN; X-ray; 2.90 A; A=32-483. DR PDB; 2VDO; X-ray; 2.51 A; A=32-483. DR PDB; 2VDP; X-ray; 2.80 A; A=32-483. DR PDB; 2VDQ; X-ray; 2.59 A; A=32-483. DR PDB; 2VDR; X-ray; 2.40 A; A=32-483. DR PDB; 3FCS; X-ray; 2.55 A; A/C=32-989. DR PDB; 3FCU; X-ray; 2.90 A; A/C/E=32-488. DR PDB; 3NID; X-ray; 2.30 A; A/C=32-488. DR PDB; 3NIF; X-ray; 2.40 A; A/C=32-488. DR PDB; 3NIG; X-ray; 2.25 A; A/C=32-488. DR PDB; 3T3M; X-ray; 2.60 A; A/C=32-488. DR PDB; 3T3P; X-ray; 2.20 A; A/C=32-488. DR PDB; 3ZDX; X-ray; 2.45 A; A/C=32-488. DR PDB; 3ZDY; X-ray; 2.45 A; A/C=32-488. DR PDB; 3ZDZ; X-ray; 2.75 A; A/C=32-488. DR PDB; 3ZE0; X-ray; 2.95 A; A/C=32-488. DR PDB; 3ZE1; X-ray; 3.00 A; A/C=32-488. DR PDB; 3ZE2; X-ray; 2.35 A; A/C=32-488. DR PDB; 4CAK; EM; 20.50 A; A=32-989. DR PDB; 4Z7N; X-ray; 2.60 A; A/C=32-486. DR PDB; 4Z7O; X-ray; 2.85 A; A/C=32-486. DR PDB; 4Z7Q; X-ray; 2.70 A; A/C=32-485. DR PDB; 5HDB; X-ray; 2.70 A; A/C=32-485. DR PDB; 6V4P; EM; 2.80 A; A=1-963. DR PDB; 7KN0; NMR; -; A=989-1029. DR PDB; 7L8P; X-ray; 2.35 A; A/C=32-488. DR PDB; 7LA4; EM; 3.30 A; A=1-1039. DR PDB; 7SC4; X-ray; 1.85 A; A/B=1019-1039. DR PDB; 7SFT; NMR; -; B=1019-1039. DR PDB; 7TCT; X-ray; 2.50 A; A/C=32-488. DR PDB; 7TD8; X-ray; 2.60 A; A/C=32-484. DR PDB; 7THO; X-ray; 2.75 A; A/C=32-485. DR PDB; 7TMZ; X-ray; 2.20 A; A/C=32-485. DR PDB; 7TPD; X-ray; 2.60 A; A/C=32-488. DR PDB; 7U60; X-ray; 2.55 A; A/C=32-486. DR PDB; 7U9F; X-ray; 2.70 A; A/C=32-485. DR PDB; 7U9V; X-ray; 2.25 A; A/C=32-485. DR PDB; 7UBR; X-ray; 2.05 A; A/C=32-485. DR PDB; 7UCY; X-ray; 2.35 A; A/C=32-488. DR PDB; 7UDG; X-ray; 2.80 A; A/C=32-488. DR PDB; 7UDH; X-ray; 2.00 A; A/C=32-488. DR PDB; 7UE0; X-ray; 2.74 A; A/C=32-488. DR PDB; 7UFH; X-ray; 3.00 A; A/C=32-488. DR PDB; 7UH8; X-ray; 2.75 A; A/C=32-488. DR PDB; 7UJE; X-ray; 2.50 A; A/C=32-485. DR PDB; 7UJK; X-ray; 2.43 A; A/C=32-488. DR PDB; 7UK9; X-ray; 2.60 A; A/C=32-488. DR PDB; 7UKO; X-ray; 2.60 A; A/C=32-488. DR PDB; 7UKP; X-ray; 2.80 A; A/C=32-488. DR PDB; 7UKT; X-ray; 2.37 A; A/C=32-488. DR PDB; 8GCD; EM; 2.97 A; A=1-1039. DR PDB; 8GCE; EM; 3.12 A; A=1-1039. DR PDB; 8T2U; EM; 3.10 A; A=32-1039. DR PDB; 8T2V; EM; 3.40 A; A=32-1039. DR PDB; 9AXL; EM; 3.30 A; A=1-1039. DR PDB; 9DAO; EM; 2.80 A; A=32-1039. DR PDB; 9DAX; EM; 3.30 A; A=32-1039. DR PDB; 9DEQ; EM; 4.10 A; A=32-1039. DR PDB; 9DER; EM; 3.90 A; A=32-1039. DR PDBsum; 1DPK; -. DR PDBsum; 1DPQ; -. DR PDBsum; 1KUP; -. DR PDBsum; 1KUZ; -. DR PDBsum; 1M8O; -. DR PDBsum; 1S4W; -. DR PDBsum; 1TYE; -. DR PDBsum; 2K1A; -. DR PDBsum; 2K9J; -. DR PDBsum; 2KNC; -. DR PDBsum; 2MTP; -. DR PDBsum; 2N9Y; -. DR PDBsum; 2VC2; -. DR PDBsum; 2VDK; -. DR PDBsum; 2VDL; -. DR PDBsum; 2VDM; -. DR PDBsum; 2VDN; -. DR PDBsum; 2VDO; -. DR PDBsum; 2VDP; -. DR PDBsum; 2VDQ; -. DR PDBsum; 2VDR; -. DR PDBsum; 3FCS; -. DR PDBsum; 3FCU; -. DR PDBsum; 3NID; -. DR PDBsum; 3NIF; -. DR PDBsum; 3NIG; -. DR PDBsum; 3T3M; -. DR PDBsum; 3T3P; -. DR PDBsum; 3ZDX; -. DR PDBsum; 3ZDY; -. DR PDBsum; 3ZDZ; -. DR PDBsum; 3ZE0; -. DR PDBsum; 3ZE1; -. DR PDBsum; 3ZE2; -. DR PDBsum; 4CAK; -. DR PDBsum; 4Z7N; -. DR PDBsum; 4Z7O; -. DR PDBsum; 4Z7Q; -. DR PDBsum; 5HDB; -. DR PDBsum; 6V4P; -. DR PDBsum; 7KN0; -. DR PDBsum; 7L8P; -. DR PDBsum; 7LA4; -. DR PDBsum; 7SC4; -. DR PDBsum; 7SFT; -. DR PDBsum; 7TCT; -. DR PDBsum; 7TD8; -. DR PDBsum; 7THO; -. DR PDBsum; 7TMZ; -. DR PDBsum; 7TPD; -. DR PDBsum; 7U60; -. DR PDBsum; 7U9F; -. DR PDBsum; 7U9V; -. DR PDBsum; 7UBR; -. DR PDBsum; 7UCY; -. DR PDBsum; 7UDG; -. DR PDBsum; 7UDH; -. DR PDBsum; 7UE0; -. DR PDBsum; 7UFH; -. DR PDBsum; 7UH8; -. DR PDBsum; 7UJE; -. DR PDBsum; 7UJK; -. DR PDBsum; 7UK9; -. DR PDBsum; 7UKO; -. DR PDBsum; 7UKP; -. DR PDBsum; 7UKT; -. DR PDBsum; 8GCD; -. DR PDBsum; 8GCE; -. DR PDBsum; 8T2U; -. DR PDBsum; 8T2V; -. DR PDBsum; 9AXL; -. DR PDBsum; 9DAO; -. DR PDBsum; 9DAX; -. DR PDBsum; 9DEQ; -. DR PDBsum; 9DER; -. DR AlphaFoldDB; P08514; -. DR BMRB; P08514; -. DR EMDB; EMD-21044; -. DR EMDB; EMD-2281; -. DR EMDB; EMD-23245; -. DR EMDB; EMD-29931; -. DR EMDB; EMD-29932; -. DR EMDB; EMD-40988; -. DR EMDB; EMD-40989; -. DR EMDB; EMD-43046; -. DR EMDB; EMD-43969; -. DR EMDB; EMD-43983; -. DR EMDB; EMD-46695; -. DR EMDB; EMD-46701; -. DR EMDB; EMD-46793; -. DR EMDB; EMD-46794; -. DR SMR; P08514; -. DR BioGRID; 109881; 22. DR ComplexPortal; CPX-1799; Integrin alphaIIb-beta3 complex. DR CORUM; P08514; -. DR DIP; DIP-68N; -. DR FunCoup; P08514; 856. DR IntAct; P08514; 6. DR MINT; P08514; -. DR STRING; 9606.ENSP00000262407; -. DR BindingDB; P08514; -. DR ChEMBL; CHEMBL212; -. DR DrugBank; DB00054; Abciximab. DR DrugBank; DB00063; Eptifibatide. DR DrugBank; DB06472; Fradafiban. DR DrugBank; DB09526; Hydroquinone. DR DrugBank; DB04863; Lefradafiban. DR DrugBank; DB00775; Tirofiban. DR DrugCentral; P08514; -. DR GuidetoPHARMACOLOGY; 2441; -. DR GlyCosmos; P08514; 8 sites, 4 glycans. DR GlyGen; P08514; 8 sites, 4 O-linked glycans (2 sites). DR iPTMnet; P08514; -. DR PhosphoSitePlus; P08514; -. DR BioMuta; ITGA2B; -. DR DMDM; 226694183; -. DR OGP; P08514; -. DR jPOST; P08514; -. DR MassIVE; P08514; -. DR PaxDb; 9606-ENSP00000262407; -. DR PeptideAtlas; P08514; -. DR ProteomicsDB; 52113; -. [P08514-1] DR ProteomicsDB; 52114; -. [P08514-2] DR ProteomicsDB; 52115; -. [P08514-3] DR TopDownProteomics; P08514-1; -. [P08514-1] DR ABCD; P08514; 23 sequenced antibodies. DR Antibodypedia; 4350; 2013 antibodies from 53 providers. DR DNASU; 3674; -. DR Ensembl; ENST00000262407.6; ENSP00000262407.5; ENSG00000005961.20. [P08514-1] DR GeneID; 3674; -. DR KEGG; hsa:3674; -. DR MANE-Select; ENST00000262407.6; ENSP00000262407.5; NM_000419.5; NP_000410.2. DR UCSC; uc002igt.2; human. [P08514-1] DR AGR; HGNC:6138; -. DR ClinPGx; PA29938; -. DR CTD; 3674; -. DR DisGeNET; 3674; -. DR GeneCards; ITGA2B; -. DR HGNC; HGNC:6138; ITGA2B. DR HPA; ENSG00000005961; Tissue enhanced (bone marrow, epididymis, lymphoid tissue). DR MalaCards; ITGA2B; -. DR MIM; 187800; phenotype. DR MIM; 273800; phenotype. DR MIM; 607759; gene. DR MIM; 621266; phenotype. DR OpenTargets; ENSG00000005961; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 853; Fetal and neonatal alloimmune thrombocytopenia. DR Orphanet; 849; Glanzmann thrombasthenia. DR VEuPathDB; HostDB:ENSG00000005961; -. DR eggNOG; KOG3637; Eukaryota. DR GeneTree; ENSGT00940000160724; -. DR HOGENOM; CLU_004111_4_1_1; -. DR InParanoid; P08514; -. DR OMA; LQMDTAN; -. DR OrthoDB; 5317514at2759; -. DR PAN-GO; P08514; 8 GO annotations based on evolutionary models. DR PhylomeDB; P08514; -. DR PathwayCommons; P08514; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-3000178; ECM proteoglycans. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins. DR Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins. DR Reactome; R-HSA-445144; Signal transduction by L1. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR SignaLink; P08514; -. DR SIGNOR; P08514; -. DR Agora; ENSG00000005961; -. DR BioGRID-ORCS; 3674; 20 hits in 1173 CRISPR screens. DR ChiTaRS; ITGA2B; human. DR EvolutionaryTrace; P08514; -. DR GeneWiki; ITGA2B; -. DR GenomeRNAi; 3674; -. DR Pharos; P08514; Tclin. DR PRO; PR:P08514; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P08514; protein. DR Bgee; ENSG00000005961; Expressed in monocyte and 130 other cell types or tissues. DR ExpressionAtlas; P08514; baseline and differential. DR GO; GO:0072562; C:blood microparticle; HDA:UniProtKB. DR GO; GO:0009986; C:cell surface; HDA:UniProtKB. DR GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl. DR GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IEA:Ensembl. DR GO; GO:0070442; C:integrin alphaIIb-beta3 complex; IDA:UniProt. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031092; C:platelet alpha granule membrane; TAS:Reactome. DR GO; GO:0050840; F:extracellular matrix binding; IEA:Ensembl. DR GO; GO:0070051; F:fibrinogen binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0038023; F:signaling receptor activity; IBA:GO_Central. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central. DR GO; GO:0007160; P:cell-matrix adhesion; NAS:ComplexPortal. DR GO; GO:0007229; P:integrin-mediated signaling pathway; HDA:UniProtKB. DR GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl. DR DisProt; DP01841; -. DR FunFam; 2.60.40.1510:FF:000001; Integrin alpha V; 1. DR FunFam; 2.130.10.130:FF:000012; Integrin alpha-IIb; 1. DR FunFam; 1.20.5.930:FF:000001; Integrin subunit alpha V; 1. DR FunFam; 2.60.40.1460:FF:000001; Integrin, alpha V; 1. DR Gene3D; 1.20.5.930; Bicelle-embedded integrin alpha(iib) transmembrane segment; 1. DR Gene3D; 2.130.10.130; Integrin alpha, N-terminal; 1. DR Gene3D; 2.60.40.1460; Integrin domains. Chain A, domain 2; 1. DR Gene3D; 2.60.40.1510; ntegrin, alpha v. Chain A, domain 3; 1. DR Gene3D; 2.60.40.1530; ntegrin, alpha v. Chain A, domain 4; 1. DR InterPro; IPR013517; FG-GAP. DR InterPro; IPR013519; Int_alpha_beta-p. DR InterPro; IPR000413; Integrin_alpha. DR InterPro; IPR018184; Integrin_alpha_C_CS. DR InterPro; IPR013649; Integrin_alpha_Ig-like_1. DR InterPro; IPR048285; Integrin_alpha_Ig-like_2. DR InterPro; IPR048286; Integrin_alpha_Ig-like_3. DR InterPro; IPR028994; Integrin_alpha_N. DR InterPro; IPR032695; Integrin_dom_sf. DR PANTHER; PTHR23220; INTEGRIN ALPHA; 1. DR PANTHER; PTHR23220:SF73; INTEGRIN ALPHA-IIB; 1. DR Pfam; PF01839; FG-GAP; 2. DR Pfam; PF08441; Integrin_A_Ig_1; 1. DR Pfam; PF20805; Integrin_A_Ig_2; 1. DR Pfam; PF20806; Integrin_A_Ig_3; 1. DR Pfam; PF00357; Integrin_alpha; 1. DR PRINTS; PR01185; INTEGRINA. DR SMART; SM00191; Int_alpha; 5. DR SUPFAM; SSF69318; Integrin alpha N-terminal domain; 1. DR SUPFAM; SSF69179; Integrin domains; 3. DR PROSITE; PS51470; FG_GAP; 7. DR PROSITE; PS00242; INTEGRIN_ALPHA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell membrane; KW Cleavage on pair of basic residues; Direct protein sequencing; KW Disease variant; Disulfide bond; Glycoprotein; Integrin; Membrane; KW Metal-binding; Proteomics identification; Pyrrolidone carboxylic acid; KW Receptor; Reference proteome; Repeat; Signal; Transmembrane; KW Transmembrane helix. FT SIGNAL 1..31 FT /evidence="ECO:0000269|PubMed:1953640, FT ECO:0000269|PubMed:3534886, ECO:0000269|PubMed:8620874" FT CHAIN 32..1039 FT /note="Integrin alpha-IIb" FT /id="PRO_0000016275" FT CHAIN 32..887 FT /note="Integrin alpha-IIb heavy chain" FT /id="PRO_0000016276" FT CHAIN 891..1039 FT /note="Integrin alpha-IIb light chain, form 1" FT /id="PRO_0000292348" FT CHAIN 903..1039 FT /note="Integrin alpha-IIb light chain, form 2" FT /id="PRO_0000016277" FT TOPO_DOM 32..993 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 994..1019 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1020..1039 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 35..96 FT /note="FG-GAP 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 110..173 FT /note="FG-GAP 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 187..238 FT /note="FG-GAP 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 251..305 FT /note="FG-GAP 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 306..371 FT /note="FG-GAP 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 373..432 FT /note="FG-GAP 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 435..496 FT /note="FG-GAP 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT MOTIF 1022..1026 FT /note="GFFKR motif" FT BINDING 274 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 276 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 278 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 281 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 283 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 328 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 330 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 332 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 334 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 336 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 396 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 398 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 400 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 402 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 404 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 457 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 459 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 461 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 463 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 465 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT MOD_RES 891 FT /note="Pyrrolidone carboxylic acid; in light chain form 1" FT /evidence="ECO:0000269|PubMed:2226834" FT CARBOHYD 46 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT CARBOHYD 601 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:3FCS" FT CARBOHYD 711 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:2775232" FT CARBOHYD 874 FT /note="O-linked (GalNAc...) serine; in variant S-874" FT CARBOHYD 878 FT /note="O-linked (GalNAc...) serine" FT /evidence="ECO:0000269|PubMed:7688323" FT CARBOHYD 962 FT /note="N-linked (GlcNAc...) asparagine" FT DISULFID 87..96 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 138..161 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 177..198 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 504..515 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 521..576 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 633..639 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 705..718 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 857..921 FT /note="Interchain (between heavy and light chains)" FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0007744|PDB:3FCS" FT DISULFID 911..916 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0007744|PDB:3FCS" FT VAR_SEQ 910..1039 FT /note="SCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWF FT NVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWK FT VGFFKRNRPPLEEDDEEGE -> VSRLSGLWPGLPGTHGAEGMGGGRGVRVCCGPLWAT FT LGPWEHFK (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_002736" FT VAR_SEQ 948..981 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_002737" FT VARIANT 40 FT /note="T -> I (in dbSNP:rs5915)" FT /evidence="ECO:0000269|PubMed:10391209" FT /id="VAR_014176" FT VARIANT 86 FT /note="L -> P (in GT1; cells co-transfected with mutated FT alpha-IIb and wild-type beta-3 scarcely expressed the FT alpha-IIb/beta-3 complex; dbSNP:rs1052533574)" FT /evidence="ECO:0000269|PubMed:12181054" FT /id="VAR_030445" FT VARIANT 139 FT /note="A -> V (in GT1; dbSNP:rs2143489510)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030446" FT VARIANT 161 FT /note="C -> W (in GT1; uncertain significance)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030447" FT VARIANT 174 FT /note="Y -> H (in GT1; abolishes the binding function of FT alpha-IIb/beta-3 for soluble ligands without disturbing FT alpha-IIb/beta-3 expression; functional defect is likely FT caused by its allosteric effect rather than by a defect in FT the ligand-binding site itself; dbSNP:rs2048640612)" FT /evidence="ECO:0000269|PubMed:12506038" FT /id="VAR_030448" FT VARIANT 176 FT /note="P -> A (in GT1; impairs surface expression of alpha- FT IIb/beta-3 and abrogates ligand binding to the activated FT integrin; dbSNP:rs2048640485)" FT /evidence="ECO:0000269|PubMed:10607701, FT ECO:0000269|PubMed:12083483" FT /id="VAR_009885" FT VARIANT 176 FT /note="P -> L (in GT1; impairs surface expression of alpha- FT IIb/beta-3; dbSNP:rs148327798)" FT /evidence="ECO:0000269|PubMed:10607701" FT /id="VAR_009886" FT VARIANT 202 FT /note="F -> C (in GT1; results in abrogation of alpha-IIb/ FT beta-3 complex formation)" FT /evidence="ECO:0000269|PubMed:15219201" FT /id="VAR_030449" FT VARIANT 207 FT /note="T -> I (in GT1; dbSNP:rs2143485911)" FT /evidence="ECO:0000269|PubMed:9215749" FT /id="VAR_030450" FT VARIANT 214 FT /note="L -> P (in GT1; disrupts the structural conformation FT and the ligand binding properties of the heterodimeric FT complex; in addition the mutation appears to confer FT susceptibility to proteolysis; dbSNP:rs137852911)" FT /evidence="ECO:0000269|PubMed:9473221" FT /id="VAR_030451" FT VARIANT 222 FT /note="F -> L (in GT1; uncertain significance; FT dbSNP:rs2048633474)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030452" FT VARIANT 267 FT /note="G -> E (in GT1; dbSNP:rs2048627164)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030453" FT VARIANT 273 FT /note="G -> D (in GT1; alters the heterodimer conformation FT thus impairing their intracellular transport; FT dbSNP:rs137852907)" FT /evidence="ECO:0000269|PubMed:8282784" FT /id="VAR_003979" FT VARIANT 313 FT /note="G -> A (in dbSNP:rs1126554)" FT /evidence="ECO:0000269|PubMed:2345548, FT ECO:0000269|PubMed:2439501" FT /id="VAR_054820" FT VARIANT 320 FT /note="F -> S (in GT1; type I; impairs surface expression FT of alpha-IIb/beta-3)" FT /evidence="ECO:0000269|PubMed:9722314" FT /id="VAR_009887" FT VARIANT 329 FT /note="V -> F (in GT1; expression of mutant subunit alpha- FT IIb/bet-3 is 28% of control; mutant pro-alpha-IIb subunit FT is retained in the endoplasmic reticulum; FT dbSNP:rs2048619428)" FT /evidence="ECO:0000269|PubMed:12424194" FT /id="VAR_030454" FT VARIANT 355 FT /note="E -> K (in GT1; type I; impairs surface expression FT of alpha-IIb/beta-3; dbSNP:rs137852910)" FT /evidence="ECO:0000269|PubMed:9722314, FT ECO:0000269|PubMed:9734640" FT /id="VAR_009888" FT VARIANT 358 FT /note="R -> H (in GT1; type II; dbSNP:rs137852908)" FT /evidence="ECO:0000269|PubMed:7706461" FT /id="VAR_003980" FT VARIANT 380 FT /note="G -> D (in GT1; uncertain significance; FT dbSNP:rs766006685)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030455" FT VARIANT 405 FT /note="I -> T (in GT1; expression of mutant subunit alpha- FT IIb/bet-3 is 11% of control; mutant pro-alpha-IIb subunit FT is retained in the endoplasmic reticulum; FT dbSNP:rs75622274)" FT /evidence="ECO:0000269|PubMed:12083483, FT ECO:0000269|PubMed:12424194, ECO:0000269|PubMed:20020534" FT /id="VAR_030456" FT VARIANT 412 FT /note="G -> R (in GT1; dbSNP:rs780786843)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030457" FT VARIANT 449 FT /note="G -> D (in GT1; type I; dbSNP:rs1598380253)" FT /evidence="ECO:0000269|PubMed:7508443" FT /id="VAR_003981" FT VARIANT 456..457 FT /note="Missing (in GT1; alteres the conformation of FT heterodimers such that they were neither recognized by the FT heterodimer-specific antibody A2A9 nor able to undergo FT further intracellular processing or transport to the cell FT surface)" FT /id="VAR_030458" FT VARIANT 581 FT /note="A -> D (in GT1; uncertain significance; FT dbSNP:rs2143458780)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030459" FT VARIANT 596 FT /note="I -> T (in GT1; type I; dbSNP:rs76811038)" FT /evidence="ECO:0000269|PubMed:20020534, FT ECO:0000269|PubMed:9215749, ECO:0000269|PubMed:9734640" FT /id="VAR_030460" FT VARIANT 649 FT /note="V -> L (in dbSNP:rs7207402)" FT /id="VAR_054821" FT VARIANT 650 FT /note="T -> M (risk factor for FMAIT2; alloantigen Kno)" FT /evidence="ECO:0000269|PubMed:19821948" FT /id="VAR_091064" FT VARIANT 705 FT /note="C -> R (in GT1; type II; the rate of subunit FT maturation and the surface exposure of glycoprotein IIb/ FT beta-3 are strongly reduced; dbSNP:rs77961246)" FT /evidence="ECO:0000269|PubMed:12083483, FT ECO:0000269|PubMed:20020534, ECO:0000269|PubMed:9920835" FT /id="VAR_030461" FT VARIANT 752 FT /note="L -> V (in GT1; uncertain significance; FT dbSNP:rs761174160)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030462" FT VARIANT 755 FT /note="R -> P (in GT1; uncertain significance; FT dbSNP:rs763762304)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030463" FT VARIANT 771 FT /note="V -> L (risk factor for FMAIT2; alloantigen War)" FT /evidence="ECO:0000269|PubMed:23305224" FT /id="VAR_091065" FT VARIANT 778 FT /note="Q -> P (in GT1; type II; dbSNP:rs74475415)" FT /evidence="ECO:0000269|PubMed:20020534, FT ECO:0000269|PubMed:9722314, ECO:0000269|PubMed:9763559" FT /id="VAR_003982" FT VARIANT 847 FT /note="L -> P (in GT1; uncertain significance; FT dbSNP:rs1344532070)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030464" FT VARIANT 868 FT /note="V -> M (risk factor for FMAIT2; alloantigen Max(a); FT Max(a)-positive individuals also carry alloantigen Bak(b))" FT /evidence="ECO:0000269|PubMed:7620155" FT /id="VAR_091066" FT VARIANT 874 FT /note="I -> S (risk factor for FMAIT2; alloantigen Bak(b); FT dbSNP:rs5911)" FT /evidence="ECO:0000269|PubMed:10391209, FT ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:2350579" FT /id="VAR_003983" FT VARIANT 934 FT /note="V -> F (in GT1; severe type 1 phenotype; the FT mutation prevented normal ITGA2B/ITGB3 complex expression FT on the cell surface; dbSNP:rs77458039)" FT /evidence="ECO:0000269|PubMed:20020534" FT /id="VAR_069917" FT VARIANT 943 FT /note="P -> L (in GT1; marked reduction in the rate of FT surface expression)" FT /evidence="ECO:0000269|PubMed:17018384" FT /id="VAR_030465" FT VARIANT 957 FT /note="S -> L (in GT1; uncertain significance; severe type FT 1 phenotype; the mutation prevented normal ITGA2B/ITGB3 FT complex expression on the cell surface; the mutation may FT interfere with correct folding of the protein; FT dbSNP:rs80002943)" FT /evidence="ECO:0000269|PubMed:20020534" FT /id="VAR_069918" FT VARIANT 968 FT /note="Y -> N (in dbSNP:rs5914)" FT /evidence="ECO:0000269|PubMed:10391209" FT /id="VAR_014177" FT VARIANT 982 FT /note="V -> M (in GT1; much reduced surface expression of FT alpha-IIb/beta-3 and a block in the maturation of pro- FT alpha-IIb; dbSNP:rs78657866)" FT /evidence="ECO:0000269|PubMed:15099289, FT ECO:0000269|PubMed:20020534" FT /id="VAR_030466" FT VARIANT 989 FT /note="A -> T (in dbSNP:rs78165611)" FT /evidence="ECO:0000269|PubMed:15099289, FT ECO:0000269|PubMed:20020534" FT /id="VAR_030467" FT VARIANT 1026 FT /note="R -> Q (in GT1 and BDPLT16; uncertain significance; FT results in low surface expression of the mutant protein; FT dbSNP:rs879255514)" FT /evidence="ECO:0000269|PubMed:9215749, FT ECO:0000269|PubMed:9834222" FT /id="VAR_030468" FT VARIANT 1026 FT /note="R -> W (in BDPLT16; uncertain significance; results FT in abnormal membrane ruffling and cytoplasmic protrusions FT as well as defective proplatelet formation; FT dbSNP:rs766503255)" FT /evidence="ECO:0000269|PubMed:21454453" FT /id="VAR_069919" FT MUTAGEN 1029..1030 FT /note="PP->AA: Imparts constitutive activity (ligand- FT binding) to alpha-IIb/beta-3." FT /evidence="ECO:0000269|PubMed:10212286" FT CONFLICT 23 FT /note="P -> A (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 120 FT /note="A -> S (in Ref. 4; BAG37735)" FT /evidence="ECO:0000305" FT CONFLICT 287..288 FT /note="GA -> VP (in Ref. 3; AAA53150)" FT /evidence="ECO:0000305" FT CONFLICT 346 FT /note="E -> D (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 565 FT /note="N -> D (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 566 FT /note="L -> V (in Ref. 11; CAA29987)" FT /evidence="ECO:0000305" FT CONFLICT 633 FT /note="C -> S (in Ref. 1; AAA60114)" FT /evidence="ECO:0000305" FT CONFLICT 729 FT /note="Q -> E (in Ref. 11; CAA29987)" FT /evidence="ECO:0000305" FT CONFLICT 971 FT /note="P -> A (in Ref. 3; AAA53150)" FT /evidence="ECO:0000305" FT CONFLICT 1029 FT /note="P -> H (in Ref. 2; AAA35926 and 7; AAA52588)" FT /evidence="ECO:0000305" FT CONFLICT 1030 FT /note="P -> T (in Ref. 7; AAA52588)" FT /evidence="ECO:0000305" FT STRAND 36..38 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 52..58 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 60..62 FT /evidence="ECO:0007829|PDB:1TYE" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 82..88 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 91..94 FT /evidence="ECO:0007829|PDB:7UCY" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 113..118 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 126..131 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 143..148 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 151..153 FT /evidence="ECO:0007829|PDB:2VDL" FT STRAND 159..165 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 166..169 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 170..174 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 189..193 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 202..206 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:7LA4" FT STRAND 211..216 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 219..222 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 225..230 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 231..237 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 268..273 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 279..281 FT /evidence="ECO:0007829|PDB:7UJE" FT STRAND 283..288 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 291..294 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 297..301 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 307..312 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 314..318 FT /evidence="ECO:0007829|PDB:7LA4" FT STRAND 324..327 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 336..341 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 349..351 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 352..355 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 358..362 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 375..379 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 391..398 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 400..402 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 404..409 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 413..416 FT /evidence="ECO:0007829|PDB:6V4P" FT STRAND 419..423 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 427..430 FT /evidence="ECO:0007829|PDB:1TYE" FT STRAND 435..439 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 450..456 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 461..463 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 465..470 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 471..473 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 475..479 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 484..493 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8T2V" FT STRAND 507..509 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 512..525 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 534..541 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 542..544 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 547..549 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 555..557 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 559..567 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 575..583 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 592..594 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 596..603 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 616..619 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 622..627 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 634..637 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 643..651 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 653..655 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 662..670 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 678..683 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 688..695 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 698..700 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 705..708 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 710..713 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 715..721 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 728..738 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 742..744 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 746..755 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 759..761 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 767..774 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 779..792 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 810..819 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 821..823 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 825..836 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 842..854 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 856..861 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 906..909 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 911..913 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 916..926 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 931..940 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 952..965 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 967..969 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 977..988 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 991..994 FT /evidence="ECO:0007829|PDB:2KNC" FT TURN 996..1001 FT /evidence="ECO:0007829|PDB:8GCD" FT HELIX 1002..1015 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 1019..1027 FT /evidence="ECO:0007829|PDB:7SC4" FT HELIX 1028..1031 FT /evidence="ECO:0007829|PDB:1DPK" FT TURN 1035..1038 FT /evidence="ECO:0007829|PDB:1DPQ" SQ SEQUENCE 1039 AA; 113377 MW; 063EE298E026F116 CRC64; MARALCPLQA LWLLEWVLLL LGPCAAPPAW ALNLDPVQLT FYAGPNGSQF GFSLDFHKDS HGRVAIVVGA PRTLGPSQEE TGGVFLCPWR AEGGQCPSLL FDLRDETRNV GSQTLQTFKA RQGLGASVVS WSDVIVACAP WQHWNVLEKT EEAEKTPVGS CFLAQPESGR RAEYSPCRGN TLSRIYVEND FSWDKRYCEA GFSSVVTQAG ELVLGAPGGY YFLGLLAQAP VADIFSSYRP GILLWHVSSQ SLSFDSSNPE YFDGYWGYSV AVGEFDGDLN TTEYVVGAPT WSWTLGAVEI LDSYYQRLHR LRGEQMASYF GHSVAVTDVN GDGRHDLLVG APLYMESRAD RKLAEVGRVY LFLQPRGPHA LGAPSLLLTG TQLYGRFGSA IAPLGDLDRD GYNDIAVAAP YGGPSGRGQV LVFLGQSEGL RSRPSQVLDS PFPTGSAFGF SLRGAVDIDD NGYPDLIVGA YGANQVAVYR AQPVVKASVQ LLVQDSLNPA VKSCVLPQTK TPVSCFNIQM CVGATGHNIP QKLSLNAELQ LDRQKPRQGR RVLLLGSQQA GTTLNLDLGG KHSPICHTTM AFLRDEADFR DKLSPIVLSL NVSLPPTEAG MAPAVVLHGD THVQEQTRIV LDCGEDDVCV PQLQLTASVT GSPLLVGADN VLELQMDAAN EGEGAYEAEL AVHLPQGAHY MRALSNVEGF ERLICNQKKE NETRVVLCEL GNPMKKNAQI GIAMLVSVGN LEEAGESVSF QLQIRSKNSQ NPNSKIVLLD VPVRAEAQVE LRGNSFPASL VVAAEEGERE QNSLDSWGPK VEHTYELHNN GPGTVNGLHL SIHLPGQSQP SDLLYILDIQ PQGGLQCFPQ PPVNPLKVDW GLPIPSPSPI HPAHHKRDRR QIFLPEPEQP SRLQDPVLVS CDSAPCTVVQ CDLQEMARGQ RAMVTVLAFL WLPSLYQRPL DQFVLQSHAW FNVSSLPYAV PPLSLPRGEA QVWTQLLRAL EERAIPIWWV LVGVLGGLLL LTILVLAMWK VGFFKRNRPP LEEDDEEGE // ID PLPP1_HUMAN Reviewed; 284 AA. AC O14494; B7ZKN8; G3XA95; O60457; O60463; Q17RZ4; DT 15-MAR-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JAN-1998, sequence version 1. DT 28-JAN-2026, entry version 198. DE RecName: Full=Phospholipid phosphatase 1 {ECO:0000305}; DE EC=3.1.3.- {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; DE EC=3.1.3.106 {ECO:0000250|UniProtKB:Q61469}; DE EC=3.1.3.4 {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; DE EC=3.6.1.75 {ECO:0000250|UniProtKB:Q61469}; DE AltName: Full=Lipid phosphate phosphohydrolase 1; DE AltName: Full=PAP2-alpha; DE AltName: Full=Phosphatidate phosphohydrolase type 2a; DE AltName: Full=Phosphatidic acid phosphatase 2a; DE Short=PAP-2a; DE Short=PAP2a; GN Name=PLPP1 {ECO:0000312|HGNC:HGNC:9228}; Synonyms=LPP1, PPAP2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBSTRATE SPECIFICITY, ACTIVITY REGULATION, PATHWAY, SUBCELLULAR LOCATION, RP GLYCOSYLATION, TISSUE SPECIFICITY, AND CAUTION. RX PubMed=9305923; DOI=10.1074/jbc.272.39.24572; RA Kai M., Wada I., Imai S., Sakane F., Kanoh H.; RT "Cloning and characterization of two human isozymes of Mg2+-independent RT phosphatidic acid phosphatase."; RL J. Biol. Chem. 272:24572-24578(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=9570154; DOI=10.1089/dna.1998.17.377; RA Leung D.W., Tompkins C.K., White T.; RT "Molecular cloning of two alternatively spliced forms of human phosphatidic RT acid phosphatase cDNAs that are differentially expressed in normal and RT tumor cells."; RL DNA Cell Biol. 17:377-385(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION. RC TISSUE=Prostate; RX PubMed=9468526; DOI=10.1074/jbc.273.8.4660; RA Ulrix W.E.J., Swinnen J., Heyns W., Verhoeven G.; RT "Identification of the phosphatidic acid phosphatase type 2a isozyme as an RT androgen-regulated gene in the human prostatic Adenocarcinoma cell line RT LNCaP."; RL J. Biol. Chem. 273:4660-4665(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE SPECIFICITY, ACTIVITY REGULATION, RP PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=9705349; DOI=10.1074/jbc.273.34.22059; RA Roberts R., Sciorra V.A., Morris A.J.; RT "Human type 2 phosphatidic acid phosphohydrolases. Substrate specificity of RT the type 2a, 2b, and 2c enzymes and cell surface activity of the 2a RT isoform."; RL J. Biol. Chem. 273:22059-22067(1998). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE RP SPECIFICITY, AND PATHWAY. RX PubMed=9607309; DOI=10.1016/s0014-5793(98)00421-9; RA Hooks S.B., Ragan S.P., Lynch K.R.; RT "Identification of a novel human phosphatidic acid phosphatase type 2 RT isoform."; RL FEBS Lett. 427:188-192(1998). RN [9] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PATHWAY, SUBCELLULAR RP LOCATION, AND GLYCOSYLATION. RX PubMed=10962286; DOI=10.1016/s1388-1981(00)00081-0; RA Roberts R.Z., Morris A.J.; RT "Role of phosphatidic acid phosphatase 2a in uptake of extracellular lipid RT phosphate mediators."; RL Biochim. Biophys. Acta 1487:33-49(2000). RN [10] RP SUBCELLULAR LOCATION, AND MOTIF. RX PubMed=14527693; DOI=10.1016/s0014-5793(03)00931-1; RA Jia Y.J., Kai M., Wada I., Sakane F., Kanoh H.; RT "Differential localization of lipid phosphate phosphatases 1 and 3 to cell RT surface subdomains in polarized MDCK cells."; RL FEBS Lett. 552:240-246(2003). RN [11] RP FUNCTION. RX PubMed=12909631; DOI=10.1074/jbc.m306709200; RA Smyth S.S., Sciorra V.A., Sigal Y.J., Pamulkar Z., Wang Z., Xu Y., RA Prestwich G.D., Morris A.J.; RT "Lipid phosphate phosphatases regulate lysophosphatidic acid production and RT signaling in platelets: studies using chemical inhibitors of lipid RT phosphate phosphatase activity."; RL J. Biol. Chem. 278:43214-43223(2003). RN [12] RP FUNCTION, AND MUTAGENESIS OF ARG-217. RX PubMed=15461590; DOI=10.1042/bj20041160; RA Zhao Y., Usatyuk P.V., Cummings R., Saatian B., He D., Watkins T., RA Morris A., Spannhake E.W., Brindley D.N., Natarajan V.; RT "Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced RT calcium release, NF-kappaB activation and interleukin-8 secretion in human RT bronchial epithelial cells."; RL Biochem. J. 385:493-502(2005). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=17005594; DOI=10.1093/jb/mvj195; RA Kai M., Sakane F., Jia Y.J., Imai S., Yasuda S., Kanoh H.; RT "Lipid phosphate phosphatases 1 and 3 are localized in distinct lipid RT rafts."; RL J. Biochem. 140:677-686(2006). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=17379599; DOI=10.1074/jbc.m701279200; RA Zhao Y., Kalari S.K., Usatyuk P.V., Gorshkova I., He D., Watkins T., RA Brindley D.N., Sun C., Bittman R., Garcia J.G., Berdyshev E.V., RA Natarajan V.; RT "Intracellular generation of sphingosine 1-phosphate in human lung RT endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine RT kinase 1."; RL J. Biol. Chem. 282:14165-14177(2007). CC -!- FUNCTION: Magnesium-independent phospholipid phosphatase of the plasma CC membrane that catalyzes the dephosphorylation of a variety of CC glycerolipid and sphingolipid phosphate esters including CC phosphatidate/PA, lysophosphatidate/LPA, diacylglycerol CC pyrophosphate/DGPP, sphingosine 1-phosphate/S1P and ceramide 1- CC phosphate/C1P (PubMed:10962286, PubMed:17379599, PubMed:9305923, CC PubMed:9607309, PubMed:9705349). Also acts on N-oleoyl ethanolamine CC phosphate/N-(9Z-octadecenoyl)-ethanolamine phosphate, a potential CC physiological compound (PubMed:9607309). Through its extracellular CC phosphatase activity allows both the hydrolysis and the cellular uptake CC of these bioactive lipid mediators from the milieu, regulating signal CC transduction in different cellular processes (PubMed:10962286, CC PubMed:12909631, PubMed:15461590, PubMed:17379599). It is for instance CC essential for the extracellular hydrolysis of S1P and subsequent CC conversion into intracellular S1P (PubMed:17379599). Involved in the CC regulation of inflammation, platelets activation, cell proliferation CC and migration among other processes (PubMed:12909631, PubMed:15461590). CC May also have an intracellular activity to regulate phospholipid- CC mediated signaling pathways (By similarity). CC {ECO:0000250|UniProtKB:O08564, ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:12909631, ECO:0000269|PubMed:15461590, CC ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phosphate + H2O = a 1,2-diacyl-sn- CC glycerol + phosphate; Xref=Rhea:RHEA:27429, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:17815, ChEBI:CHEBI:43474, ChEBI:CHEBI:58608; EC=3.1.3.4; CC Evidence={ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27430; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphate + H2O = 1,2- CC dihexadecanoyl-sn-glycerol + phosphate; Xref=Rhea:RHEA:43236, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:72859, CC ChEBI:CHEBI:82929; Evidence={ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43237; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1,2- CC di-(9Z-octadecenoyl)-sn-glycerol + phosphate; Xref=Rhea:RHEA:43244, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:52333, CC ChEBI:CHEBI:74546; Evidence={ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43245; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a monoacyl-sn-glycero-3-phosphate + H2O = a monoacylglycerol + CC phosphate; Xref=Rhea:RHEA:46736, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:17408, ChEBI:CHEBI:43474, ChEBI:CHEBI:77589; CC Evidence={ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46737; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z)-octadecenoyl-sn-glycero-3-phosphate + H2O = (9Z- CC octadecenoyl)-glycerol + phosphate; Xref=Rhea:RHEA:50884, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:75937, CC ChEBI:CHEBI:84973; Evidence={ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50885; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1-acyl-sn-glycero-3-phosphate + H2O = a 1-acyl-sn-glycerol + CC phosphate; Xref=Rhea:RHEA:33155, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:57970, ChEBI:CHEBI:64683; CC EC=3.1.3.106; Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33156; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1-(9Z- CC octadecenoyl)-sn-glycerol + phosphate; Xref=Rhea:RHEA:39835, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:74544, CC ChEBI:CHEBI:75757; Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39836; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycerol 3-diphosphate + H2O = a 1,2-diacyl- CC sn-glycero-3-phosphate + phosphate + H(+); Xref=Rhea:RHEA:27449, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:58608, ChEBI:CHEBI:59996; EC=3.6.1.75; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27450; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=sphing-4-enine 1-phosphate + H2O = sphing-4-enine + phosphate; CC Xref=Rhea:RHEA:27518, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:57756, ChEBI:CHEBI:60119; CC Evidence={ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27519; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=an N-acylsphing-4-enine 1-phosphate + H2O = an N-acylsphing-4- CC enine + phosphate; Xref=Rhea:RHEA:33743, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:52639, ChEBI:CHEBI:57674; CC Evidence={ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33744; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(octanoyl)-sphing-4-enine-1-phosphate + H2O = N- CC octanoylsphing-4-enine + phosphate; Xref=Rhea:RHEA:62040, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:45815, CC ChEBI:CHEBI:85376; Evidence={ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62041; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(9Z-octadecenoyl)-ethanolamine phosphate + H2O = N-(9Z- CC octadecenoyl) ethanolamine + phosphate; Xref=Rhea:RHEA:62160, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:71466, CC ChEBI:CHEBI:145465; Evidence={ECO:0000269|PubMed:9607309}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62161; CC Evidence={ECO:0000305|PubMed:9607309}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CC H2O = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol + phosphate; CC Xref=Rhea:RHEA:41255, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:64839, ChEBI:CHEBI:75466; CC Evidence={ECO:0000250|UniProtKB:O08564}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41256; CC Evidence={ECO:0000250|UniProtKB:O08564}; CC -!- ACTIVITY REGULATION: Magnesium-independent phospholipid phosphatase CC (PubMed:9305923). Insensitive to N-ethylmaleimide (PubMed:9305923). CC Inhibited by sphingosine, zinc ions and modestly by propanolol CC (PubMed:9305923, PubMed:9705349). Inhibited by vanadate CC (PubMed:10962286). {ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9705349}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=98 uM for 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate CC {ECO:0000269|PubMed:9607309}; CC KM=170 uM for (9Z)-octadecenoyl-sn-glycero-3-phosphate CC {ECO:0000269|PubMed:9607309}; CC KM=116 uM for N-(9Z-octadecenoyl)-ethanolamine phosphate CC {ECO:0000269|PubMed:9607309}; CC Vmax=0.54 nmol/min/mg enzyme with 1,2-dihexadecanoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.50 nmol/min/mg enzyme with (9Z)-octadecenoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.30 nmol/min/mg enzyme with N-(octanoyl)-sphing-4-enine-1- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.32 nmol/min/mg enzyme with sphing-4-enine 1-phosphate as CC substrate {ECO:0000269|PubMed:9705349}; CC Vmax=41 nmol/min/mg enzyme with 1,2-di-(9Z-octadecenoyl)-sn-glycero- CC 3-phosphate as substrate {ECO:0000269|PubMed:9607309}; CC Vmax=33 nmol/min/mg enzyme with (9Z)-octadecenoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9607309}; CC Vmax=29 nmol/min/mg enzyme with N-(9Z-octadecenoyl)-ethanolamine CC phosphate as substrate {ECO:0000269|PubMed:9607309}; CC -!- PATHWAY: Lipid metabolism; phospholipid metabolism. CC {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}. CC -!- SUBUNIT: Forms functional homodimers and homooligomers that are not CC required for substrate recognition and catalytic activity (By CC similarity). Can also form heterooligomers with PLPP2 and PLPP3 (By CC similarity). {ECO:0000250|UniProtKB:O88956, CC ECO:0000250|UniProtKB:Q61469}. CC -!- INTERACTION: CC O14494; P05067: APP; NbExp=3; IntAct=EBI-2865290, EBI-77613; CC O14494; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-2865290, EBI-1383687; CC O14494; P29466-3: CASP1; NbExp=3; IntAct=EBI-2865290, EBI-12248206; CC O14494; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-2865290, EBI-9087876; CC O14494; O15529: GPR42; NbExp=3; IntAct=EBI-2865290, EBI-18076404; CC O14494; P17612: PRKACA; NbExp=3; IntAct=EBI-2865290, EBI-476586; CC O14494; P49768-2: PSEN1; NbExp=3; IntAct=EBI-2865290, EBI-11047108; CC O14494; Q8WWF3: SSMEM1; NbExp=3; IntAct=EBI-2865290, EBI-17280858; CC O14494; Q15583: TGIF1; NbExp=3; IntAct=EBI-2865290, EBI-714215; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:9705349}; Multi-pass membrane protein {ECO:0000255}. CC Apical cell membrane {ECO:0000269|PubMed:14527693}; Multi-pass membrane CC protein {ECO:0000255}. Membrane raft {ECO:0000269|PubMed:17005594}; CC Multi-pass membrane protein {ECO:0000255}. Membrane, caveola CC {ECO:0000250|UniProtKB:Q61469}; Multi-pass membrane protein CC {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=Alpha-1, hLPP1, PAP2-a1; CC IsoId=O14494-1; Sequence=Displayed; CC Name=2; Synonyms=Alpha-2, hLPP1-a, PAP2-a2; CC IsoId=O14494-2; Sequence=VSP_009651; CC -!- TISSUE SPECIFICITY: Widely expressed with highest expression found in CC prostate (PubMed:9305923). Found to be down-regulated in colon CC adenocarcinomas (PubMed:9570154). {ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9570154}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Predominant in kidney, lung, placenta CC and liver. {ECO:0000269|PubMed:9570154}. CC -!- TISSUE SPECIFICITY: [Isoform 2]: Predominant in heart and pancreas. CC {ECO:0000269|PubMed:9570154}. CC -!- INDUCTION: By androgens. {ECO:0000269|PubMed:9468526}. CC -!- PTM: N-glycosylated (PubMed:10962286, PubMed:9305923). N-linked sugars CC are of the complex type. N-glycosylation is not required for the CC phosphatase activity (By similarity). {ECO:0000250|UniProtKB:Q61469, CC ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923}. CC -!- SIMILARITY: Belongs to the PA-phosphatase related phosphoesterase CC family. {ECO:0000305}. CC -!- CAUTION: Some reports could not detect a significant activity with CC sphingosine 1-phosphate as substrate. {ECO:0000269|PubMed:9305923}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB000888; BAA22593.1; -; mRNA. DR EMBL; AF014402; AAC16032.1; -; mRNA. DR EMBL; AF014403; AAC16033.1; -; mRNA. DR EMBL; Y14436; CAC14588.1; -; mRNA. DR EMBL; AF017116; AAC32041.1; -; mRNA. DR EMBL; AC010480; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC025777; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471123; EAW54920.1; -; Genomic_DNA. DR EMBL; CH471123; EAW54922.1; -; Genomic_DNA. DR EMBL; BC039847; AAH39847.1; -; mRNA. DR EMBL; BC117133; AAI17134.1; -; mRNA. DR EMBL; BC143281; AAI43282.1; -; mRNA. DR CCDS; CCDS34159.1; -. [O14494-1] DR CCDS; CCDS34160.1; -. [O14494-2] DR RefSeq; NP_003702.2; NM_003711.3. [O14494-1] DR RefSeq; NP_795714.1; NM_176895.3. [O14494-2] DR AlphaFoldDB; O14494; -. DR BioGRID; 114169; 41. DR FunCoup; O14494; 507. DR IntAct; O14494; 23. DR MINT; O14494; -. DR STRING; 9606.ENSP00000264775; -. DR SwissLipids; SLP:000000160; -. DR DEPOD; PLPP1; -. DR GlyCosmos; O14494; 1 site, No reported glycans. DR GlyGen; O14494; 1 site. DR iPTMnet; O14494; -. DR PhosphoSitePlus; O14494; -. DR SwissPalm; O14494; -. DR BioMuta; PLPP1; -. DR jPOST; O14494; -. DR MassIVE; O14494; -. DR PeptideAtlas; O14494; -. DR ProteomicsDB; 33687; -. DR ProteomicsDB; 48037; -. [O14494-1] DR ProteomicsDB; 48038; -. [O14494-2] DR Pumba; O14494; -. DR Antibodypedia; 11159; 186 antibodies from 27 providers. DR DNASU; 8611; -. DR Ensembl; ENST00000264775.9; ENSP00000264775.5; ENSG00000067113.18. [O14494-2] DR Ensembl; ENST00000307259.9; ENSP00000302229.8; ENSG00000067113.18. [O14494-1] DR GeneID; 8611; -. DR KEGG; hsa:8611; -. DR MANE-Select; ENST00000307259.9; ENSP00000302229.8; NM_003711.4; NP_003702.2. DR UCSC; uc003jpz.5; human. [O14494-1] DR AGR; HGNC:9228; -. DR ClinPGx; PA33552; -. DR CTD; 8611; -. DR DisGeNET; 8611; -. DR GeneCards; PLPP1; -. DR HGNC; HGNC:9228; PLPP1. DR HPA; ENSG00000067113; Low tissue specificity. DR MIM; 607124; gene. DR OpenTargets; ENSG00000067113; -. DR VEuPathDB; HostDB:ENSG00000067113; -. DR GeneTree; ENSGT00940000156730; -. DR HOGENOM; CLU_021458_3_1_1; -. DR InParanoid; O14494; -. DR OMA; NQHRYIE; -. DR OrthoDB; 8907274at2759; -. DR PAN-GO; O14494; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14494; -. DR PathwayCommons; O14494; -. DR Reactome; R-HSA-9845614; Sphingolipid catabolism. DR SignaLink; O14494; -. DR UniPathway; UPA00085; -. DR Agora; ENSG00000067113; -. DR BioGRID-ORCS; 8611; 19 hits in 1152 CRISPR screens. DR ChiTaRS; PLPP1; human. DR GeneWiki; PPAP2A; -. DR GenomeRNAi; 8611; -. DR Pharos; O14494; Tbio. DR PRO; PR:O14494; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; O14494; protein. DR Bgee; ENSG00000067113; Expressed in decidua and 202 other cell types or tissues. DR ExpressionAtlas; O14494; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0005901; C:caveola; ISS:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0106235; F:ceramide-1-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0000810; F:diacylglycerol diphosphate phosphatase activity; ISS:UniProtKB. DR GO; GO:0042577; F:lipid phosphatase activity; IDA:UniProtKB. DR GO; GO:0052642; F:lysophosphatidic acid phosphatase activity; IEA:UniProtKB-EC. DR GO; GO:0008195; F:phosphatidate phosphatase activity; IDA:UniProtKB. DR GO; GO:0042392; F:sphingosine-1-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB. DR GO; GO:0006672; P:ceramide metabolic process; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; NAS:UniProtKB. DR GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; TAS:UniProtKB. DR GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0046839; P:phospholipid dephosphorylation; IDA:UniProtKB. DR GO; GO:0006644; P:phospholipid metabolic process; IDA:UniProtKB. DR GO; GO:0019216; P:regulation of lipid metabolic process; NAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IMP:UniProtKB. DR GO; GO:0030149; P:sphingolipid catabolic process; TAS:Reactome. DR GO; GO:0006670; P:sphingosine metabolic process; IDA:UniProtKB. DR CDD; cd03384; PAP2_wunen; 1. DR FunFam; 1.20.144.10:FF:000007; phospholipid phosphatase 1 isoform X2; 1. DR Gene3D; 1.20.144.10; Phosphatidic acid phosphatase type 2/haloperoxidase; 1. DR InterPro; IPR043216; PAP-like. DR InterPro; IPR000326; PAP2/HPO. DR InterPro; IPR036938; PAP2/HPO_sf. DR PANTHER; PTHR10165; LIPID PHOSPHATE PHOSPHATASE; 1. DR PANTHER; PTHR10165:SF26; PHOSPHOLIPID PHOSPHATASE 1; 1. DR Pfam; PF01569; PAP2; 1. DR SMART; SM00014; acidPPc; 1. DR SUPFAM; SSF48317; Acid phosphatase/Vanadium-dependent haloperoxidase; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Glycoprotein; Hydrolase; KW Lipid metabolism; Membrane; Proteomics identification; Reference proteome; KW Transmembrane; Transmembrane helix. FT CHAIN 1..284 FT /note="Phospholipid phosphatase 1" FT /id="PRO_0000220905" FT TOPO_DOM 1..6 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 7..27 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 28..53 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 54..74 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 75..94 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 95..115 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 116..164 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 165..185 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 186..199 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 200..220 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 221..229 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 230..250 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 251..284 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT REGION 120..128 FT /note="Phosphatase sequence motif I" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 168..171 FT /note="Phosphatase sequence motif II" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 216..227 FT /note="Phosphatase sequence motif III" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 260..284 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 5..7 FT /note="PDZ-binding; involved in localization to the apical FT cell membrane" FT /evidence="ECO:0000269|PubMed:14527693" FT COMPBIAS 269..284 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 171 FT /note="Proton donors" FT /evidence="ECO:0000250|UniProtKB:O34349" FT ACT_SITE 223 FT /note="Nucleophile" FT /evidence="ECO:0000250|UniProtKB:O34349" FT SITE 227 FT /note="Stabilizes the active site histidine for FT nucleophilic attack" FT /evidence="ECO:0000250|UniProtKB:O34349" FT CARBOHYD 142 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 21..70 FT /note="GLPFAILTSRHTPFQRGVFCNDESIKYPYKEDTIPYALLGGIIIPFSIIV FT -> SMPMAVLKLGQIYPFQRGFFCKDNSINYPYHDSTVTSTVLILVGVGLPISS (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:9570154" FT /id="VSP_009651" FT MUTAGEN 217 FT /note="R->K: Decreased lipid phosphatase activity." FT /evidence="ECO:0000269|PubMed:15461590" FT CONFLICT 27 FT /note="L -> FTSRHI (in Ref. 4; AAC32041)" FT /evidence="ECO:0000305" FT CONFLICT 91 FT /note="R -> S (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:55 FT /note="V -> A (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:56 FT /note="T -> A (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:69 FT /note="I -> V (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" SQ SEQUENCE 284 AA; 32156 MW; FC2F00617EE07EB3 CRC64; MFDKTRLPYV ALDVLCVLLA GLPFAILTSR HTPFQRGVFC NDESIKYPYK EDTIPYALLG GIIIPFSIIV IILGETLSVY CNLLHSNSFI RNNYIATIYK AIGTFLFGAA ASQSLTDIAK YSIGRLRPHF LDVCDPDWSK INCSDGYIEY YICRGNAERV KEGRLSFYSG HSSFSMYCML FVALYLQARM KGDWARLLRP TLQFGLVAVS IYVGLSRVSD YKHHWSDVLT GLIQGALVAI LVAVYVSDFF KERTSFKERK EEDSHTTLHE TPTTGNHYPS NHQP // ID RN5A_HUMAN Reviewed; 741 AA. AC Q05823; Q5W0L2; Q6AI46; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1996, sequence version 2. DT 28-JAN-2026, entry version 218. DE RecName: Full=2-5A-dependent ribonuclease; DE Short=2-5A-dependent RNase; DE EC=3.1.26.-; DE AltName: Full=Ribonuclease 4; DE AltName: Full=Ribonuclease L; DE Short=RNase L; GN Name=RNASEL {ECO:0000303|PubMed:40010341}; Synonyms=RNS4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF LYS-240 AND LYS-274. RC TISSUE=Kidney; RX PubMed=7680958; DOI=10.1016/0092-8674(93)90403-d; RA Zhou A., Hassel B.A., Silverman R.H.; RT "Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator RT of interferon action."; RL Cell 72:753-765(1993). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=11063255; DOI=10.1007/s003350010194; RA Zhou A., Nie H., Silverman R.H.; RT "Analysis and origins of the human and mouse RNase L genes: mediators of RT interferon action."; RL Mamm. Genome 11:989-992(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Colon carcinoma; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP CHARACTERIZATION OF RNASEL ACTIVITY. RX PubMed=7514601; DOI=10.1016/s0021-9258(17)36767-4; RA Dong B., Xu L., Zhou A., Hassel B.A., Lee X., Torrence P.F., RA Silverman R.H.; RT "Intrinsic molecular activities of the interferon-induced 2-5A-dependent RT RNase."; RL J. Biol. Chem. 269:14153-14158(1994). RN [8] RP INTERACTION WITH ABCE1. RX PubMed=7539425; DOI=10.1074/jbc.270.22.13308; RA Bisbal C., Martinand C., Silhol M., Lebleu B., Salehzada T.; RT "Cloning and characterization of a RNase L inhibitor. A new component of RT the interferon-regulated 2-5A pathway."; RL J. Biol. Chem. 270:13308-13317(1995). RN [9] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11585831; DOI=10.1074/jbc.m107482200; RA Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.; RT "The 2-5A/RNase L/RNase L inhibitor (RNI) pathway regulates mitochondrial RT mRNAs stability in interferon alpha-treated H9 cells."; RL J. Biol. Chem. 276:48473-48482(2001). RN [10] RP ERRATUM OF PUBMED:11585831. RA Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.; RL J. Biol. Chem. 277:13354-13354(2002). RN [11] RP REVIEW. RX PubMed=9856285; DOI=10.1016/s0753-3322(99)80006-7; RA Castelli J., Wood K.A., Youle R.J.; RT "The 2-5A system in viral infection and apoptosis."; RL Biomed. Pharmacother. 52:386-390(1998). RN [12] RP MUTAGENESIS OF LYS-392. RX PubMed=9862963; DOI=10.1093/nar/27.2.439; RA Dong B., Silverman R.H.; RT "Alternative function of a protein kinase homology domain in 2', 5'- RT oligoadenylate dependent RNase L."; RL Nucleic Acids Res. 27:439-445(1999). RN [13] RP MUTAGENESIS OF HIS-583; PRO-584; TRP-632; ASP-661; ARG-667 AND HIS-672. RX PubMed=11333017; DOI=10.1017/s1355838201002230; RA Dong B., Niwa M., Walter P., Silverman R.H.; RT "Basis for regulated RNA cleavage by functional analysis of RNase L and RT Ire1p."; RL RNA 7:361-373(2001). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-684, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [15] RP FUNCTION. RX PubMed=26263979; DOI=10.3390/ijms160817611; RA Siddiqui M.A., Mukherjee S., Manivannan P., Malathi K.; RT "RNase L cleavage products promote switch from autophagy to apoptosis by RT caspase-mediated cleavage of beclin-1."; RL Int. J. Mol. Sci. 16:17611-17636(2015). RN [16] RP FUNCTION. RX PubMed=40010341; DOI=10.1016/j.immuni.2025.01.016; RA Huai W., Yang K., Xing C., Song K., Lyu H., Williams N.S., Wu J., Yan N.; RT "OAS cross-activates RNase L intercellularly through cell-to-cell transfer RT of 2-5A to spread innate immunity."; RL Immunity 58:797-810.e6(2025). RN [17] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-305 IN COMPLEX WITH THE RP ACTIVATOR 2-5A. RX PubMed=15385955; DOI=10.1038/sj.emboj.7600420; RA Tanaka N., Nakanishi M., Kusakabe Y., Goto Y., Kitade Y., Nakamura K.T.; RT "Structural basis for recognition of 2',5'-linked oligoadenylates by human RT ribonuclease L."; RL EMBO J. 23:3929-3938(2004). RN [18] RP VARIANTS SER-59; PHE-406; GLN-462 AND GLU-541. RX PubMed=11941539; DOI=10.1086/340450; RA Roekman A., Ikonen T., Seppaelae E.H., Nupponen N., Autio V., Mononen N., RA Bailey-Wilson J., Trent J., Carpten J., Matikainen M.P., Koivisto P.A., RA Tammela T.L.J., Kallioniemi O.-P., Schleutker J.; RT "Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in RT patients and families with prostate cancer."; RL Am. J. Hum. Genet. 70:1299-1304(2002). RN [19] RP VARIANTS SER-59; GLN-462 AND GLU-541. RX PubMed=11799394; DOI=10.1038/ng823; RA Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J., Faruque M., RA Moses T., Ewing C., Gillanders E., Hu P., Bujnovszky P., Makalowska I., RA Baffoe-Bonnie A., Faith D., Smith J., Stephan D., Wiley K., Brownstein M., RA Gildea D., Kelly B., Jenkins R., Hostetter G., Matikainen M., RA Schleutker J., Klinger K., Connors T., Xiang Y., Wang Z., De Marzo A., RA Papadopoulos N., Kallioniemi O.-P., Burk R., Meyers D., Groenberg H., RA Meltzer P., Silverman R., Bailey-Wilson J., Walsh P., Isaacs W., Trent J.; RT "Germline mutations in the ribonuclease L gene in families showing linkage RT with HPC1."; RL Nat. Genet. 30:181-184(2002). RN [20] RP CHARACTERIZATION OF VARIANTS GLN-462 AND GLU-541. RX PubMed=12415269; DOI=10.1038/ng1021; RA Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M., Klein E.A., RA Catalona W.J., Nupponen N., Carpten J.D., Trent J.M., Silverman R.H., RA Witte J.S.; RT "RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer RT cases."; RL Nat. Genet. 32:581-583(2002). RN [21] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-97; THR-289; GLN-462; GLU-541 AND RP HIS-592. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Endoribonuclease that functions in the interferon (IFN) CC antiviral response (PubMed:11585831, PubMed:26263979). In INF treated CC and virus infected cells, RNASEL probably mediates its antiviral CC effects through a combination of direct cleavage of single-stranded CC viral RNAs, inhibition of protein synthesis through the degradation of CC rRNA, induction of apoptosis, and induction of other antiviral genes CC (PubMed:11585831, PubMed:26263979). RNASEL mediated apoptosis is the CC result of a JNK-dependent stress-response pathway leading to cytochrome CC c release from mitochondria and caspase-dependent apoptosis CC (PubMed:11585831, PubMed:26263979). Therefore, activation of RNASEL CC could lead to elimination of virus infected cells under some CC circumstances (PubMed:11585831, PubMed:26263979). In the crosstalk CC between autophagy and apoptosis proposed to induce autophagy as an CC early stress response to small double-stranded RNA and at later stages CC of prolonged stress to activate caspase-dependent proteolytic cleavage CC of BECN1 to terminate autophagy and promote apoptosis CC (PubMed:26263979). Might play a central role in the regulation of mRNA CC turnover (PubMed:11585831). Cleaves 3' of UpNp dimers, with preference CC for UU and UA sequences, to sets of discrete products ranging from CC between 4 and 22 nucleotides in length. Involved in intercellular CC immune signaling (PubMed:40010341). Cross-activated by 2',5'- CC oligoadenylates (2-5A) previously generated in RNA virus-infected CC cells, triggers type I interferon signaling in uninfected neighboring CC cells to limit local spread of infection (PubMed:40010341). CC {ECO:0000269|PubMed:11585831, ECO:0000269|PubMed:26263979, CC ECO:0000269|PubMed:40010341}. CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Note=Manganese or magnesium. Required for optimal RNA cleavage rates.; CC -!- ACTIVITY REGULATION: After binding to 2-5A (5'-phosphorylated 2',5'- CC linked oligoadenylates) the homodimerization and subsequent activation CC occurs. Inhibited by RNASEL inhibitor ABCE1/RLI, a cytoplasmic member CC of the ATP-binding cassette (ABC) transporter family. CC -!- SUBUNIT: Monomer (inactive form) or homodimer. Interacts with ABCE1; CC this interaction inhibits the RNASEL. {ECO:0000269|PubMed:15385955, CC ECO:0000269|PubMed:7539425}. CC -!- INTERACTION: CC Q05823; P46940: IQGAP1; NbExp=2; IntAct=EBI-8390477, EBI-297509; CC Q05823-1; Q05823-1: RNASEL; NbExp=2; IntAct=EBI-16094551, EBI-16094551; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11585831}. CC Mitochondrion {ECO:0000269|PubMed:11585831}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q05823-1; Sequence=Displayed; CC Name=2; CC IsoId=Q05823-2; Sequence=VSP_056272, VSP_056273; CC -!- TISSUE SPECIFICITY: Highly expressed in spleen and thymus followed by CC prostate, testis, uterus, small intestine, colon and peripheral blood CC leukocytes. CC -!- INDUCTION: By interferons. Virus replication in higher vertebrates is CC restrained by IFNs that cause cells to transcribe genes encoding CC antiviral proteins, such as 2'-5' oligoadenylate synthetases (OASs). CC oligoadenylate synthetase is stimulated by dsRNA to produce 5'- CC phosphorylated, 2'-5'-linked oligoadenylates (2-5A), whose function is CC to activate RNASEL. CC -!- DOMAIN: The nine ankyrin repeats also called 2-5A sensor constitute the CC N-terminus 2-5A binding domain. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. It allows the homodimerization. CC -!- DOMAIN: The ribonuclease domain is located in the C-terminus. A single CC active nuclease domain in a dimer is sufficient for ribonuclease CC activity (By similarity). {ECO:0000250}. CC -!- DISEASE: Prostate cancer, hereditary, 1 (HPC1) [MIM:601518]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000305|PubMed:11799394, CC ECO:0000305|PubMed:11941539, ECO:0000305|PubMed:12415269, CC ECO:0000305|PubMed:17344846}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L10381; AAA18032.1; -; Genomic_DNA. DR EMBL; CR627369; CAH10468.1; -; mRNA. DR EMBL; AL138776; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471067; EAW91128.1; -; Genomic_DNA. DR EMBL; BC090934; AAH90934.1; -; mRNA. DR EMBL; BC114433; AAI14434.1; -; mRNA. DR CCDS; CCDS1347.1; -. [Q05823-1] DR PIR; A45771; A45771. DR RefSeq; NP_066956.1; NM_021133.4. [Q05823-1] DR RefSeq; XP_047283062.1; XM_047427106.1. [Q05823-2] DR RefSeq; XP_054194044.1; XM_054338069.1. [Q05823-2] DR PDB; 1WDY; X-ray; 1.80 A; A=21-305. DR PDB; 4G8K; X-ray; 2.40 A; A/B=1-337. DR PDB; 4G8L; X-ray; 2.80 A; A/B/C/D=1-337. DR PDB; 4OAU; X-ray; 2.60 A; C=21-719. DR PDB; 4OAV; X-ray; 2.10 A; B/D=21-719. DR PDBsum; 1WDY; -. DR PDBsum; 4G8K; -. DR PDBsum; 4G8L; -. DR PDBsum; 4OAU; -. DR PDBsum; 4OAV; -. DR AlphaFoldDB; Q05823; -. DR SMR; Q05823; -. DR BioGRID; 111969; 43. DR CORUM; Q05823; -. DR DIP; DIP-61367N; -. DR FunCoup; Q05823; 673. DR IntAct; Q05823; 42. DR MINT; Q05823; -. DR STRING; 9606.ENSP00000356530; -. DR BindingDB; Q05823; -. DR ChEMBL; CHEMBL3575; -. DR GlyGen; Q05823; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q05823; -. DR PhosphoSitePlus; Q05823; -. DR BioMuta; RNASEL; -. DR DMDM; 1350802; -. DR jPOST; Q05823; -. DR MassIVE; Q05823; -. DR PaxDb; 9606-ENSP00000356530; -. DR PeptideAtlas; Q05823; -. DR ProteomicsDB; 58353; -. [Q05823-1] DR ProteomicsDB; 66189; -. DR Pumba; Q05823; -. DR Antibodypedia; 1127; 232 antibodies from 30 providers. DR DNASU; 6041; -. DR Ensembl; ENST00000367559.7; ENSP00000356530.3; ENSG00000135828.12. [Q05823-1] DR Ensembl; ENST00000539397.1; ENSP00000440844.1; ENSG00000135828.12. [Q05823-2] DR GeneID; 6041; -. DR KEGG; hsa:6041; -. DR MANE-Select; ENST00000367559.7; ENSP00000356530.3; NM_021133.4; NP_066956.1. DR UCSC; uc001gpk.4; human. [Q05823-1] DR AGR; HGNC:10050; -. DR ClinPGx; PA34418; -. DR CTD; 6041; -. DR DisGeNET; 6041; -. DR GeneCards; RNASEL; -. DR HGNC; HGNC:10050; RNASEL. DR HPA; ENSG00000135828; Low tissue specificity. DR MalaCards; RNASEL; -. DR MIM; 176807; phenotype. DR MIM; 180435; gene. DR MIM; 601518; phenotype. DR OpenTargets; ENSG00000135828; -. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000135828; -. DR eggNOG; KOG1027; Eukaryota. DR eggNOG; KOG4177; Eukaryota. DR GeneTree; ENSGT00940000161114; -. DR HOGENOM; CLU_022542_0_0_1; -. DR InParanoid; Q05823; -. DR OMA; YGSESHK; -. DR OrthoDB; 194358at2759; -. DR PAN-GO; Q05823; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q05823; -. DR BioCyc; MetaCyc:HS06069-MONOMER; -. DR BRENDA; 4.6.1.19; 2681. DR PathwayCommons; Q05823; -. DR Reactome; R-HSA-8983711; OAS antiviral response. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR SignaLink; Q05823; -. DR SIGNOR; Q05823; -. DR Agora; ENSG00000135828; -. DR BioGRID-ORCS; 6041; 9 hits in 1192 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; RNASEL; human. DR EvolutionaryTrace; Q05823; -. DR GeneWiki; Ribonuclease_L; -. DR GeneWiki; RNASEL; -. DR GenomeRNAi; 6041; -. DR Pharos; Q05823; Tchem. DR PRO; PR:Q05823; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q05823; protein. DR Bgee; ENSG00000135828; Expressed in amniotic fluid and 174 other cell types or tissues. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0016363; C:nuclear matrix; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl. DR GO; GO:0003723; F:RNA binding; IDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; NAS:UniProtKB. DR GO; GO:0004540; F:RNA nuclease activity; IDA:ARUK-UCL. DR GO; GO:0019843; F:rRNA binding; IEA:Ensembl. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0051607; P:defense response to virus; IDA:UniProtKB. DR GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl. DR GO; GO:0006397; P:mRNA processing; IEA:InterPro. DR GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB. DR GO; GO:0046326; P:positive regulation of D-glucose import; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB. DR GO; GO:0043488; P:regulation of mRNA stability; IEA:Ensembl. DR GO; GO:0006396; P:RNA processing; IBA:GO_Central. DR GO; GO:0006364; P:rRNA processing; IEA:Ensembl. DR CDD; cd10423; RNase_RNase-L; 1. DR FunFam; 1.25.40.20:FF:000231; 2-5A-dependent ribonuclease; 1. DR FunFam; 1.10.510.10:FF:000618; Ribonuclease L; 1. DR FunFam; 1.20.1440.180:FF:000003; Ribonuclease L; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 1.20.1440.180; KEN domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR010513; KEN_dom. DR InterPro; IPR038357; KEN_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR042745; RNase-L_RNase. DR PANTHER; PTHR24141; 2-5A-DEPENDENT RIBONUCLEASE; 1. DR PANTHER; PTHR24141:SF1; 2-5A-DEPENDENT RIBONUCLEASE; 1. DR Pfam; PF12796; Ank_2; 3. DR Pfam; PF13857; Ank_5; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF06479; Ribonuc_2-5A; 1. DR PRINTS; PR01415; ANKYRIN. DR SMART; SM00248; ANK; 8. DR SMART; SM00580; PUG; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 6. DR PROSITE; PS51392; KEN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ANK repeat; KW Antiviral defense; ATP-binding; Cytoplasm; Endonuclease; Hydrolase; KW Immunity; Innate immunity; Metal-binding; Mitochondrion; Nuclease; KW Nucleotide-binding; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; Zinc; Zinc-finger. FT CHAIN 1..741 FT /note="2-5A-dependent ribonuclease" FT /id="PRO_0000067051" FT REPEAT 24..53 FT /note="ANK 1" FT REPEAT 58..87 FT /note="ANK 2" FT REPEAT 91..120 FT /note="ANK 3" FT REPEAT 124..153 FT /note="ANK 4" FT REPEAT 167..197 FT /note="ANK 5" FT REPEAT 201..234 FT /note="ANK 6" FT REPEAT 238..268 FT /note="ANK 7" FT REPEAT 272..301 FT /note="ANK 8" FT REPEAT 303..329 FT /note="ANK 9" FT DOMAIN 365..586 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 589..723 FT /note="KEN" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00725" FT ZN_FING 395..444 FT /note="C6-type; atypical" FT REGION 1..21 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 229..242 FT /note="2-5A binding (P-loop) 1" FT REGION 253..275 FT /note="2-5A binding (P-loop) 2" FT REGION 715..741 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9..18 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 684 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT VAR_SEQ 636..652 FT /note="INECVMKKMNKFYEKRG -> MSKLRHRQIIFPTTQNQ (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_056272" FT VAR_SEQ 653..741 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_056273" FT VARIANT 59 FT /note="G -> S (in dbSNP:rs151296858)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539" FT /id="VAR_013509" FT VARIANT 97 FT /note="I -> L (in dbSNP:rs56250729)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042358" FT VARIANT 289 FT /note="A -> T (in dbSNP:rs35553278)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042359" FT VARIANT 406 FT /note="S -> F (in dbSNP:rs145787003)" FT /evidence="ECO:0000269|PubMed:11941539" FT /id="VAR_013510" FT VARIANT 462 FT /note="R -> Q (risk factor for prostate cancer; reduced FT enzymatic activity; dbSNP:rs486907)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269, FT ECO:0000269|PubMed:17344846" FT /id="VAR_012056" FT VARIANT 541 FT /note="D -> E (no change in enzymatic activity; FT dbSNP:rs627928)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269, FT ECO:0000269|PubMed:17344846" FT /id="VAR_012057" FT VARIANT 592 FT /note="R -> H (in dbSNP:rs35896902)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042360" FT MUTAGEN 240 FT /note="K->N: Reduced 2-5A binding activity; almost complete FT loss of 2-5A binding activity; when associated with N-274." FT /evidence="ECO:0000269|PubMed:7680958" FT MUTAGEN 274 FT /note="K->N: Reduced 2-5A binding activity; almost complete FT loss of 2-5A binding activity; when associated with N-240." FT /evidence="ECO:0000269|PubMed:7680958" FT MUTAGEN 392 FT /note="K->R: Complete loss of enzymatic activity and enzyme FT dimerization. No change in binding to 2-5A and RNA." FT /evidence="ECO:0000269|PubMed:9862963" FT MUTAGEN 583 FT /note="H->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 584 FT /note="P->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 632 FT /note="W->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 661 FT /note="D->A: Complete loss of enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 667 FT /note="R->A: Complete loss of enzymatic activity. No change FT in 2-5A binding and enzyme dimerization." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 672 FT /note="H->A: Complete loss of enzymatic activity. No change FT in 2-5A binding activity and enzyme dimerization." FT /evidence="ECO:0000269|PubMed:11333017" FT HELIX 22..34 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 38..46 FT /evidence="ECO:0007829|PDB:1WDY" FT TURN 56..58 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 62..68 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 72..80 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 95..102 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 105..113 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 128..134 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 138..146 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 159..163 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 171..178 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 181..189 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 205..211 FT /evidence="ECO:0007829|PDB:1WDY" FT TURN 215..217 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 218..227 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 237..239 FT /evidence="ECO:0007829|PDB:4G8K" FT HELIX 242..248 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 252..260 FT /evidence="ECO:0007829|PDB:1WDY" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 276..282 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 286..295 FT /evidence="ECO:0007829|PDB:1WDY" FT STRAND 301..303 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 304..310 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 314..322 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 341..344 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 345..352 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 361..363 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 367..369 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 370..374 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 377..395 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 399..409 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 420..425 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 427..435 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 438..440 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 441..445 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 459..477 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 488..490 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 491..493 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 514..532 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 533..535 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 539..544 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 547..551 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 557..567 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 576..580 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 584..586 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 589..600 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 603..606 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 613..618 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 628..631 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 638..645 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 646..648 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 649..652 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 659..672 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 681..685 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 688..695 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 699..707 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 711..715 FT /evidence="ECO:0007829|PDB:4OAV" SQ SEQUENCE 741 AA; 83533 MW; 91385EA307E3CE1D CRC64; MESRDHNNPQ EGPTSSSGRR AAVEDNHLLI KAVQNEDVDL VQQLLEGGAN VNFQEEEGGW TPLHNAVQMS REDIVELLLR HGADPVLRKK NGATPFILAA IAGSVKLLKL FLSKGADVNE CDFYGFTAFM EAAVYGKVKA LKFLYKRGAN VNLRRKTKED QERLRKGGAT ALMDAAEKGH VEVLKILLDE MGADVNACDN MGRNALIHAL LSSDDSDVEA ITHLLLDHGA DVNVRGERGK TPLILAVEKK HLGLVQRLLE QEHIEINDTD SDGKTALLLA VELKLKKIAE LLCKRGASTD CGDLVMTARR NYDHSLVKVL LSHGAKEDFH PPAEDWKPQS SHWGAALKDL HRIYRPMIGK LKFFIDEKYK IADTSEGGIY LGFYEKQEVA VKTFCEGSPR AQREVSCLQS SRENSHLVTF YGSESHRGHL FVCVTLCEQT LEACLDVHRG EDVENEEDEF ARNVLSSIFK AVQELHLSCG YTHQDLQPQN ILIDSKKAAH LADFDKSIKW AGDPQEVKRD LEDLGRLVLY VVKKGSISFE DLKAQSNEEV VQLSPDEETK DLIHRLFHPG EHVRDCLSDL LGHPFFWTWE SRYRTLRNVG NESDIKTRKS ESEILRLLQP GPSEHSKSFD KWTTKINECV MKKMNKFYEK RGNFYQNTVG DLLKFIRNLG EHIDEEKHKK MKLKIGDPSL YFQKTFPDLV IYVYTKLQNT EYRKHFPQTH SPNKPQCDGA GGASGLASPG C // ID TRPM6_HUMAN Reviewed; 2022 AA. AC Q9BX84; Q6VPR8; Q6VPR9; Q6VPS0; Q6VPS1; Q6VPS2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2002, sequence version 2. DT 28-JAN-2026, entry version 184. DE RecName: Full=Transient receptor potential cation channel subfamily M member 6; DE EC=2.7.11.1 {ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}; DE AltName: Full=Channel kinase 2; DE AltName: Full=Melastatin-related TRP cation channel 6; DE Contains: DE RecName: Full=TRPM6 kinase, cleaved form {ECO:0000303|PubMed:28784805}; GN Name=TRPM6; Synonyms=CHAK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A). RC TISSUE=Kidney; RX PubMed=11357414; RA Riazanova L.V., Pavur K.S., Petrov A.N., Dorovkov M.V., Riazanov A.G.; RT "Novel type of signaling molecules: protein kinases covalently linked to RT ion channels."; RL Mol. Biol. (Mosk.) 35:321-332(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A), AND VARIANT HOMG1 LEU-141. RC TISSUE=Kidney, and Small intestine; RX PubMed=12032568; DOI=10.1038/ng889; RA Schlingmann K.P., Weber S., Peters M., Niemann Nejsum L.N., Vitzthum H., RA Klingel K., Kratz M., Haddad E., Ristoff E., Dinour D., Syrrou M., RA Nielsen S., Sassen M.C., Waldegger S., Seyberth H.W., Konrad M.; RT "Hypomagnesemia with secondary hypocalcemia is caused by mutations in RT TRPM6, a new member of the TRPM gene family."; RL Nat. Genet. 31:166-170(2002). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRPM6A; TRPM6B; TRPM6C; TRPM6T; RP M6-KINASE 1; M6-KINASE 2 AND M6-KINASE 3), CHARACTERIZATION OF VARIANT RP HOMG1 LEU-141, INTERACTION WITH TRPM7, AND SUBUNIT. RC TISSUE=Lung cancer; RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [5] RP FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, AND SUBCELLULAR RP LOCATION. RX PubMed=14576148; DOI=10.1074/jbc.m311201200; RA Voets T., Nilius B., Hoefs S., van der Kemp A.W., Droogmans G., RA Bindels R.J., Hoenderop J.G.; RT "TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ RT absorption."; RL J. Biol. Chem. 279:19-25(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP CHARACTERIZATION OF VARIANT HOMG1 LEU-141. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [7] RP SUBUNIT, AND VARIANT HOMG1 ARG-1017. RX PubMed=17197439; DOI=10.1074/jbc.m611117200; RA Chubanov V., Schlingmann K.P., Waering J., Heinzinger J., Kaske S., RA Waldegger S., Mederos y Schnitzler M., Gudermann T.; RT "Hypomagnesemia with secondary hypocalcemia due to a missense mutation in RT the putative pore-forming region of TRPM6."; RL J. Biol. Chem. 282:7656-7667(2007). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [9] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH RACK1, RP PHOSPHORYLATION AT THR-1851, AND MUTAGENESIS OF LYS-1804 AND THR-1851. RX PubMed=18258429; DOI=10.1016/j.cub.2007.12.058; RA Cao G., Thebault S., van der Wijst J., van der Kemp A., Lasonder E., RA Bindels R.J., Hoenderop J.G.; RT "RACK1 inhibits TRPM6 activity via phosphorylation of the fused alpha- RT kinase domain."; RL Curr. Biol. 18:168-176(2008). RN [10] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=24385424; DOI=10.1074/jbc.m113.512285; RA Zhang Z., Yu H., Huang J., Faouzi M., Schmitz C., Penner R., Fleig A.; RT "The TRPM6 kinase domain determines the Mg.ATP sensitivity of TRPM7/M6 RT heteromeric ion channels."; RL J. Biol. Chem. 289:5217-5227(2014). RN [11] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 1063-ASN--LEU-1065. RX PubMed=28784805; DOI=10.1073/pnas.1708427114; RA Krapivinsky G., Krapivinsky L., Renthal N.E., Santa-Cruz A., Manasian Y., RA Clapham D.E.; RT "Histone phosphorylation by TRPM6's cleaved kinase attenuates adjacent RT arginine methylation to regulate gene expression."; RL Proc. Natl. Acad. Sci. U.S.A. 114:E7092-E7100(2017). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-75; ILE-338; CYS-1007; ARG-1243; RP ARG-1274; ILE-1393; GLU-1584; ARG-1663; SER-1673 AND ILE-1724. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [13] RP VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053; PRO-1143 AND ASN-1754, VARIANT RP ARG-1663, CHARACTERIZATION OF VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053; RP PRO-1143 AND ASN-1754, CHARACTERIZATION OF VARIANT ARG-1663, AND RP SUBCELLULAR LOCATION. RX PubMed=23942199; DOI=10.1038/ejhg.2013.178; RA Lainez S., Schlingmann K.P., van der Wijst J., Dworniczak B., RA van Zeeland F., Konrad M., Bindels R.J., Hoenderop J.G.; RT "New TRPM6 missense mutations linked to hypomagnesemia with secondary RT hypocalcemia."; RL Eur. J. Hum. Genet. 22:497-504(2014). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain (PubMed:14576148, CC PubMed:16636202, PubMed:18258429, PubMed:18365021). Crucial for Mg(2+) CC homeostasis. Has an important role in epithelial Mg(2+) transport and CC in the active Mg(2+) absorption in the gut and kidney CC (PubMed:14576148). However, whether TRPM6 forms functional homomeric CC channels by itself or functions primarily as a subunit of heteromeric CC TRPM6-TRPM7 channels, is still under debate (PubMed:14576148, CC PubMed:16636202, PubMed:24385424). {ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202, ECO:0000269|PubMed:18258429, CC ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:24385424}. CC -!- FUNCTION: [TRPM6 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. The cleaved kinase fragments can translocate to the nucleus, CC and bind chromatin-remodeling complex proteins to ultimately CC phosphorylate specific Ser/Thr residues of histones known to be CC functionally important for cell differentiation and development. CC {ECO:0000269|PubMed:28784805}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000269|PubMed:16636202}; CC -!- ACTIVITY REGULATION: Strongly inhibited by intracellular Mg(2+); CC unlikely to be active at physiological levels of intracellular Mg(2+) CC (PubMed:14576148, PubMed:16636202, PubMed:24385424). In the heteromeric CC TRPM6-TRPM7 channels complexes, TRPM7 are able to offset the very high CC sensitivity of TRPM6 to cytosolic Mg(2+) to physiologically relevant CC concentrations, whereas TRPM6 relieve TRPM7 from the inhibitory action CC of Mg-ATP. Consequently, the association of TRPM6 with TRPM7 allow for CC high constitutive activity of TRPM6/7 in the presence of physiological CC levels of Mg(2+) and Mg-ATP (By similarity). The kinase activity is CC controlled through the autophosphorylation of a serine/threonine-rich CC region located to the N-terminal of the catalytic domain CC (PubMed:18258429, PubMed:18365021). {ECO:0000250|UniProtKB:Q8CIR4, CC ECO:0000269|PubMed:14576148, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:24385424}. CC -!- SUBUNIT: Homomers (PubMed:16636202). Forms heteromers with TRPM7; TRPM6 CC increases the current amplitude of TRPM6/7 heteromers as compared to CC TRPM7 homomer (PubMed:14976260, PubMed:16636202, PubMed:17197439). CC Interacts (via kinase domain) with RACK1 (PubMed:18258429). CC {ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:17197439, ECO:0000269|PubMed:18258429}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23942199}; CC Multi-pass membrane protein {ECO:0000305}. Apical cell membrane CC {ECO:0000269|PubMed:14576148}; Multi-pass membrane protein CC {ECO:0000305}. Note=TRPM6 requires the presence of TRPM7 to be targeted CC to the cell membrane (in HEK 293 cells). {ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:17197439}. CC -!- SUBCELLULAR LOCATION: [TRPM6 kinase, cleaved form]: Nucleus CC {ECO:0000269|PubMed:28784805}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=TRPM6a {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-1; Sequence=Displayed; CC Name=TRPM6b {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-2; Sequence=VSP_012069; CC Name=TRPM6c {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-3; Sequence=VSP_012070; CC Name=TRPM6t {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-4; Sequence=VSP_012075, VSP_012076; CC Name=M6-kinase 1 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-5; Sequence=VSP_012074; CC Name=M6-kinase 2 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-6; Sequence=VSP_012073; CC Name=M6-kinase 3 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-7; Sequence=VSP_012071, VSP_012072; CC -!- TISSUE SPECIFICITY: Highly expressed in kidney and colon. Isoform CC TRPM6a and isoform TRPM6b, are coexpressed with TRPM7 in kidney, and CC testis, and are also found in several cell lines of lung origin. CC Isoform TRPM6c is detected only in testis and in NCI-H510A small cell CC lung carcinoma cells. CC -!- PTM: Autophosphorylated; autophosphorylation controlls the protein CC kinase activity of TRPM6 towards their substrates (PubMed:18258429, CC PubMed:18365021). Autophosphorylation of Thr-1851 in the kinase domain CC is essential for the inhibitory effect of RACK1 (PubMed:18258429). CC {ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminus of TRPM6 is proteolytically cleaved in vivo, in a CC cell type-specific fashion, releasing the kinase module from the CC transmembrane domain. The cleaved kinase fragments are translocated to CC the nucleus to phosphorylate histones and regulate gene expression. CC {ECO:0000269|PubMed:28784805}. CC -!- DISEASE: Hypomagnesemia 1 (HOMG1) [MIM:602014]: A disorder due to a CC primary defect in intestinal magnesium absorption. It is characterized CC by low levels of serum magnesium alongside with a normal renal CC magnesium secretion, secondary hypocalcemia and calcinocis. Affected CC individuals show neurologic symptoms of hypomagnesemic hypocalcemia, CC including seizures and muscle spasms, during infancy. Hypocalcemia is CC secondary to parathyroid failure resulting from magnesium deficiency. CC Untreated, the disorder may be fatal or may result in neurological CC damage. {ECO:0000269|PubMed:12032568, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202, ECO:0000269|PubMed:17197439, CC ECO:0000269|PubMed:23942199}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform M6-kinase 1]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform M6-kinase 2]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform M6-kinase 3]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM6 sub-subfamily. CC {ECO:0000305}. CC -!- CAUTION: Whether TRPM6 forms functional homomeric channels by itself is CC still under debate. According to PubMed:14576148 and PubMed:16636202, CC TRPM6 are able to form TRPM6 channels with similar properties to those CC of TRPM7, with biophysical characteristics resembling those of TRPM7 CC including the high channel pore selectivity for divalent cations and CC regulation by intracellular Mg(2+) (PubMed:14576148, PubMed:16636202). CC In contrast, others studies report that TRPM6 does not produce CC functional currents by itself and TRPM6 does not efficiently form CC homotetramers channels in the plasma membrane, but requires TRPM7 to be CC co-targeted to the cell surface (PubMed:14976260, PubMed:17197439). CC Further, homotetramers TRPM6 are highly sensitive to intracellular free CC Mg(2+) and therefore unlikely to be active at physiological levels of CC intracellular Mg(2+) (PubMed:24385424). {ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:17197439, ECO:0000269|PubMed:24385424}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF350881; AAK31202.2; -; mRNA. DR EMBL; AF448232; AAM21562.1; -; mRNA. DR EMBL; AY333282; AAR03487.1; -; mRNA. DR EMBL; AY333283; AAR03488.1; -; mRNA. DR EMBL; AY333284; AAR03489.1; -; mRNA. DR EMBL; AY333285; AAR03490.1; -; mRNA. DR EMBL; AY333286; AAR03491.1; -; mRNA. DR EMBL; AY333287; AAR03492.1; -; mRNA. DR EMBL; AY333288; AAR03493.1; -; mRNA. DR EMBL; AL354795; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS55318.1; -. [Q9BX84-3] DR CCDS; CCDS55319.1; -. [Q9BX84-2] DR CCDS; CCDS6647.1; -. [Q9BX84-1] DR RefSeq; NP_001170781.1; NM_001177310.2. [Q9BX84-2] DR RefSeq; NP_001170782.1; NM_001177311.2. [Q9BX84-3] DR RefSeq; NP_060132.3; NM_017662.4. [Q9BX84-1] DR AlphaFoldDB; Q9BX84; -. DR SMR; Q9BX84; -. DR BioGRID; 126713; 8. DR CORUM; Q9BX84; -. DR FunCoup; Q9BX84; 552. DR IntAct; Q9BX84; 3. DR MINT; Q9BX84; -. DR STRING; 9606.ENSP00000354006; -. DR BindingDB; Q9BX84; -. DR ChEMBL; CHEMBL1628470; -. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR GuidetoPHARMACOLOGY; 498; -. DR TCDB; 1.A.4.5.8; the transient receptor potential ca2+/cation channel (trp-cc) family. DR GlyGen; Q9BX84; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BX84; -. DR MetOSite; Q9BX84; -. DR PhosphoSitePlus; Q9BX84; -. DR BioMuta; TRPM6; -. DR DMDM; 56404951; -. DR CPTAC; CPTAC-2831; -. DR CPTAC; CPTAC-2987; -. DR jPOST; Q9BX84; -. DR MassIVE; Q9BX84; -. DR PaxDb; 9606-ENSP00000354006; -. DR PeptideAtlas; Q9BX84; -. DR ProteomicsDB; 79380; -. [Q9BX84-1] DR ProteomicsDB; 79381; -. [Q9BX84-2] DR ProteomicsDB; 79382; -. [Q9BX84-3] DR ProteomicsDB; 79383; -. [Q9BX84-4] DR ProteomicsDB; 79384; -. [Q9BX84-5] DR ProteomicsDB; 79385; -. [Q9BX84-6] DR ProteomicsDB; 79386; -. [Q9BX84-7] DR ABCD; Q9BX84; 1 sequenced antibody. DR Antibodypedia; 2049; 136 antibodies from 24 providers. DR DNASU; 140803; -. DR Ensembl; ENST00000360774.6; ENSP00000354006.1; ENSG00000119121.23. [Q9BX84-1] DR Ensembl; ENST00000361255.7; ENSP00000354962.3; ENSG00000119121.23. [Q9BX84-3] DR Ensembl; ENST00000449912.6; ENSP00000396672.2; ENSG00000119121.23. [Q9BX84-2] DR Ensembl; ENST00000715553.1; ENSP00000520473.1; ENSG00000119121.23. [Q9BX84-4] DR GeneID; 140803; -. DR KEGG; hsa:140803; -. DR MANE-Select; ENST00000360774.6; ENSP00000354006.1; NM_017662.5; NP_060132.3. DR UCSC; uc004ajk.1; human. [Q9BX84-1] DR AGR; HGNC:17995; -. DR ClinPGx; PA38479; -. DR CTD; 140803; -. DR DisGeNET; 140803; -. DR GeneCards; TRPM6; -. DR HGNC; HGNC:17995; TRPM6. DR HPA; ENSG00000119121; Tissue enriched (intestine). DR MalaCards; TRPM6; -. DR MIM; 602014; phenotype. DR MIM; 607009; gene. DR OpenTargets; ENSG00000119121; -. DR Orphanet; 30924; Primary hypomagnesemia with secondary hypocalcemia. DR VEuPathDB; HostDB:ENSG00000119121; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000158164; -. DR HOGENOM; CLU_001390_2_0_1; -. DR InParanoid; Q9BX84; -. DR OMA; EVVQTWY; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q9BX84; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9BX84; -. DR PathwayCommons; Q9BX84; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q9BX84; -. DR SIGNOR; Q9BX84; -. DR Agora; ENSG00000119121; -. DR BioGRID-ORCS; 140803; 7 hits in 1184 CRISPR screens. DR ChiTaRS; TRPM6; human. DR GeneWiki; TRPM6; -. DR GenomeRNAi; 140803; -. DR Pharos; Q9BX84; Tchem. DR PRO; PR:Q9BX84; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9BX84; protein. DR Bgee; ENSG00000119121; Expressed in colonic mucosa and 125 other cell types or tissues. DR ExpressionAtlas; Q9BX84; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0031526; C:brush border membrane; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IBA:GO_Central. DR GO; GO:0015085; F:calcium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:1903830; P:magnesium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB. DR CDD; cd16972; Alpha_kinase_ChaK2_TRPM6; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR005821; Ion_trans_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029597; TRPM6_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF15; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 6; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF00520; Ion_trans; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 1. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Calcium; Calcium channel; KW Calcium transport; Cell membrane; Disease variant; Ion channel; KW Ion transport; Kinase; Membrane; Metal-binding; Nucleotide-binding; KW Nucleus; Phosphoprotein; Primary hypomagnesemia; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Transmembrane; Transmembrane helix; Transport; Zinc. FT CHAIN 1..2022 FT /note="Transient receptor potential cation channel FT subfamily M member 6" FT /id="PRO_0000215329" FT CHAIN ?..2022 FT /note="TRPM6 kinase, cleaved form" FT /evidence="ECO:0000269|PubMed:28784805" FT /id="PRO_0000461405" FT TOPO_DOM 1..741 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 742..762 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 763..841 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 842..862 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 863..905 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 906..926 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 927..939 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 940..960 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 961..972 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 973..993 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 994..1012 FT /note="Extracellular" FT /evidence="ECO:0000255" FT INTRAMEM 1013..1033 FT /note="Pore-forming" FT /evidence="ECO:0000255" FT TOPO_DOM 1034..1047 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 1048..1068 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1069..2022 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 1750..1980 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 1479..1516 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1997..2022 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1483..1493 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1512 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1998..2016 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1923 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1778 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1779 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1780 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1804 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1876 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1879 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1909 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1933 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1966 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1968 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1972 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1851 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18258429" FT VAR_SEQ 1..11 FT /note="MKEQPVLERLQ -> MIILSK (in isoform TRPM6b)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012069" FT VAR_SEQ 1..11 FT /note="MKEQPVLERLQ -> MTAPVT (in isoform TRPM6c)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012070" FT VAR_SEQ 281 FT /note="R -> P (in isoform M6-kinase 3)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012071" FT VAR_SEQ 282..1734 FT /note="Missing (in isoform M6-kinase 3)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012072" FT VAR_SEQ 500..1666 FT /note="Missing (in isoform M6-kinase 2)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012073" FT VAR_SEQ 547..1595 FT /note="Missing (in isoform M6-kinase 1)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012074" FT VAR_SEQ 1926..1943 FT /note="GVGENLTDPSVIKPEVKQ -> ALWFWDSMLKARLGGWRM (in isoform FT TRPM6t)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012075" FT VAR_SEQ 1944..2022 FT /note="Missing (in isoform TRPM6t)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012076" FT VARIANT 75 FT /note="G -> V (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1193127627)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042387" FT VARIANT 141 FT /note="S -> L (in HOMG1; abolishes channel activity. FT Impairs homo- and heterooligomeric formation with TRPM7 FT resulting in intracellular retention; dbSNP:rs121912625)" FT /evidence="ECO:0000269|PubMed:12032568, FT ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202" FT /id="VAR_019963" FT VARIANT 338 FT /note="M -> I (in dbSNP:rs56155062)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042388" FT VARIANT 708 FT /note="L -> P (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071480" FT VARIANT 872 FT /note="E -> G (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071481" FT VARIANT 948 FT /note="F -> L (in dbSNP:rs13290391)" FT /id="VAR_052380" FT VARIANT 1007 FT /note="W -> C (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042389" FT VARIANT 1017 FT /note="P -> R (in HOMG1; does not affect protein FT expression. Does not affect coassembly with TRPM7. Impairs FT channel activity of TRPM6/7 complexes)" FT /evidence="ECO:0000269|PubMed:17197439" FT /id="VAR_089905" FT VARIANT 1053 FT /note="Y -> C (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071482" FT VARIANT 1071 FT /note="N -> D (in dbSNP:rs2274922)" FT /id="VAR_019964" FT VARIANT 1143 FT /note="L -> P (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071483" FT VARIANT 1243 FT /note="H -> R (in dbSNP:rs55694430)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042390" FT VARIANT 1274 FT /note="Q -> R (in dbSNP:rs34608911)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042391" FT VARIANT 1393 FT /note="V -> I (in dbSNP:rs3750425)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019965" FT VARIANT 1584 FT /note="K -> E (in dbSNP:rs2274924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019966" FT VARIANT 1663 FT /note="Q -> R (no effect on channel activity or cell FT membrane localization; dbSNP:rs55679040)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:23942199" FT /id="VAR_042392" FT VARIANT 1673 FT /note="L -> S (in dbSNP:rs56254742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042393" FT VARIANT 1724 FT /note="T -> I (in dbSNP:rs56290308)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042394" FT VARIANT 1754 FT /note="S -> N (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071484" FT MUTAGEN 1063..1065 FT /note="NLL->FAP: Abolishes channel activity. Abolishes FT endogenous protein cleavage." FT /evidence="ECO:0000269|PubMed:28784805" FT MUTAGEN 1804 FT /note="K->R: Abolishes kinase activity but does not affect FT expression levels or binding to RACK1." FT /evidence="ECO:0000269|PubMed:18258429" FT MUTAGEN 1851 FT /note="T->A: Significantly decreases autophosphorylation. FT Does not alter binding to RACK1 but prevents inhibition by FT RACK1." FT /evidence="ECO:0000269|PubMed:18258429" FT MUTAGEN 1851 FT /note="T->D: Significantly decreases autophosphorylation. FT Does not alter binding to RACK1 or inhibition by RACK1." FT /evidence="ECO:0000269|PubMed:18258429" SQ SEQUENCE 2022 AA; 231708 MW; 59346B3BE3300466 CRC64; MKEQPVLERL QSQKSWIKGV FDKRECSTII PSSKNPHRCT PVCQVCQNLI RCYCGRLIGD HAGIDYSWTI SAAKGKESEQ WSVEKHTTKS PTDTFGTINF QDGEHTHHAK YIRTSYDTKL DHLLHLMLKE WKMELPKLVI SVHGGIQNFT MPSKFKEIFS QGLVKAAETT GAWIITEGIN TGVSKHVGDA LKSHSSHSLR KIWTVGIPPW GVIENQRDLI GKDVVCLYQT LDNPLSKLTT LNSMHSHFIL SDDGTVGKYG NEMKLRRNLE KYLSLQKIHC RSRQGVPVVG LVVEGGPNVI LSVWETVKDK DPVVVCEGTG RAADLLAFTH KHLADEGMLR PQVKEEIICM IQNTFNFSLK QSKHLFQILM ECMVHRDCIT IFDADSEEQQ DLDLAILTAL LKGTNLSASE QLNLAMAWDR VDIAKKHILI YEQHWKPDAL EQAMSDALVM DRVDFVKLLI EYGVNLHRFL TIPRLEELYN TKQGPTNTLL HHLVQDVKQH TLLSGYRITL IDIGLVVEYL IGRAYRSNYT RKHFRALYNN LYRKYKHQRH SSGNRNESAE STLHSQFIRT AQPYKFKEKS IVLHKSRKKS KEQNVSDDPE STGFLYPYND LLVWAVLMKR QKMAMFFWQH GEEATVKAVI ACILYRAMAH EAKESHMVDD ASEELKNYSK QFGQLALDLL EKAFKQNERM AMTLLTYELR NWSNSTCLKL AVSGGLRPFV SHTCTQMLLT DMWMGRLKMR KNSWLKIIIS IILPPTILTL EFKSKAEMSH VPQSQDFQFM WYYSDQNASS SKESASVKEY DLERGHDEKL DENQHFGLES GHQHLPWTRK VYEFYSAPIV KFWFYTMAYL AFLMLFTYTV LVEMQPQPSV QEWLVSIYIF TNAIEVVREI CISEPGKFTQ KVKVWISEYW NLTETVAIGL FSAGFVLRWG DPPFHTAGRL IYCIDIIFWF SRLLDFFAVN QHAGPYVTMI AKMTANMFYI VIIMAIVLLS FGVARKAILS PKEPPSWSLA RDIVFEPYWM IYGEVYAGEI DVCSSQPSCP PGSFLTPFLQ AVYLFVQYII MVNLLIAFFN NVYLDMESIS NNLWKYNRYR YIMTYHEKPW LPPPLILLSH VGLLLRRLCC HRAPHDQEEG DVGLKLYLSK EDLKKLHDFE EQCVEKYFHE KMEDVNCSCE ERIRVTSERV TEMYFQLKEM NEKVSFIKDS LLSLDSQVGH LQDLSALTVD TLKVLSAVDT LQEDEALLAK RKHSTCKKLP HSWSNVICAE VLGSMEIAGE KKYQYYSMPS SLLRSLAGGR HPPRVQRGAL LEITNSKREA TNVRNDQERQ ETQSSIVVSG VSPNRQAHSK YGQFLLVPSN LKRVPFSAET VLPLSRPSVP DVLATEQDIQ TEVLVHLTGQ TPVVSDWASV DEPKEKHEPI AHLLDGQDKA EQVLPTLSCT PEPMTMSSPL SQAKIMQTGG GYVNWAFSEG DETGVFSIKK KWQTCLPSTC DSDSSRSEQH QKQAQDSSLS DNSTRSAQSS ECSEVGPWLQ PNTSFWINPL RRYRPFARSH SFRFHKEEKL MKICKIKNLS GSSEIGQGAW VKAKMLTKDR RLSKKKKNTQ GLQVPIITVN ACSQSDQLNP EPGENSISEE EYSKNWFTVS KFSHTGVEPY IHQKMKTKEI GQCAIQISDY LKQSQEDLSK NSLWNSRSTN LNRNSLLKSS IGVDKISASL KSPQEPHHHY SAIERNNLMR LSQTIPFTPV QLFAGEEITV YRLEESSPLN LDKSMSSWSQ RGRAAMIQVL SREEMDGGLR KAMRVVSTWS EDDILKPGQV FIVKSFLPEV VRTWHKIFQE STVLHLCLRE IQQQRAAQKL IYTFNQVKPQ TIPYTPRFLE VFLIYCHSAN QWLTIEKYMT GEFRKYNNNN GDEITPTNTL EELMLAFSHW TYEYTRGELL VLDLQGVGEN LTDPSVIKPE VKQSRGMVFG PANLGEDAIR NFIAKHHCNS CCRKLKLPDL KRNDYSPERI NSTFGLEIKI ESAEEPPARE TGRNSPEDDM QL // ID TRPM7_HUMAN Reviewed; 1865 AA. AC Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Transient receptor potential cation channel subfamily M member 7; DE EC=2.7.11.1 {ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; DE AltName: Full=Channel-kinase 1; DE AltName: Full=Long transient receptor potential channel 7 {ECO:0000303|PubMed:11385574}; DE Short=LTrpC-7; DE Short=LTrpC7; DE Contains: DE RecName: Full=TRPM7 kinase, cleaved form {ECO:0000250|UniProtKB:Q923J1}; DE Short=M7CK; DE Contains: DE RecName: Full=TRPM7 channel, cleaved form {ECO:0000250|UniProtKB:Q923J1}; GN Name=TRPM7; Synonyms=CHAK1, LTRPC7 {ECO:0000303|PubMed:11385574}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY RP REGULATION. RX PubMed=11385574; DOI=10.1038/35079092; RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RT "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell RT viability."; RL Nature 411:590-595(2001). RN [2] RP ERRATUM OF PUBMED:11385574. RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RL Nature 412:660-660(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RX PubMed=14594813; DOI=10.1074/jbc.m308820200; RA Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.; RT "Characterization of the protein kinase activity of TRPM7/ChaK1, a protein RT kinase fused to the transient receptor potential ion channel."; RL J. Biol. Chem. 279:3708-3716(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND VARIANT RP ILE-1482. RC TISSUE=Colon, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF LYS-1648 AND GLY-1799. RX PubMed=12887921; DOI=10.1016/s0092-8674(03)00556-7; RA Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K., Penner R., RA Kurosaki T., Fleig A., Scharenberg A.M.; RT "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7."; RL Cell 114:191-200(2003). RN [7] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15485879; DOI=10.1074/jbc.c400441200; RA Dorovkov M.V., Ryazanov A.G.; RT "Phosphorylation of annexin I by TRPM7 channel-kinase."; RL J. Biol. Chem. 279:50643-50646(2004). RN [8] RP INTERACTION WITH TRPM6. RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [9] RP INTERACTION WITH TRPM6. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [10] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18394644; DOI=10.1016/j.jmb.2008.02.057; RA Clark K., Middelbeek J., Lasonder E., Dulyaninova N.G., Morrice N.A., RA Ryazanov A.G., Bresnick A.R., Figdor C.G., van Leeuwen F.N.; RT "TRPM7 regulates myosin IIA filament stability and protein localization by RT heavy chain phosphorylation."; RL J. Mol. Biol. 378:790-803(2008). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP THR-1163; SER-1191; SER-1193; SER-1255; SER-1258; THR-1265; SER-1287; RP SER-1358; SER-1361; SER-1387; SER-1390; SER-1396; SER-1404; THR-1405; RP SER-1407; THR-1435; SER-1446; THR-1455; SER-1456; SER-1463; SER-1468; RP THR-1471; SER-1476; SER-1477; THR-1482; SER-1493; SER-1504; THR-1508; RP SER-1513; SER-1527; SER-1533; THR-1537; THR-1542; SER-1543; THR-1551; RP SER-1567; SER-1569; THR-1583; SER-1598; SER-1615; SER-1660; THR-1685; RP SER-1779; THR-1830 AND SER-1860. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-1387; SER-1390; RP SER-1395; SER-1404; SER-1477; SER-1527 AND SER-1569, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [17] RP PALMITOYLATION AT CYS-1143; CYS-1144 AND CYS-1146, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=36027648; DOI=10.1016/j.ceca.2022.102639; RA Gao X., Kuo C.W., Main A., Brown E., Rios F.J., Camargo L.L., Mary S., RA Wypijewski K., Goek C., Touyz R.M., Fuller W.; RT "Palmitoylation regulates cellular distribution of and transmembrane Ca RT flux through TrpM7."; RL Cell Calcium 106:102639-102639(2022). RN [18] RP VARIANT ILE-1482, CHARACTERIZATION OF VARIANT ILE-1482, AND ACTIVITY RP REGULATION. RX PubMed=16051700; DOI=10.1073/pnas.0505149102; RA Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R., Ryazanov A.G., RA Haymer D.S., Garruto R.M.; RT "A TRPM7 variant shows altered sensitivity to magnesium that may contribute RT to the pathogenesis of two Guamanian neurodegenerative disorders."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005). RN [19] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574; SER-720; RP VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306; LYS-1444 AND RP ILE-1482. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, VARIANT ASP-1046, RP CHARACTERIZATION OF VARIANT ASP-1046, AND INVOLVEMENT IN HYPOMAGNESEMIA RP WITH SECONDARY HYPOCALCEMIA. RX PubMed=35561741; DOI=10.1093/ndt/gfac182; RA Vargas-Poussou R., Claverie-Martin F., Prot-Bertoye C., Carotti V., RA van der Wijst J., Perdomo-Ramirez A., Fraga-Rodriguez G.M., Hureaux M., RA Bos C., Latta F., Houillier P., Hoenderop J., de Baaij J.; RT "Possible role for rare TRPM7 variants in patients with hypomagnesemia with RT secondary hypocalcemia."; RL Nephrol. Dial. Transplant. 0:0-0(2022). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain. The channel is highly CC permeable to divalent cations, specifically calcium (Ca2+), magnesium CC (Mg2+) and zinc (Zn2+) and mediates their influx (PubMed:11385574, CC PubMed:12887921, PubMed:15485879, PubMed:24316671, PubMed:35561741, CC PubMed:36027648). Controls a wide range of biological processes such as CC Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel CC and intracellular Ca(2+) signaling, embryonic development, immune CC responses, cell motility, proliferation and differentiation (By CC similarity). The C-terminal alpha-kinase domain autophosphorylates CC cytoplasmic residues of TRPM7 (PubMed:18365021). In vivo, TRPM7 CC phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in CC activating SMAD signaling pathways. In vitro, TRPM7 kinase CC phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of CC proteins with diverse cellular functions (PubMed:15485879, CC PubMed:18394644). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:12887921, CC ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644, ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741, ECO:0000269|PubMed:36027648}. CC -!- FUNCTION: [TRPM7 channel, cleaved form]: The cleaved channel exhibits CC substantially higher current and potentiates Fas receptor signaling. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- FUNCTION: [TRPM7 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. In immune cells, the TRPM7 kinase domain is clipped from the CC channel domain by caspases in response to Fas-receptor stimulation. The CC cleaved kinase fragments can translocate to the nucleus, and bind CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones known to CC be functionally important for cell differentiation and embryonic CC development. {ECO:0000250|UniProtKB:Q923J1}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:12887921, ECO:0000269|PubMed:35561741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:36027648}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000250|UniProtKB:Q923J1}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000250|UniProtKB:Q923J1}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q923J1}; CC -!- ACTIVITY REGULATION: Channel displays constitutive activity. Channel CC activity is negatively regulated by cytosolic Mg(2+) and Mg-ATP CC (PubMed:11385574, PubMed:16051700). Channel activity is negatively CC regulated by low intracellular pH (By similarity). Resting free CC cytosolic Mg(2+) and Mg-ATP concentrations seem to be sufficient to CC block native TRPM7 channel activity (By similarity). TRPM7 channel CC activity is highly dependent on membrane levels of phosphatidylinositol CC 4,5 bisphosphate (PIP2). PIP2 hydrolysis negatively regulates TRPM7 CC channel activity (By similarity). TRPM7 kinase activity does not affect CC channel activity (By similarity). The kinase activity is controlled CC through the autophosphorylation of a serine/threonine-rich region CC located N-terminal to the catalytic domain (PubMed:18365021). CC {ECO:0000250|UniProtKB:Q923J1, ECO:0000250|UniProtKB:Q925B3, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:16051700, CC ECO:0000269|PubMed:18365021}. CC -!- SUBUNIT: Homotetramer (By similarity). Interacts with PLCB1 (By CC similarity). Forms heteromers with TRPM6; heteromeric channels are CC functionally different from the homomeric channels (PubMed:14976260, CC PubMed:16636202). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000250|UniProtKB:Q925B3, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Cytoplasmic vesicle membrane CC {ECO:0000250|UniProtKB:Q923J1}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Note=Localized largely in intracellular CC Zn(2+)-storage vesicles. {ECO:0000250|UniProtKB:Q923J1}. CC -!- SUBCELLULAR LOCATION: [TRPM7 kinase, cleaved form]: Nucleus CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- PTM: Palmitoylated; palmitoylation at Cys-1143, Cys-1144 and Cys-1146 CC promotes TRPM7 trafficking from the Golgi to the surface membrane. CC {ECO:0000269|PubMed:36027648}. CC -!- PTM: Autophosphorylated; autophosphorylation of C-terminus regulates CC TRPM7 kinase activity towards its substrates. CC {ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminal kinase domain can be cleaved from the channel CC segment in a cell-type-specific fashion. TRPM7 is cleaved by caspase-8, CC dissociating the kinase from the ion-conducting pore. The cleaved CC kinase fragments (M7CKs) can translocate to the cell nucleus and binds CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- DISEASE: Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 CC (ALS-PDC1) [MIM:105500]: A neurodegenerative disorder characterized by CC chronic, progressive and uniformly fatal amyotrophic lateral sclerosis CC and parkinsonism-dementia. Both diseases are known to occur in the same CC kindred, the same sibship and even the same individual. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=TRPM7 variants have been identified as a potential cause CC of disease in patients suffering from seizures and muscle cramps due to CC magnesium deficiency and episodes of hypocalcemia. CC {ECO:0000269|PubMed:35561741}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAC11462.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAD18773.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY032950; AAK44211.1; -; mRNA. DR EMBL; AF346629; AAK19738.2; -; mRNA. DR EMBL; AK000124; BAA90958.1; -; mRNA. DR EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA. DR EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA. DR EMBL; BC051024; AAH51024.1; -; mRNA. DR CCDS; CCDS42035.1; -. DR RefSeq; NP_001288141.1; NM_001301212.1. DR RefSeq; NP_060142.3; NM_017672.5. DR AlphaFoldDB; Q96QT4; -. DR SMR; Q96QT4; -. DR BioGRID; 120177; 153. DR CORUM; Q96QT4; -. DR FunCoup; Q96QT4; 1775. DR IntAct; Q96QT4; 44. DR MINT; Q96QT4; -. DR STRING; 9606.ENSP00000495860; -. DR BindingDB; Q96QT4; -. DR ChEMBL; CHEMBL1250412; -. DR DrugBank; DB04447; 1,4-Dithiothreitol. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR DrugBank; DB06757; Manganese cation. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR GuidetoPHARMACOLOGY; 499; -. DR TCDB; 1.A.4.5.1; the transient receptor potential ca2+/cation channel (trp-cc) family. DR CarbonylDB; Q96QT4; -. DR iPTMnet; Q96QT4; -. DR PhosphoSitePlus; Q96QT4; -. DR SwissPalm; Q96QT4; -. DR BioMuta; TRPM7; -. DR DMDM; 56404941; -. DR jPOST; Q96QT4; -. DR MassIVE; Q96QT4; -. DR PaxDb; 9606-ENSP00000320239; -. DR PeptideAtlas; Q96QT4; -. DR ProteomicsDB; 77898; -. DR Pumba; Q96QT4; -. DR Antibodypedia; 24755; 465 antibodies from 40 providers. DR DNASU; 54822; -. DR Ensembl; ENST00000646667.1; ENSP00000495860.1; ENSG00000092439.16. DR GeneID; 54822; -. DR KEGG; hsa:54822; -. DR MANE-Select; ENST00000646667.1; ENSP00000495860.1; NM_017672.6; NP_060142.3. DR UCSC; uc001zyt.5; human. DR AGR; HGNC:17994; -. DR ClinPGx; PA38273; -. DR CTD; 54822; -. DR DisGeNET; 54822; -. DR GeneCards; TRPM7; -. DR HGNC; HGNC:17994; TRPM7. DR HPA; ENSG00000092439; Tissue enriched (parathyroid). DR MalaCards; TRPM7; -. DR MIM; 105500; phenotype. DR MIM; 605692; gene. DR OpenTargets; ENSG00000092439; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 90020; Parkinson-dementia complex of Guam. DR VEuPathDB; HostDB:ENSG00000092439; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000157091; -. DR InParanoid; Q96QT4; -. DR OMA; SSKDPHX; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q96QT4; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96QT4; -. DR PathwayCommons; Q96QT4; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q96QT4; -. DR SIGNOR; Q96QT4; -. DR Agora; ENSG00000092439; -. DR BioGRID-ORCS; 54822; 406 hits in 1198 CRISPR screens. DR ChiTaRS; TRPM7; human. DR GeneWiki; TRPM7; -. DR GenomeRNAi; 54822; -. DR Pharos; Q96QT4; Tchem. DR PRO; PR:Q96QT4; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96QT4; protein. DR Bgee; ENSG00000092439; Expressed in left ventricle myocardium and 179 other cell types or tissues. DR ExpressionAtlas; Q96QT4; baseline and differential. DR GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0001726; C:ruffle; IEA:Ensembl. DR GO; GO:0003779; F:actin binding; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0017022; F:myosin binding; IEA:Ensembl. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IEA:Ensembl. DR GO; GO:0031032; P:actomyosin structure organization; IEA:Ensembl. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0010961; P:intracellular magnesium ion homeostasis; ISS:UniProtKB. DR GO; GO:0010960; P:magnesium ion homeostasis; IDA:UniProtKB. DR GO; GO:0015693; P:magnesium ion transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0006829; P:zinc ion transport; ISS:UniProtKB. DR CDD; cd16971; Alpha_kinase_ChaK1_TRMP7; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029601; TRPM7_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF8; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 7; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 2. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Acetylation; Amyotrophic lateral sclerosis; ATP-binding; Calcium; KW Calcium channel; Calcium transport; Cell membrane; Coiled coil; KW Cytoplasmic vesicle; Disease variant; Ion channel; Ion transport; Kinase; KW Lipoprotein; Membrane; Metal-binding; Necrosis; Neurodegeneration; KW Nucleotide-binding; Nucleus; Palmitate; Parkinsonism; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Transmembrane; KW Transmembrane helix; Transport; Zinc. FT CHAIN 1..1865 FT /note="Transient receptor potential cation channel FT subfamily M member 7" FT /id="PRO_0000215331" FT CHAIN 1..? FT /note="TRPM7 channel, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461294" FT CHAIN ?..1865 FT /note="TRPM7 kinase, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461295" FT TOPO_DOM 1..850 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 851..876 FT /note="Helical; Name=1" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 877..882 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 883..904 FT /note="Helical; Name=2" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 905..923 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 924..943 FT /note="Helical; Name=3" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 944..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..980 FT /note="Helical; Name=4" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 981..999 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1000..1023 FT /note="Helical; Name=5" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1024..1025 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1026..1066 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1067..1069 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1070..1098 FT /note="Helical; Name=6" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1099..1865 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 1594..1824 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 544..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1386..1407 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1492..1511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1524..1543 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1836..1865 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1198..1250 FT /evidence="ECO:0000250" FT COMPBIAS 544..555 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 560..573 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1386..1398 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1511 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1844..1865 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1767 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1621 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1622 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1623 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1624 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1648 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1720 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1721 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1723 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1753 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1810 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1812 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1816 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 101 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1163 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1191 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1193 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1224 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1255 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1258 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1265 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1287 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1301 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1358 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1361 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1386 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1387 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1390 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1396 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1404 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1405 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1407 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1435 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1446 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1455 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1456 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1463 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1467 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1468 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1471 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1476 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1477 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 1482 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1493 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1500 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1504 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1508 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1513 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1527 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1533 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1537 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1542 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1543 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1551 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1567 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1569 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1583 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1598 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1615 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1660 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1685 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1779 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1830 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1851 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1860 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT LIPID 1143 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1144 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT VARIANT 68 FT /note="G -> V (in dbSNP:rs56064201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042395" FT VARIANT 406 FT /note="S -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042396" FT VARIANT 459 FT /note="I -> T (in dbSNP:rs55924090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042397" FT VARIANT 574 FT /note="K -> N (in dbSNP:rs56040619)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042398" FT VARIANT 720 FT /note="T -> S (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1040254222)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042399" FT VARIANT 830 FT /note="M -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042400" FT VARIANT 949 FT /note="F -> Y (in dbSNP:rs55681028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042401" FT VARIANT 1033 FT /note="A -> G (in dbSNP:rs34530969)" FT /id="VAR_052381" FT VARIANT 1046 FT /note="G -> D (found in a patient with hypomagnesemia and FT secondary hypocalcemia; likely pathogenic; de novo variant; FT causes severely reduced Mg(2+) uptake in transfected cells; FT dbSNP:rs2059709974)" FT /evidence="ECO:0000269|PubMed:35561741" FT /id="VAR_086707" FT VARIANT 1064 FT /note="Q -> R (in dbSNP:rs56298128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042402" FT VARIANT 1145 FT /note="I -> V (in dbSNP:rs34711809)" FT /id="VAR_052382" FT VARIANT 1211 FT /note="I -> T (in dbSNP:rs56090496)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042403" FT VARIANT 1254 FT /note="A -> V (in dbSNP:rs56288221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042404" FT VARIANT 1306 FT /note="D -> E (in dbSNP:rs55970334)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042405" FT VARIANT 1444 FT /note="R -> K (in dbSNP:rs55840070)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042406" FT VARIANT 1482 FT /note="T -> I (mutant channels are functional but show FT increased susceptibility to inhibition by intracellular FT Mg(2+) concentrations compared to wild-type channels; FT dbSNP:rs8042919)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846" FT /id="VAR_019967" FT MUTAGEN 1648 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT MUTAGEN 1799 FT /note="G->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT CONFLICT 573..575 FT /note="EKM -> KKK (in Ref. 4; BAD18773)" FT /evidence="ECO:0000305" FT CONFLICT 998 FT /note="A -> S (in Ref. 5)" FT /evidence="ECO:0000305" FT CONFLICT 1496 FT /note="Missing (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" FT CONFLICT 1520 FT /note="D -> V (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" SQ SEQUENCE 1865 AA; 212697 MW; BE732674D52D7485 CRC64; MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS VRLML // ID WRN_HUMAN Reviewed; 1432 AA. AC Q14191; A1KYY9; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 08-FEB-2011, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN {ECO:0000305}; DE AltName: Full=DNA helicase, RecQ-like type 3; DE AltName: Full=RecQ protein-like 2; DE AltName: Full=Werner syndrome protein {ECO:0000303|PubMed:9618508}; DE Includes: DE RecName: Full=3'-5' exonuclease; DE EC=3.1.-.- {ECO:0000269|PubMed:11863428}; DE Includes: DE RecName: Full=ATP-dependent helicase; DE EC=5.6.2.4 {ECO:0000269|PubMed:9611231, ECO:0000305|PubMed:9288107}; DE AltName: Full=DNA 3'-5' helicase WRN {ECO:0000305}; GN Name=WRN; Synonyms=RECQ3, RECQL2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-1074. RX PubMed=8602509; DOI=10.1126/science.272.5259.258; RA Yu C.-E., Oshima J., Fu Y.-H., Wijsman E.M., Hisama F., Alisch R., RA Matthews S., Nakura J., Miki T., Ouais S., Martin G.M., Mulligan J., RA Schellenberg G.D.; RT "Positional cloning of the Werner's syndrome gene."; RL Science 272:258-262(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-1074. RX PubMed=16723399; DOI=10.1073/pnas.0600645103; RA Agrelo R., Cheng W.H., Setien F., Ropero S., Espada J., Fraga M.F., RA Herranz M., Paz M.F., Sanchez-Cespedes M., Artiga M.J., Guerrero D., RA Castells A., von Kobbe C., Bohr V.A., Esteller M.; RT "Epigenetic inactivation of the premature aging Werner syndrome gene in RT human cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 103:8822-8827(2006). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-1074. RA Paeper B.W., Gayle M., Brady W., Swartz A., Gillett L.A., Alisch R.S., RA Mulligan J., Galas D., Fu Y.-H.; RT "Genomic structure of the human Werner's gene and cloning of the mouse RT homolog."; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-114; LYS-343; ILE-387; RP SER-533; CYS-612; PHE-708; CYS-834; SER-912; LEU-1079; ALA-1133; ILE-1339 RP AND ARG-1367. RG NIEHS SNPs program; RL Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [6] RP FUNCTION AS A HELICASE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-577. RX PubMed=9288107; DOI=10.1038/ng0997-100; RA Gray M.D., Shen J.C., Kamath-Loeb A.S., Blank A., Sopher B.L., Martin G.M., RA Oshima J., Loeb L.A.; RT "The Werner syndrome protein is a DNA helicase."; RL Nat. Genet. 17:100-103(1997). RN [7] RP FUNCTION AS A HELICASE. RX PubMed=9224595; DOI=10.1093/nar/25.15.2973; RA Suzuki N., Shimamoto A., Imamura O., Kuromitsu J., Kitao S., Goto M., RA Furuichi Y.; RT "DNA helicase activity in Werner's syndrome gene product synthesized in a RT baculovirus system."; RL Nucleic Acids Res. 25:2973-2978(1997). RN [8] RP FUNCTION AS A 3'-5' HELICASE, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=9611231; DOI=10.1093/nar/26.12.2879; RA Shen J.C., Gray M.D., Oshima J., Loeb L.A.; RT "Characterization of Werner syndrome protein DNA helicase activity: RT directionality, substrate dependence and stimulation by replication protein RT A."; RL Nucleic Acids Res. 26:2879-2885(1998). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=9618508; DOI=10.1073/pnas.95.12.6887; RA Marciniak R.A., Lombard D.B., Johnson F.B., Guarente L.; RT "Nucleolar localization of the Werner syndrome protein in human cells."; RL Proc. Natl. Acad. Sci. U.S.A. 95:6887-6892(1998). RN [10] RP REPEATS. RX PubMed=10049920; DOI=10.1093/genetics/151.3.1027; RA Kusano K., Berres M.E., Engels W.R.; RT "Evolution of the RECQ family of helicases: a Drosophila homolog, Dmblm, is RT similar to the human Bloom syndrome gene."; RL Genetics 151:1027-1039(1999). RN [11] RP FUNCTION, AND COFACTOR. RX PubMed=10212265; DOI=10.1074/jbc.274.18.12797; RA Fry M., Loeb L.A.; RT "Human werner syndrome DNA helicase unwinds tetrahelical structures of the RT fragile X syndrome repeat sequence d(CGG)n."; RL J. Biol. Chem. 274:12797-12802(1999). RN [12] RP POSSIBLE INVOLVEMENT IN CRC. RX PubMed=9989816; DOI=10.1038/sj.onc.1202340; RA Chughtai S.A., Crundwell M.C., Cruickshank N.R., Affie E., Armstrong S., RA Knowles M.A., Takle L.A., Kuo M., Khan N., Phillips S.M., Neoptolemos J.P., RA Morton D.G.; RT "Two novel regions of interstitial deletion on chromosome 8p in colorectal RT cancer."; RL Oncogene 18:657-665(1999). RN [13] RP FUNCTION AS AN EXONUCLEASE, MUTAGENESIS OF GLU-84, DNA-BINDING, INTERACTION RP WITH PCNA, AND SUBUNIT. RX PubMed=11863428; DOI=10.1021/bi0157161; RA Xue Y., Ratcliff G.C., Wang H., Davis-Searles P.R., Gray M.D., Erie D.A., RA Redinbo M.R.; RT "A minimal exonuclease domain of WRN forms a hexamer on DNA and possesses RT both 3'- 5' exonuclease and 5'-protruding strand endonuclease activities."; RL Biochemistry 41:2901-2912(2002). RN [14] RP PHOSPHORYLATION. RX PubMed=11889123; DOI=10.1074/jbc.m111523200; RA Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Miller S.P., RA Cheng W.H., Snowden C.M., Ramsden D.A., Bohr V.A.; RT "Werner protein is a target of DNA-dependent protein kinase in vivo and in RT vitro, and its catalytic activities are regulated by phosphorylation."; RL J. Biol. Chem. 277:18291-18302(2002). RN [15] RP INTERACTION WITH EXO1. RX PubMed=12704184; DOI=10.1074/jbc.m212798200; RA Sharma S., Sommers J.A., Driscoll H.C., Uzdilla L.A., Wilson T.M., RA Brosh R.M. Jr.; RT "The exonucleolytic and endonucleolytic cleavage activities of human RT exonuclease 1 are stimulated by an interaction with the carboxyl-terminal RT region of the Werner syndrome protein."; RL J. Biol. Chem. 278:23487-23496(2003). RN [16] RP INTERACTION WITH SUPV3L1. RX PubMed=17961633; DOI=10.1016/j.mad.2007.09.001; RA Pereira M., Mason P., Szczesny R.J., Maddukuri L., Dziwura S., RA Jedrzejczak R., Paul E., Wojcik A., Dybczynska L., Tudek B., Bartnik E., RA Klysik J., Bohr V.A., Stepien P.P.; RT "Interaction of human SUV3 RNA/DNA helicase with BLM helicase; loss of the RT SUV3 gene results in mouse embryonic lethality."; RL Mech. Ageing Dev. 128:609-617(2007). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=17563354; DOI=10.1073/pnas.0702513104; RA Kamath-Loeb A.S., Lan L., Nakajima S., Yasui A., Loeb L.A.; RT "Werner syndrome protein interacts functionally with translesion DNA RT polymerases."; RL Proc. Natl. Acad. Sci. U.S.A. 104:10394-10399(2007). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [19] RP FUNCTION, SUBUNIT, AND DNA-BINDING. RX PubMed=18596042; DOI=10.1074/jbc.m803370200; RA Compton S.A., Tolun G., Kamath-Loeb A.S., Loeb L.A., Griffith J.D.; RT "The Werner syndrome protein binds replication fork and Holliday junction RT DNAs as an oligomer."; RL J. Biol. Chem. 283:24478-24483(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-440 AND SER-467, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19652551; DOI=10.4161/cc.8.17.9410; RA Zecevic A., Menard H., Gurel V., Hagan E., DeCaro R., Zhitkovich A.; RT "WRN helicase promotes repair of DNA double-strand breaks caused by RT aberrant mismatch repair of chromium-DNA adducts."; RL Cell Cycle 8:2769-2778(2009). RN [23] RP FUNCTION. RX PubMed=19283071; DOI=10.1371/journal.pone.0004825; RA Opresko P.L., Sowd G., Wang H.; RT "The Werner syndrome helicase/exonuclease processes mobile D-loops through RT branch migration and degradation."; RL PLoS ONE 4:E4825-E4825(2009). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-426; SER-440; SER-453 AND RP SER-467, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML. RX PubMed=21639834; DOI=10.1134/s000629791105004x; RA Liu J., Song Y., Qian J., Liu B., Dong Y., Tian B., Sun Z.; RT "Promyelocytic leukemia protein interacts with werner syndrome helicase and RT regulates double-strand break repair in gamma-irradiation-induced DNA RT damage responses."; RL Biochemistry (Mosc.) 76:550-554(2011). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1133, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [28] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [29] RP POSSIBLE INVOLVEMENT IN CRC. RX PubMed=24308539; DOI=10.1186/1755-8794-6-54; RA Lee H., Flaherty P., Ji H.P.; RT "Systematic genomic identification of colorectal cancer genes delineating RT advanced from early clinical stage and metastasis."; RL BMC Med. Genomics 6:54-54(2013). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-478; SER-1133 AND SER-1400, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [31] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH XRCC5 AND XRCC6, DOMAIN, RP XLM MOTIF, KBM MOTIFS, AND MUTAGENESIS OF TRP-18 AND GLU-84. RX PubMed=27063109; DOI=10.1038/ncomms11242; RA Grundy G.J., Rulten S.L., Arribas-Bosacoma R., Davidson K., Kozik Z., RA Oliver A.W., Pearl L.H., Caldecott K.W.; RT "The Ku-binding motif is a conserved module for recruitment and stimulation RT of non-homologous end-joining proteins."; RL Nat. Commun. 7:11242-11242(2016). RN [32] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-154; LYS-241 AND LYS-252, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [33] {ECO:0007744|PDB:2AXL} RP STRUCTURE BY NMR OF 949-1092. RX PubMed=16339893; DOI=10.1073/pnas.0509380102; RA Hu J.S., Feng H., Zeng W., Lin G.X., Xi X.G.; RT "Solution structure of a multifunctional DNA- and protein-binding motif of RT human Werner syndrome protein."; RL Proc. Natl. Acad. Sci. U.S.A. 102:18379-18384(2005). RN [34] {ECO:0007744|PDB:2FBT, ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, ECO:0007744|PDB:2FBY, ECO:0007744|PDB:2FC0} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 38-236 IN COMPLEXES WITH RP MAGNESIUM; MANGANESE; EUROPIUM AND GMP, PARTIAL PROTEIN SEQUENCE, RP IDENTIFICATION BY MASS SPECTROMETRY, CATALYTIC ACTIVITY, COFACTOR, RP MUTAGENESIS OF GLU-84; TRP-145 AND TYR-212, AND CHARACTERIZATION OF RP VARIANTS ILE-114 AND PRO-172. RX PubMed=16622405; DOI=10.1038/nsmb1088; RA Perry J.J., Yannone S.M., Holden L.G., Hitomi C., Asaithamby A., Han S., RA Cooper P.K., Chen D.J., Tainer J.A.; RT "WRN exonuclease structure and molecular mechanism imply an editing role in RT DNA end processing."; RL Nat. Struct. Mol. Biol. 13:414-422(2006). RN [35] RP REVIEW ON VARIANTS. RX PubMed=10220139; RX DOI=10.1002/(sici)1098-1004(1999)13:4<271::aid-humu2>3.0.co;2-q; RA Moser M.J., Oshima J., Monnat R.J. Jr.; RT "WRN mutations in Werner syndrome."; RL Hum. Mutat. 13:271-279(1999). RN [36] {ECO:0007744|PDB:2DGZ} RP STRUCTURE BY NMR OF 1140-1239. RG RIKEN structural genomics initiative (RSGI); RA Abe C., Muto Y., Inoue M., Kigawa T., Terada T., Shirouzu M., Yokoyama S.; RT "Solution structure of the helicase and RNase D C-terminal domain in Werner RT syndrome ATP-dependent helicase."; RL Submitted (SEP-2006) to the PDB data bank. RN [37] {ECO:0007744|PDB:2E1E, ECO:0007744|PDB:2E1F} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1142-1242, PARTIAL PROTEIN RP SEQUENCE, IDENTIFICATION BY MASS SPECTROMETRY, AND CIRCULAR DICHROISM. RX PubMed=17148451; DOI=10.1074/jbc.m610142200; RA Kitano K., Yoshihara N., Hakoshima T.; RT "Crystal structure of the HRDC domain of human Werner syndrome protein, RT WRN."; RL J. Biol. Chem. 282:2717-2728(2007). RN [38] {ECO:0007744|PDB:3AAF} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 949-1079 IN COMPLEX WITH RP DOUBLE-STRANDED DNA, INTERACTION WITH DNA, AND MUTAGENESIS OF ARG-987; RP SER-989; ARG-993; PHE-1037 AND MET-1038. RX PubMed=20159463; DOI=10.1016/j.str.2009.12.011; RA Kitano K., Kim S.Y., Hakoshima T.; RT "Structural basis for DNA strand separation by the unconventional winged- RT helix domain of RecQ helicase WRN."; RL Structure 18:177-187(2010). RN [39] {ECO:0007744|PDB:6TYV} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 8-23 IN COMPLEX WITH X.LAEVIS RP XRCC5. RX PubMed=31733588; DOI=10.1016/j.dnarep.2019.102739; RA Kim K., Min J., Kirby T.W., Gabel S.A., Pedersen L.C., London R.E.; RT "Ligand binding characteristics of the Ku80 von Willebrand domain."; RL DNA Repair 85:102739-102739(2020). RN [40] {ECO:0007744|PDB:6YHR} RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 517-1093 IN COMPLEX WITH ADP AND RP ZINC, FUNCTION, DOMAIN, AND MUTAGENESIS OF GLU-84; LYS-577 AND GLU-669. RX PubMed=33199508; DOI=10.26508/lsa.202000795; RA Newman J.A., Gavard A.E., Lieb S., Ravichandran M.C., Hauer K., Werni P., RA Geist L., Boettcher J., Engen J.R., Rumpel K., Samwer M., Petronczki M., RA Gileadi O.; RT "Structure of the helicase core of Werner helicase, a key target in RT microsatellite instability cancers."; RL Life. Sci Alliance 4:0-0(2021). RN [41] RP VARIANT ARG-1367. RX PubMed=9021029; RX DOI=10.1002/(sici)1096-8628(19970211)68:4<494::aid-ajmg30>3.0.co;2-l; RA Ye L., Miki T., Nakura J., Oshima J., Kamino K., Rakugi H., Ikegami H., RA Higaki J., Edland S.D., Martin G.M., Ogihara T.; RT "Association of a polymorphic variant of the Werner helicase gene with RT myocardial infarction in a Japanese population."; RL Am. J. Med. Genet. 68:494-498(1997). RN [42] RP ERRATUM OF PUBMED:9021029. RA Ye L., Miki T., Nakura J., Oshima J., Kamino K., Rakugi H., Ikegami H., RA Higaki J., Edland S.D., Martin G.M., Ogihara T.; RL Am. J. Med. Genet. 70:103-103(1997). RN [43] RP VARIANTS ILE-387 AND PHE-1074. RX PubMed=9450180; RA Meisslitzer C., Ruppitsch W., Weirich-Schwaiger H., Weirich H.G., RA Jabkowsky J., Klein G., Schweiger M., Hirsch-Kauffmann M.; RT "Werner syndrome: characterization of mutations in the WRN gene in an RT affected family."; RL Eur. J. Hum. Genet. 5:364-370(1997). RN [44] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RECQL5. RX PubMed=23180761; DOI=10.1093/nar/gks1134; RA Popuri V., Huang J., Ramamoorthy M., Tadokoro T., Croteau D.L., Bohr V.A.; RT "RECQL5 plays co-operative and complementary roles with WRN syndrome RT helicase."; RL Nucleic Acids Res. 41:881-899(2013). RN [45] RP VARIANT ILE-387. RX PubMed=10206685; RX DOI=10.1002/(sici)1098-1004(1998)11:5<413::aid-humu16>3.0.co;2-i; RA Vidal V., Bay J.-O., Champomier F., Grancho M., Beauville L., RA Glowaczower C., Lemery D., Ferrara M., Bignon Y.-J.; RT "The 1396del A mutation and a missense mutation or a rare polymorphism of RT the WRN gene detected in a French Werner family with a severe phenotype and RT a case of an unusual vulvar cancer."; RL Hum. Mutat. 11:413-414(1998). RN [46] RP VARIANTS ALA-324 AND ARG-1367. RX PubMed=10069711; RX DOI=10.1002/(sici)1096-8628(19990219)82:5<399::aid-ajmg8>3.3.co;2-i; RA Castro E., Ogburn C.E., Hunt K.E., Tilvis R., Louhija J., Penttinen R., RA Erkkola R., Panduro A., Riestra R., Piussan C., Deeb S.S., Wang L., RA Edland S.D., Martin G.M., Oshima J.; RT "Polymorphisms at the Werner locus: I. Newly identified polymorphisms, RT ethnic variability of 1367Cys/Arg, and its stability in a population of RT Finnish centenarians."; RL Am. J. Med. Genet. 82:399-403(1999). RN [47] RP VARIANTS ARG-32; ILE-114; PRO-172; LYS-240; TRP-383; ILE-387; LEU-724; RP PHE-1074; GLU-1269 AND ARG-1367. RX PubMed=11161804; DOI=10.1006/geno.2000.6405; RA Passarino G., Shen P., Van Kirk J.B., Lin A.A., De Benedictis G., RA Cavalli-Sforza L.L., Oefner P.J., Underhill P.A.; RT "The Werner syndrome gene and global sequence variation."; RL Genomics 71:118-122(2001). RN [48] RP VARIANTS WRN ASN-125 AND GLU-135. RX PubMed=16673358; DOI=10.1002/humu.20337; RA Huang S., Lee L., Hanson N.B., Lenaerts C., Hoehn H., Poot M., Rubin C.D., RA Chen D.-F., Yang C.-C., Juch H., Dorn T., Spiegel R., Oral E.A., Abid M., RA Battisti C., Lucci-Cordisco E., Neri G., Steed E.H., Kidd A., Isley W., RA Showalter D., Vittone J.L., Konstantinow A., Ring J., Meyer P., RA Wenger S.L., Herbay A.V., Wollina U., Schuelke M., Huizenga C.R., RA Leistritz D.F., Martin G.M., Mian I.S., Oshima J.; RT "The spectrum of WRN mutations in Werner syndrome patients."; RL Hum. Mutat. 27:558-567(2006). RN [49] RP VARIANT [LARGE SCALE ANALYSIS] VAL-92. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [50] RP VARIANT [LARGE SCALE ANALYSIS] LEU-1141. RX PubMed=18987736; DOI=10.1038/nature07485; RA Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., RA Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., RA Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., RA Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., RA Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., RA Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., RA Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., RA Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., RA DiPersio J.F., Wilson R.K.; RT "DNA sequencing of a cytogenetically normal acute myeloid leukaemia RT genome."; RL Nature 456:66-72(2008). CC -!- FUNCTION: Multifunctional enzyme that has magnesium and ATP-dependent CC 3'-5' DNA-helicase activity on partially duplex substrates CC (PubMed:9224595, PubMed:9288107, PubMed:9611231). Also has 3'->5' CC exonuclease activity towards double-stranded (ds)DNA with a 5'-overhang CC (PubMed:11863428). Has no nuclease activity towards single-stranded CC (ss)DNA or blunt-ended dsDNA (PubMed:11863428). Helicase activity is CC most efficient with (d)ATP, but (d)CTP will substitute with reduced CC efficiency; strand displacement is enhanced by single-strand binding- CC protein (heterotrimeric replication protein A complex, RPA1, RPA2, CC RPA3) (PubMed:9611231). Binds preferentially to DNA substrates CC containing alternate secondary structures, such as replication forks CC and Holliday junctions. May play an important role in the dissociation CC of joint DNA molecules that can arise as products of homologous CC recombination, at stalled replication forks or during DNA repair. CC Alleviates stalling of DNA polymerases at the site of DNA lesions. CC Plays a role in the formation of DNA replication focal centers; stably CC associates with foci elements generating binding sites for RP-A (By CC similarity). Plays a role in double-strand break repair after gamma- CC irradiation (PubMed:9224595, PubMed:9288107, PubMed:9611231). Unwinds CC some G-quadruplex DNA (d(CGG)n tracts); unwinding seems to occur in CC both 5'-3' and 3'-5' direction and requires a short single-stranded CC tail (PubMed:10212265). d(CGG)n tracts have a propensity to assemble CC into tetraplex structures; other G-rich substrates from a telomeric or CC IgG switch sequence are not unwound (PubMed:10212265). Depletion leads CC to chromosomal breaks and genome instability (PubMed:33199508). CC {ECO:0000250|UniProtKB:O09053, ECO:0000269|PubMed:10212265, CC ECO:0000269|PubMed:11863428, ECO:0000269|PubMed:17563354, CC ECO:0000269|PubMed:18596042, ECO:0000269|PubMed:19283071, CC ECO:0000269|PubMed:19652551, ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:27063109, ECO:0000269|PubMed:33199508, CC ECO:0000269|PubMed:9224595, ECO:0000269|PubMed:9288107, CC ECO:0000269|PubMed:9611231}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Couples ATP hydrolysis with the unwinding of duplex DNA by CC translocating in the 3'-5' direction.; EC=5.6.2.4; CC Evidence={ECO:0000269|PubMed:9611231, ECO:0000305|PubMed:10212265, CC ECO:0000305|PubMed:9224595, ECO:0000305|PubMed:9288107}; CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=5.6.2.4; CC Evidence={ECO:0000269|PubMed:16622405, ECO:0000269|PubMed:9224595, CC ECO:0000269|PubMed:9288107, ECO:0000269|PubMed:9611231}; CC -!- COFACTOR: CC Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240; CC Evidence={ECO:0000269|PubMed:16622405}; CC Note=Binds 2 magnesium or manganese ions in the exonuclease domain; has CC high exonuclease activity with both ions in vitro (PubMed:16622405). CC Unwinding of G-quadruplex DNA requires Mg(2+) (PubMed:10212265). CC {ECO:0000269|PubMed:10212265, ECO:0000269|PubMed:16622405}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:33199508, ECO:0000312|PDB:6YHR}; CC Note=Binds a Zn(2+) ion in the helicase domain (PubMed:33199508). CC {ECO:0000269|PubMed:33199508, ECO:0000312|PDB:6YHR}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=51 uM for ATP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=119 uM for dATP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=2.1 uM for CTP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=3.9 uM for dCTP in helicase activity {ECO:0000269|PubMed:9611231}; CC -!- SUBUNIT: Monomer, and homooligomer (PubMed:11863428, PubMed:18596042, CC PubMed:20159463). May exist as homodimer, homotrimer, homotetramer CC and/or homohexamer (PubMed:11863428, PubMed:18596042, PubMed:20159463). CC Homotetramer, or homohexamer, when bound to DNA (PubMed:11863428, CC PubMed:18596042, PubMed:20159463). Interacts via its N-terminal domain CC with WRNIP1 (By similarity). Interacts with EXO1, PCNA and SUPV3L1 CC (PubMed:12704184, PubMed:17961633). Interacts with PML (isoform PML-4) CC (PubMed:21639834). Interacts (via KBM motif) with XRCC5 and XRCC6; CC promoting recruitment to DNA damage sites (PubMed:27063109). Interacts CC with RECQL5; this interaction stimulates WRN helicase activity on DNA CC fork duplexes (PubMed:23180761). {ECO:0000250|UniProtKB:O09053, CC ECO:0000269|PubMed:11863428, ECO:0000269|PubMed:12704184, CC ECO:0000269|PubMed:17961633, ECO:0000269|PubMed:18596042, CC ECO:0000269|PubMed:20159463, ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:23180761, ECO:0000269|PubMed:27063109}. CC -!- INTERACTION: CC Q14191; P54132: BLM; NbExp=9; IntAct=EBI-368417, EBI-621372; CC Q14191; P45973: CBX5; NbExp=3; IntAct=EBI-368417, EBI-78219; CC Q14191; P39748: FEN1; NbExp=9; IntAct=EBI-368417, EBI-707816; CC Q14191; P16104: H2AX; NbExp=6; IntAct=EBI-368417, EBI-494830; CC Q14191; P09874: PARP1; NbExp=8; IntAct=EBI-368417, EBI-355676; CC Q14191; P43351: RAD52; NbExp=9; IntAct=EBI-368417, EBI-706448; CC Q14191; P27694: RPA1; NbExp=9; IntAct=EBI-368417, EBI-621389; CC Q14191; Q96EB6: SIRT1; NbExp=9; IntAct=EBI-368417, EBI-1802965; CC Q14191; Q15554: TERF2; NbExp=8; IntAct=EBI-368417, EBI-706637; CC Q14191; P04637: TP53; NbExp=5; IntAct=EBI-368417, EBI-366083; CC Q14191; P12956: XRCC6; NbExp=11; IntAct=EBI-368417, EBI-353208; CC -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:23180761, CC ECO:0000269|PubMed:9618508}. Nucleus {ECO:0000269|PubMed:17563354, CC ECO:0000269|PubMed:19652551, ECO:0000269|PubMed:23180761}. Nucleus, CC nucleoplasm {ECO:0000269|PubMed:21639834}. Chromosome CC {ECO:0000269|PubMed:27063109}. Note=Gamma-irradiation leads to its CC translocation from nucleoli to nucleoplasm and PML regulates the CC irradiation-induced WRN relocation (PubMed:21639834). Localizes to DNA CC damage sites (PubMed:27063109). {ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:27063109}. CC -!- DOMAIN: The KBM 2 (Ku-binding motif 2) and XLM (XLF-like motif) mediate CC cooperative interaction with XRCC5/Ku80 and XRCC6/Ku70 and recruitment CC to DNA damage sites (PubMed:27063109). The isolated helicase core CC (residues 517-1093) interacts weakly with the HDRC domain in vitro CC (PubMed:33199508). {ECO:0000269|PubMed:27063109, CC ECO:0000269|PubMed:33199508}. CC -!- PTM: Phosphorylated by PRKDC. {ECO:0000269|PubMed:11889123}. CC -!- DISEASE: Werner syndrome (WRN) [MIM:277700]: A rare autosomal recessive CC progeroid syndrome characterized by the premature onset of multiple CC age-related disorders, including atherosclerosis, cancer, non-insulin- CC dependent diabetes mellitus, ocular cataracts and osteoporosis. The CC major cause of death, at a median age of 47, is myocardial infarction. CC {ECO:0000269|PubMed:16673358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000305|PubMed:24308539, CC ECO:0000305|PubMed:9989816}. Note=The disease may be caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the helicase family. RecQ subfamily. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=WRN; Note=WRN mutation db (Warner disease); CC URL="http://www.pathology.washington.edu/werner/ws_wrn.html"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/284/WRN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L76937; AAC41981.1; -; Genomic_DNA. DR EMBL; AY818673; AAX21098.1; -; mRNA. DR EMBL; AF091214; AAC63361.1; -; mRNA. DR EMBL; AF181897; AAF06162.1; -; Genomic_DNA. DR EMBL; AF181896; AAF06162.1; JOINED; Genomic_DNA. DR EMBL; AY442327; AAR05448.1; -; Genomic_DNA. DR EMBL; AC084736; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS6082.1; -. DR RefSeq; NP_000544.2; NM_000553.6. DR PDB; 2AXL; NMR; -; A=949-1092. DR PDB; 2DGZ; NMR; -; A=1140-1239. DR PDB; 2E1E; X-ray; 2.30 A; A=1142-1242. DR PDB; 2E1F; X-ray; 2.00 A; A=1142-1242. DR PDB; 2FBT; X-ray; 2.05 A; A=38-236. DR PDB; 2FBV; X-ray; 2.40 A; A=38-236. DR PDB; 2FBX; X-ray; 2.20 A; A=38-236. DR PDB; 2FBY; X-ray; 2.00 A; A=38-236. DR PDB; 2FC0; X-ray; 2.00 A; A=38-236. DR PDB; 3AAF; X-ray; 1.90 A; A/B=949-1079. DR PDB; 6TYV; X-ray; 1.93 A; B=8-23. DR PDB; 6YHR; X-ray; 2.20 A; A=517-1093. DR PDB; 7GQS; X-ray; 1.57 A; A=517-945. DR PDB; 7GQT; X-ray; 2.21 A; A=517-945. DR PDB; 7GQU; X-ray; 1.54 A; A=517-945. DR PDB; 7XUT; X-ray; 1.60 A; A/B=435-451. DR PDB; 8PFL; X-ray; 1.80 A; A=517-945. DR PDB; 8PFO; X-ray; 1.90 A; A=517-945. DR PDB; 8PFP; X-ray; 1.60 A; A=517-945. DR PDB; 8YLE; X-ray; 1.86 A; A=517-945. DR PDB; 9OG3; X-ray; 2.06 A; A=526-946. DR PDB; 9OG8; X-ray; 1.66 A; A=526-946. DR PDB; 9OW9; X-ray; 2.34 A; A=500-942. DR PDB; 9OWA; X-ray; 1.98 A; A=500-942. DR PDB; 9OWB; X-ray; 1.56 A; A/B/C/D=500-942. DR PDB; 9OWC; X-ray; 1.67 A; A=500-942. DR PDB; 9OWD; X-ray; 1.96 A; A=500-942. DR PDBsum; 2AXL; -. DR PDBsum; 2DGZ; -. DR PDBsum; 2E1E; -. DR PDBsum; 2E1F; -. DR PDBsum; 2FBT; -. DR PDBsum; 2FBV; -. DR PDBsum; 2FBX; -. DR PDBsum; 2FBY; -. DR PDBsum; 2FC0; -. DR PDBsum; 3AAF; -. DR PDBsum; 6TYV; -. DR PDBsum; 6YHR; -. DR PDBsum; 7GQS; -. DR PDBsum; 7GQT; -. DR PDBsum; 7GQU; -. DR PDBsum; 7XUT; -. DR PDBsum; 8PFL; -. DR PDBsum; 8PFO; -. DR PDBsum; 8PFP; -. DR PDBsum; 8YLE; -. DR PDBsum; 9OG3; -. DR PDBsum; 9OG8; -. DR PDBsum; 9OW9; -. DR PDBsum; 9OWA; -. DR PDBsum; 9OWB; -. DR PDBsum; 9OWC; -. DR PDBsum; 9OWD; -. DR AlphaFoldDB; Q14191; -. DR BMRB; Q14191; -. DR SMR; Q14191; -. DR BioGRID; 113323; 124. DR CORUM; Q14191; -. DR DIP; DIP-31380N; -. DR ELM; Q14191; -. DR FunCoup; Q14191; 2264. DR IntAct; Q14191; 67. DR MINT; Q14191; -. DR STRING; 9606.ENSP00000298139; -. DR BindingDB; Q14191; -. DR ChEMBL; CHEMBL2146312; -. DR GuidetoPHARMACOLOGY; 3259; -. DR GlyGen; Q14191; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q14191; -. DR PhosphoSitePlus; Q14191; -. DR SwissPalm; Q14191; -. DR BioMuta; WRN; -. DR DMDM; 322510082; -. DR jPOST; Q14191; -. DR MassIVE; Q14191; -. DR PaxDb; 9606-ENSP00000298139; -. DR PeptideAtlas; Q14191; -. DR ProteomicsDB; 59913; -. DR Pumba; Q14191; -. DR ABCD; Q14191; 1 sequenced antibody. DR Antibodypedia; 10619; 313 antibodies from 41 providers. DR DNASU; 7486; -. DR Ensembl; ENST00000298139.7; ENSP00000298139.5; ENSG00000165392.12. DR GeneID; 7486; -. DR KEGG; hsa:7486; -. DR MANE-Select; ENST00000298139.7; ENSP00000298139.5; NM_000553.6; NP_000544.2. DR UCSC; uc003xio.5; human. DR AGR; HGNC:12791; -. DR ClinPGx; PA367; -. DR CTD; 7486; -. DR DisGeNET; 7486; -. DR GeneCards; WRN; -. DR GeneReviews; WRN; -. DR HGNC; HGNC:12791; WRN. DR HPA; ENSG00000165392; Low tissue specificity. DR MalaCards; WRN; -. DR MIM; 114500; phenotype. DR MIM; 277700; phenotype. DR MIM; 604611; gene. DR OpenTargets; ENSG00000165392; -. DR Orphanet; 902; Werner syndrome. DR VEuPathDB; HostDB:ENSG00000165392; -. DR eggNOG; KOG0351; Eukaryota. DR eggNOG; KOG4373; Eukaryota. DR GeneTree; ENSGT00940000159168; -. DR HOGENOM; CLU_001103_11_1_1; -. DR InParanoid; Q14191; -. DR OMA; TYLIHMV; -. DR OrthoDB; 10261556at2759; -. DR PAN-GO; Q14191; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q14191; -. DR BRENDA; 3.6.4.12; 2681. DR PathwayCommons; Q14191; -. DR Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere. DR Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand. DR Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q14191; -. DR SIGNOR; Q14191; -. DR Agora; ENSG00000165392; -. DR BioGRID-ORCS; 7486; 55 hits in 1158 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; WRN; human. DR EvolutionaryTrace; Q14191; -. DR GeneWiki; Werner_syndrome_ATP-dependent_helicase; -. DR GenomeRNAi; 7486; -. DR Pharos; Q14191; Tbio. DR PRO; PR:Q14191; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q14191; protein. DR Bgee; ENSG00000165392; Expressed in calcaneal tendon and 165 other cell types or tissues. DR ExpressionAtlas; Q14191; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0000781; C:chromosome, telomeric region; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005657; C:replication fork; ISS:BHF-UCL. DR GO; GO:0043138; F:3'-5' DNA helicase activity; IDA:UniProtKB. DR GO; GO:0008408; F:3'-5' exonuclease activity; IDA:UniProtKB. DR GO; GO:0070337; F:3'-flap-structured DNA binding; IDA:BHF-UCL. DR GO; GO:1905773; F:8-hydroxy-2'-deoxyguanosine DNA binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB. DR GO; GO:0000405; F:bubble DNA binding; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003678; F:DNA helicase activity; IDA:UniProtKB. DR GO; GO:0004527; F:exonuclease activity; IDA:MGI. DR GO; GO:0061749; F:forked DNA-dependent helicase activity; IDA:BHF-UCL. DR GO; GO:0000400; F:four-way junction DNA binding; IDA:BHF-UCL. DR GO; GO:0009378; F:four-way junction helicase activity; IDA:UniProtKB. DR GO; GO:0051880; F:G-quadruplex DNA binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB. DR GO; GO:0032405; F:MutLalpha complex binding; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0061821; F:telomeric D-loop binding; IDA:BHF-UCL. DR GO; GO:0061849; F:telomeric G-quadruplex DNA binding; IDA:BHF-UCL. DR GO; GO:0000403; F:Y-form DNA binding; IDA:UniProtKB. DR GO; GO:0006284; P:base-excision repair; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IDA:MGI. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0032392; P:DNA geometric change; IDA:BHF-UCL. DR GO; GO:0006259; P:DNA metabolic process; IDA:UniProtKB. DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; IDA:UniProtKB. DR GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IBA:GO_Central. DR GO; GO:0006298; P:mismatch repair; IDA:BHF-UCL. DR GO; GO:0051345; P:positive regulation of hydrolase activity; IDA:UniProtKB. DR GO; GO:0098530; P:positive regulation of strand invasion; IDA:BHF-UCL. DR GO; GO:1902570; P:protein localization to nucleolus; IDA:MGI. DR GO; GO:0040009; P:regulation of growth rate; IEA:Ensembl. DR GO; GO:0031297; P:replication fork processing; IDA:UniProtKB. DR GO; GO:0090399; P:replicative senescence; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IDA:UniProtKB. DR GO; GO:0010225; P:response to UV-C; IDA:UniProtKB. DR GO; GO:0090656; P:t-circle formation; TAS:BHF-UCL. DR GO; GO:0000723; P:telomere maintenance; IDA:BHF-UCL. DR GO; GO:0032201; P:telomere maintenance via semi-conservative replication; TAS:Reactome. DR GO; GO:0061820; P:telomeric D-loop disassembly; IDA:BHF-UCL. DR CDD; cd18017; DEXHc_RecQ3; 1. DR CDD; cd06129; RNaseD_like; 1. DR CDD; cd18794; SF2_C_RecQ; 1. DR DisProt; DP00443; -. DR FunFam; 1.10.10.10:FF:000369; Werner syndrome ATP-dependent helicase; 1. DR FunFam; 1.10.150.80:FF:000005; Werner syndrome ATP-dependent helicase homolog; 1. DR FunFam; 3.30.420.10:FF:000053; Werner syndrome ATP-dependent helicase homolog; 1. DR FunFam; 3.40.50.300:FF:000941; Werner syndrome RecQ like helicase; 1. DR FunFam; 3.40.50.300:FF:001023; Werner syndrome RecQ like helicase; 1. DR Gene3D; 1.10.150.80; HRDC domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR IDEAL; IID00246; -. DR InterPro; IPR002562; 3'-5'_exonuclease_dom. DR InterPro; IPR011545; DEAD/DEAH_box_helicase_dom. DR InterPro; IPR004589; DNA_helicase_ATP-dep_RecQ. DR InterPro; IPR014001; Helicase_ATP-bd. DR InterPro; IPR001650; Helicase_C-like. DR InterPro; IPR029491; Helicase_HTH. DR InterPro; IPR010997; HRDC-like_sf. DR InterPro; IPR002121; HRDC_dom. DR InterPro; IPR044876; HRDC_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR032284; RecQ_Zn-bd. DR InterPro; IPR012337; RNaseH-like_sf. DR InterPro; IPR036397; RNaseH_sf. DR InterPro; IPR018982; RQC_domain. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR NCBIfam; TIGR00614; recQ_fam; 1. DR PANTHER; PTHR13710:SF120; BIFUNCTIONAL 3'-5' EXONUCLEASE_ATP-DEPENDENT HELICASE WRN; 1. DR PANTHER; PTHR13710; DNA HELICASE RECQ FAMILY MEMBER; 1. DR Pfam; PF00270; DEAD; 1. DR Pfam; PF01612; DNA_pol_A_exo1; 1. DR Pfam; PF00271; Helicase_C; 1. DR Pfam; PF00570; HRDC; 1. DR Pfam; PF14493; HTH_40; 1. DR Pfam; PF16124; RecQ_Zn_bind; 1. DR Pfam; PF09382; RQC; 1. DR SMART; SM00474; 35EXOc; 1. DR SMART; SM00487; DEXDc; 1. DR SMART; SM00490; HELICc; 1. DR SMART; SM00341; HRDC; 1. DR SMART; SM00956; RQC; 1. DR SUPFAM; SSF47819; HRDC-like; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR SUPFAM; SSF53098; Ribonuclease H-like; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS51192; HELICASE_ATP_BIND_1; 1. DR PROSITE; PS51194; HELICASE_CTER; 1. DR PROSITE; PS50967; HRDC; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Chromosome; KW Direct protein sequencing; Disease variant; DNA damage; DNA repair; KW DNA-binding; Exonuclease; Helicase; Hydrolase; Isomerase; Isopeptide bond; KW Magnesium; Metal-binding; Multifunctional enzyme; Nuclease; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Ubl conjugation; Zinc. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..1432 FT /note="Bifunctional 3'-5' exonuclease/ATP-dependent FT helicase WRN" FT /id="PRO_0000205045" FT DOMAIN 60..228 FT /note="3'-5' exonuclease" FT /evidence="ECO:0000255, ECO:0000269|PubMed:11863428" FT REPEAT 424..450 FT /note="1" FT /evidence="ECO:0000269|PubMed:10049920" FT REPEAT 451..477 FT /note="2" FT /evidence="ECO:0000269|PubMed:10049920" FT DOMAIN 558..724 FT /note="Helicase ATP-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT DOMAIN 749..899 FT /note="Helicase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00542" FT DOMAIN 1150..1229 FT /note="HRDC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00328" FT REGION 2..277 FT /note="Interaction with WRNIP1" FT /evidence="ECO:0000250|UniProtKB:O09053" FT REGION 424..477 FT /note="2 X 27 AA tandem repeats of H-L-S-P-N-D-N-E-N-D-T-S- FT Y-V-I-E-S-D-E-D-L-E-M-E-M-L-K" FT REGION 498..529 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 987..993 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:20159463" FT MOTIF 11..23 FT /note="KBM 1" FT /evidence="ECO:0000305|PubMed:27063109" FT MOTIF 668..671 FT /note="DEAH box" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT MOTIF 1403..1412 FT /note="KBM 2" FT /evidence="ECO:0000305|PubMed:27063109" FT MOTIF 1419..1432 FT /note="XLM" FT /evidence="ECO:0000305|PubMed:27063109" FT COMPBIAS 507..525 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 82 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 82 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 84 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 216 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 546 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 548 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000312|PDB:6YHR" FT BINDING 550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508" FT BINDING 553 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 574 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000312|PDB:6YHR" FT BINDING 908 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 935 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 936 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 939 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT SITE 145 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:20159463" FT SITE 1037 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:20159463" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 426 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 440 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 453 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1133 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 154 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 241 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 252 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 32 FT /note="K -> R (in dbSNP:rs34477820)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017453" FT VARIANT 92 FT /note="G -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036318" FT VARIANT 114 FT /note="V -> I (no effect on exonuclease activity; FT dbSNP:rs2230009)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16622405, ECO:0000269|Ref.4" FT /id="VAR_017454" FT VARIANT 125 FT /note="K -> N (in WRN; dbSNP:rs387906337)" FT /evidence="ECO:0000269|PubMed:16673358" FT /id="VAR_026588" FT VARIANT 135 FT /note="K -> E (in WRN; dbSNP:rs267607008)" FT /evidence="ECO:0000269|PubMed:16673358" FT /id="VAR_026589" FT VARIANT 172 FT /note="T -> P (no effect on exonuclease activity; FT dbSNP:rs367991517)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16622405" FT /id="VAR_017455" FT VARIANT 240 FT /note="N -> K (in dbSNP:rs148229804)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017456" FT VARIANT 324 FT /note="T -> A (in dbSNP:rs1800390)" FT /evidence="ECO:0000269|PubMed:10069711" FT /id="VAR_006904" FT VARIANT 329 FT /note="Q -> R (in dbSNP:rs4987237)" FT /id="VAR_020450" FT VARIANT 343 FT /note="E -> K (in dbSNP:rs11574222)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018941" FT VARIANT 383 FT /note="L -> F (in dbSNP:rs4987238)" FT /id="VAR_020451" FT VARIANT 383 FT /note="L -> W" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017457" FT VARIANT 387 FT /note="M -> I (in dbSNP:rs1800391)" FT /evidence="ECO:0000269|PubMed:10206685, FT ECO:0000269|PubMed:11161804, ECO:0000269|PubMed:9450180, FT ECO:0000269|Ref.4" FT /id="VAR_006905" FT VARIANT 533 FT /note="N -> S (in dbSNP:rs11574240)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018942" FT VARIANT 612 FT /note="S -> C (in dbSNP:rs11574250)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018943" FT VARIANT 708 FT /note="S -> F (in dbSNP:rs11574289)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018944" FT VARIANT 711 FT /note="R -> W (in dbSNP:rs34560788)" FT /id="VAR_057124" FT VARIANT 724 FT /note="Q -> L" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017458" FT VARIANT 834 FT /note="R -> C (in dbSNP:rs3087425)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014913" FT VARIANT 912 FT /note="I -> S (in dbSNP:rs11574323)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018945" FT VARIANT 1074 FT /note="L -> F (in dbSNP:rs1801195)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16723399, ECO:0000269|PubMed:8602509, FT ECO:0000269|PubMed:9450180, ECO:0000269|Ref.3" FT /id="VAR_007903" FT VARIANT 1079 FT /note="S -> L (in dbSNP:rs3087414)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014914" FT VARIANT 1133 FT /note="S -> A (in dbSNP:rs11574358)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018946" FT VARIANT 1141 FT /note="S -> L (in dbSNP:rs139323683)" FT /evidence="ECO:0000269|PubMed:18987736" FT /id="VAR_054162" FT VARIANT 1269 FT /note="K -> E (in dbSNP:rs746648510)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017459" FT VARIANT 1339 FT /note="V -> I (in dbSNP:rs11574395)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018947" FT VARIANT 1367 FT /note="C -> R (associated with a higher risk of myocardial FT infarction; dbSNP:rs1346044)" FT /evidence="ECO:0000269|PubMed:10069711, FT ECO:0000269|PubMed:11161804, ECO:0000269|PubMed:9021029, FT ECO:0000269|Ref.4" FT /id="VAR_006906" FT MUTAGEN 18 FT /note="W->G: Abolished interaction with XRCC5 and XRCC6." FT /evidence="ECO:0000269|PubMed:27063109" FT MUTAGEN 84 FT /note="E->A: Abolishes exonuclease activity. Restores FT chromosome stability in depletion experiments." FT /evidence="ECO:0000269|PubMed:11863428, FT ECO:0000269|PubMed:16622405, ECO:0000269|PubMed:27063109, FT ECO:0000269|PubMed:33199508" FT MUTAGEN 88 FT /note="L->A: No effect on exonuclease activity." FT MUTAGEN 145 FT /note="W->A: Reduces exonuclease activity." FT /evidence="ECO:0000269|PubMed:16622405" FT MUTAGEN 212 FT /note="Y->F: Strongly reduces exonuclease activity." FT /evidence="ECO:0000269|PubMed:16622405" FT MUTAGEN 577 FT /note="K->M: Loss of helicase activity, loss of DNA- FT dependent ATPase activity. Does not restore chromosome FT stability in depletion experiments." FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000269|PubMed:9288107" FT MUTAGEN 669 FT /note="E->A: Does not restore chromosome stability in FT depletion experiments." FT /evidence="ECO:0000269|PubMed:33199508" FT MUTAGEN 987 FT /note="R->A: Reduces affinity for DNA about 8-fold. Loss of FT DNA binding; when associated with A-993." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 989 FT /note="S->A: Reduces affinity for DNA about 4-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 993 FT /note="R->A: Reduces affinity for DNA about 20-fold. Loss FT of DNA binding; when associated with A-987." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 993 FT /note="R->E: Loss of DNA binding." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 1037 FT /note="F->A: Reduces affinity for DNA about 8-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 1038 FT /note="M->A: Reduces affinity for DNA about 4-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT HELIX 17..19 FT /evidence="ECO:0007829|PDB:6TYV" FT HELIX 39..41 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 51..56 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 59..72 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 78..84 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 114..116 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 117..119 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 122..128 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 133..139 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 140..151 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 157..160 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 161..169 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 177..185 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 193..196 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 202..204 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 207..228 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 435..447 FT /evidence="ECO:0007829|PDB:7XUT" FT HELIX 524..527 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 534..544 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 551..563 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 567..570 FT /evidence="ECO:0007829|PDB:7GQU" FT TURN 575..577 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 579..588 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 590..595 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 616..618 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 625..632 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 637..641 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 643..648 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 650..659 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 662..667 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 670..673 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 677..679 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 682..688 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 689..693 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 699..704 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 708..718 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 724..727 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 735..741 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 746..750 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 751..753 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 761..765 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 767..770 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 774..786 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 791..795 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 816..821 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 826..828 FT /evidence="ECO:0007829|PDB:7GQS" FT STRAND 835..840 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 845..853 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 862..868 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 873..875 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:7GQS" FT HELIX 886..904 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 909..915 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 917..919 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 924..929 FT /evidence="ECO:0007829|PDB:7GQU" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 937..944 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 956..958 FT /evidence="ECO:0007829|PDB:6YHR" FT HELIX 960..972 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 973..975 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 980..986 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 996..1000 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 1002..1009 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 1012..1024 FT /evidence="ECO:0007829|PDB:3AAF" FT STRAND 1027..1032 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 1036..1038 FT /evidence="ECO:0007829|PDB:2AXL" FT STRAND 1039..1043 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 1045..1054 FT /evidence="ECO:0007829|PDB:3AAF" FT STRAND 1062..1064 FT /evidence="ECO:0007829|PDB:6YHR" FT TURN 1067..1069 FT /evidence="ECO:0007829|PDB:6YHR" FT HELIX 1147..1171 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1175..1178 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1181..1190 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1195..1198 FT /evidence="ECO:0007829|PDB:2E1F" FT STRAND 1201..1203 FT /evidence="ECO:0007829|PDB:2DGZ" FT HELIX 1206..1211 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1213..1225 FT /evidence="ECO:0007829|PDB:2E1F" SQ SEQUENCE 1432 AA; 162461 MW; 63F10D19E90AA461 CRC64; MSEKKLETTA QQRKCPEWMN VQNKRCAVEE RKACVRKSVF EDDLPFLEFT GSIVYSYDAS DCSFLSEDIS MSLSDGDVVG FDMEWPPLYN RGKLGKVALI QLCVSESKCY LFHVSSMSVF PQGLKMLLEN KAVKKAGVGI EGDQWKLLRD FDIKLKNFVE LTDVANKKLK CTETWSLNSL VKHLLGKQLL KDKSIRCSNW SKFPLTEDQK LYAATDAYAG FIIYRNLEIL DDTVQRFAIN KEEEILLSDM NKQLTSISEE VMDLAKHLPH AFSKLENPRR VSILLKDISE NLYSLRRMII GSTNIETELR PSNNLNLLSF EDSTTGGVQQ KQIREHEVLI HVEDETWDPT LDHLAKHDGE DVLGNKVERK EDGFEDGVED NKLKENMERA CLMSLDITEH ELQILEQQSQ EEYLSDIAYK STEHLSPNDN ENDTSYVIES DEDLEMEMLK HLSPNDNEND TSYVIESDED LEMEMLKSLE NLNSGTVEPT HSKCLKMERN LGLPTKEEEE DDENEANEGE EDDDKDFLWP APNEEQVTCL KMYFGHSSFK PVQWKVIHSV LEERRDNVAV MATGYGKSLC FQYPPVYVGK IGLVISPLIS LMEDQVLQLK MSNIPACFLG SAQSENVLTD IKLGKYRIVY VTPEYCSGNM GLLQQLEADI GITLIAVDEA HCISEWGHDF RDSFRKLGSL KTALPMVPIV ALTATASSSI REDIVRCLNL RNPQITCTGF DRPNLYLEVR RKTGNILQDL QPFLVKTSSH WEFEGPTIIY CPSRKMTQQV TGELRKLNLS CGTYHAGMSF STRKDIHHRF VRDEIQCVIA TIAFGMGINK ADIRQVIHYG APKDMESYYQ EIGRAGRDGL QSSCHVLWAP ADINLNRHLL TEIRNEKFRL YKLKMMAKME KYLHSSRCRR QIILSHFEDK QVQKASLGIM GTEKCCDNCR SRLDHCYSMD DSEDTSWDFG PQAFKLLSAV DILGEKFGIG LPILFLRGSN SQRLADQYRR HSLFGTGKDQ TESWWKAFSR QLITEGFLVE VSRYNKFMKI CALTKKGRNW LHKANTESQS LILQANEELC PKKLLLPSSK TVSSGTKEHC YNQVPVELST EKKSNLEKLY SYKPCDKISS GSNISKKSIM VQSPEKAYSS SQPVISAQEQ ETQIVLYGKL VEARQKHANK MDVPPAILAT NKILVDMAKM RPTTVENVKR IDGVSEGKAA MLAPLLEVIK HFCQTNSVQT DLFSSTKPQE EQKTSLVAKN KICTLSQSMA ITYSLFQEKK MPLKSIAESR ILPLMTIGMH LSQAVKAGCP LDLERAGLTP EVQKIIADVI RNPPVNSDMS KISLIRMLVP ENIDTYLIHM AIEILKHGPD SGLQPSCDVN KRRCFPGSEE ICSSSKRSKE EVGINTETSS AERKRRLPVW FAKGSDTSKK LMDKTKRGGL FS //